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CHAPTER I 
 
INTRODUCTION 
 
History and classification 
Phospholipase D (PLD) activity was first described in plant studies when 
Hanahan and Chaikoff reported the metabolism of nitrogen containing phospholipids into 
phosphatidic acid (PtdOH) and choline in carrots (enzyme commission number 
EC3.1.4.4) (Hanahan and Chaikoff, 1947a). Further investigation using carrot (Hanahan 
and Chaikoff, 1947b) and cabbage (Hanahan and Chaikoff, 1948) extracts confirmed the 
presence of an enzyme capable of hydrolyzing phosphatidylcholine (PC) when added 
exogenously to the plant preparation. These early studies paved the way for the 
purification of a soluble PLD from cottonseed extracts (Tookey and Balls, 1956). In 
addition to hydrolyzing phospholipids such as PC, PLD enzymes catalyze a 
transphosphatidylation reaction in the presence of primary alcohols where the 
phosphatidyl group from PC is transferred to the alcohol instead of water to generate a 
phosphatidyl alcohol at the expense of PtdOH (Yang et al., 1967) (Figure 1). Thus, the 
gold-standard technique for measuring PLD activity in vivo is to measure production of 
metabolically stable phosphatidyl alcohols in the presence of primary alcohols such as 
butanol or ethanol (Brown et al., 2007). Almost thirty years after the initial description of 
PLD in plants, Saito and Kanfer provided the first evidence of a PLD activity in a 
mammalian tissue by partially purifying a PLD enzyme from rat brain particulate fractions 
(Saito and Kanfer, 1975; 1973). PLD enzymes are now known to be ubiquitously 
expressed and PLD activity has been described in almost all organisms from viruses and 
prokaryotes up to fungi, plants, and higher eukaryotes such as humans (reviewed in 
Selvy et al., 2011). 
 2!
 
 
Figure 1. PLD hydrolysis and transphosphatidylation. Shown are substrates and 
products of PLD-catalyzed hydrolysis in the presence of water, or transphosphatidylation 
in the presence of butanol.  
 
PLD was first cloned from castor beans (Wang et al., 1994), and the sequence 
information enabled other groups to clone PLD enzymes from many other organisms. To 
date, over 4000 sequences for PLDs from various organisms have been deposited into 
the NCBI GenBank (Selvy et al., 2011). Two PLD isoforms have been cloned in humans 
and are commonly referenced as PLD1 (Hammond et al., 1995) and PLD2 (Lopez et al., 
1998). PLD1 and PLD2 orthologues have also been cloned from mice (Colley et al., 
1997a; 1997b) and rat (Kodaki and Yamashita, 1997; Park et al., 1997). Although many 
PLD enzymes, both prokaryotic and eukaryotic, were initially described based on their 
ability to hydrolyze PC, cloning and subsequent sequence analyses revealed the truly 
diverse nature of these enzymes. The overall sequence homology between plant, yeast, 
and mammalian enzymes is quite low, with only four small regions of sequence similarity 
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termed conserved regions (CR) I, II, III, and IV (Morris et al., 1996). CR II and CR IV 
contain phospholipase catalytic sequences, termed HKD domains (Koonin, 1996), 
characterized by the sequence HxKx4Dx6G(G/S) where x’s denote amino acids between 
the histidine, lysine, and aspartic acid residues. Based on sequence analyses of PLDs 
from various organisms, enzymes with the characteristic HKD catalytic domain are 
categorized as part of a PLD “superfamily” and include PLD enzymes from prokaryotes, 
fungi, plants, and mammals (Koonin, 1996; Ponting and Kerr, 1996). Additionally, non-
PLD enzymes with HKD domains such as endonucleases (Pohlman et al., 1993), 
cardiolipin synthase (CLS) (Ivanisevic et al., 1995), and phosphatidylserine synthase 
(PSS) (DeChavigny et al., 1991) are included in the PLD superfamily. Not all HKD 
enzymes share all four conserved regions as PLD from Streptomyces contains only CR 
I, II, and IV, with I and IV being the most similar to eukaryotic PLD and the CLS/PSS 
bacterial enzymes contain only regions I and IV (Morris et al., 1996). As will be 
discussed below, these HKD enzymes are all believed to share a similar reaction 
mechanism.  
In addition to the PC-hydrolyzing PLDs, several other PLDs have been identified 
and cloned in humans. Glycosylphosphatidylinositol PLD (GPI-PLD), a non-HKD PLD, 
hydrolyses GPIs to produce an inositol glycan and PtdOH and functions primarily to 
release GPI-anchored proteins from membranes (Schofield and Rademacher, 2000). N-
acyl phosphatidylethanolamine PLD (NAPE-PLD) is another non-HKD PLD that 
hydrolyzes NAPE to produce PtdOH and N-acylethanolamine, which is further 
metabolized into anandamide, a ligand for cannabinoid receptors (Okamoto et al., 2004). 
Autotaxin, or lysophospholipase D, is a non-HKD PLD that hydrolyzes 
lysophospholipids, such as lysophospholipase C (LPC) to produce the potent mitogen, 
lysophosphatidic acid (LPA) (Houben and Moolenaar, 2011). In addition to these non-
HKD PLD enzymes, a mitochondrial PLD, mitoPLD or PLD6, was recently cloned and 
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shown to encode one copy of the HKD catalytic sequence (Choi et al., 2006). MitoPLD is 
believed regulate mitochondrial fusion by hydrolyzing mitochondrial cardiolipin (CL) 
instead of PC to produce PtdOH (Choi et al., 2006). Although these non-HKD/non-
canonical PLD mediate important biological events, the remainder of this dissertation will 
focus on the mammalian PLD enzymes.  
 
Structure and mechanism 
Human PLD1 has three known splice variants termed PLD1a, PLD1b (Hammond 
et al., 1997), and PLD1c (Steed et al., 1998). PLD1b is 38 amino acids shorter than 
PLD1a and appears to have similar regulatory and catalytic properties (Hammond et al., 
1997). By contrast, PLD1c contains an early truncation mutation and has been theorized 
to function as an inhibitor of endogenous PLD activity (Steed et al., 1998). Likewise, 
splice variants for PLD2 have been published, but little is known about their functions in 
vivo (Steed et al., 1998). Full-length PLD1 and PLD2 share approximately 50% 
sequence identity and have similar domain structures. As such, PLD1 and PLD2 seem 
to exhibit the same substrate preferences, namely mono- and di-unsaturated PC (Pettitt 
et al., 2001). At their amino termini, PLD1/2 contain tandem phox homology (PX) and 
pleckstrin homology (PH) domains (Steed et al., 1998; Sung et al., 1999b), which are 
known to mediate interactions with lipid membranes (Lemmon, 2008) and are believed 
to regulate PLD localization within the cell (Figure 2). The PX/PH domains were defined 
by predicted secondary structures, as there is little primary sequence similarity to other 
known PX/PH proteins. PLD from lower eukaryotes such as yeast (Rose et al., 1995) 
and plant (Qin and Wang, 2002) also encode PX and PH domains.  These domains are 
not required for catalytic activity as PX/PH truncation mutants are catalytically active in 
vitro (Sung et al., 1999a). Conserved regions I-IV, including the two catalytic HKD 
domains, are C-terminal to the PX/PH domains and vary in length among the different 
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PLD isoforms. The PLD1 isoforms contain a unique “loop” region between CRII and 
CRIII of approximately 120 amino acids in PLD1a; this loop is 38 amino acids shorter in 
PLD1b (Hammond et al., 1997). This function of this loop region is unknown, but it is 
believed to inhibit the enzyme in vivo since deletion of this region results in a more highly 
active protein in vitro (Sung et al., 1999b). The function of the carboxy terminus of the 
protein is also unknown, but any mutations to this end of the enzyme results in a 
catalytically inactive protein, suggesting that this region participates in formation or 
stabilization of the active site (Liu et al., 2001). 
 
 
 
Figure 2. Schematic of human PLD isoforms and splice variants. Human PLDs encode 
amino-terminal PX and PH domains followed by two catalytic “HKD” domains, 
characteristic of the PLD superfamily. PLD1a and PLD1b vary by 38 amino acids in a 
“loop” region between the two HKD domains. The PLD1c splice variant contains an early 
truncation mutation resulting in an inactive protein. Numbers indicate amino acid 
positions. 
 
 Early studies using strategically radiolabeled substrates and intermediates 
suggested that PLD enzymes use a two-step “ping pong” reaction mechanism where a 
covalent phospho-enzyme intermediate is created before release of the product (Jiang et 
al., 1984; Stanacev and Stuhne-Sekalec, 1970). This reaction mechanism was 
supported by structural studies using Yersinia pestis murine toxin (Rudolph et al., 1999) 
and nuc endonuclease (Gottlin et al., 1998), both members of the HKD-containing PLD 
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superfamily. In the first step, a histidine residue from one HKD domain serves as a 
nucleophile to attack the phosphate group of substrate PC to form a phosphatidyl 
histidine. The histidine from the second HKD domain donates protons to the choline 
leaving group to assist in formation of the phosphatidyl histidine. The second histidine 
then abstracts protons from water and the activated water molecule hydrolyzes the 
phosphatidyl histidine intermediate to release PtdOH (Rudolph et al., 1999). In this 
reaction scheme, alcohol is a better nucleophile than water and so 
transphosphatidylation is preferred reaction over hydrolysis in the presence of alcohol. 
Crystal structures of the HKD-containing PLD from Streptomyces (PMF-PLD) and the 
HKD-containing nuc endonuclease (Stuckey and Dixon, 1999) have been solved and 
support these previously established biochemical insights into the molecular 
mechanisms of PLD hydrolase activity. Likewise, crystal structures for PMF-PLD 
demonstrated the two HKD domains situated adjacent to each other along an axis of 
symmetry. Although nuc contains only one HKD domain, it crystallized as a homodimer 
with the two HKD domains similarly situated along an axis of symmetry with the HKD 
domains coming together to form the active site. The crystal structures thus supported 
the mechanism of catalytic histidine residues. The exact functions of the lysines and 
aspartic acids are unknown, but they are believed to stabilize the phosphatidyl histidine 
intermediate as has been reported with similar enzymes such as nucleoside diphosphate 
kinase (Morera et al., 1995). 
 
Localization and tissue distribution 
 The PLD enzymes are ubiquitously expressed and are found in almost all 
mammalian tissues. mRNA analyses demonstrated that PLD1 is highly enriched in 
human heart, brain, pancreas, uterus, and intestine and PLD2 is highly enriched in brain, 
placenta, lung, thymus, prostate, and uterine tissue (Lopez et al., 1998). Early studies 
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into PLD subcellular localization were limited to measurements of PLD enzymatic activity 
following subcellular fractionation (Edwards and Murray, 1995). Molecular cloning 
allowed for characterization of PLD1 and PLD2 subcellular localization through the use 
of fluorescent fusion proteins and isoform-specific antibodies to track endogenous 
protein. Many studies examining PLD subcellular localization have overexpressed PLD1 
or PLD2 and this has led to some controversy over localization of endogenous proteins. 
However, the work of multiple, independent investigators has produced a relatively 
consistent pattern of PLD1 and PLD2 localization. 
 Under resting conditions, PLD1 resides on perinuclear, intracellular membranes 
of secretory vesicles, lysosomes, endosomes, Golgi, and endoplasmic reticulum (Brown 
et al., 1998a; Du et al., 2003; Freyberg et al., 2001)Freyberg 2001, Du 2003, (Colley et 
al., 1997b; Du et al., 2004). On the other hand, PLD1 is basally localized to the plasma 
membrane in neuroendocrine cells such as chromaffin (Vitale et al., 2001) and PC12 
cells (Du et al., 2003), although PC12 cells express very low levels of endogenous PLD1 
(Gibbs and Meier, 2000). IgE stimulation of RBL-2H3 mast cells (Brown 1998) or PMA 
stimulation of fibroblasts (Kim et al., 1999b) and COS-7 cells (Du et al., 2003) results in 
PLD1 relocalization to the plasma membrane suggesting that PLD1 activation might 
require relocalization following extracellular stimulation. As such, mutations that prevent 
post-translational palmitoylation and plasma membrane recruitment reduce PMA 
stimulated PLD1 activity (see “Regulation of PLD”). The varied and dynamic subcellular 
localization patterns of PLD1 correlate with a diverse functional roles.  
 In contrast to PLD1, PLD2 primarily localizes to plasma membranes under basal 
conditions. Studies measuring overexpressed (Colley et al., 1997b; Du et al., 2004; 
O'Luanaigh et al., 2002) and endogenous PLD2 (Du et al., 2004; Park et al., 2000; Sarri 
et al., 2003) support a plasma membrane localization pattern. PLD2 is enriched in 
detergent-insoluble, lipid-raft fractions (Czarny et al., 1999; Zheng and Bollinger Bollag, 
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2003), which contain clusters of cell-surface receptors and other signal transduction 
molecules (Simons and Toomre, 2000). Agonist stimulation typically results in PLD2-
receptor co-localization both at the plasma membrane and in endocytic vesicles and 
PLD2 has been proposed to participate in receptor endocyosis and recycling (Du et al., 
2004). Additionally, stimulation of fibroblasts with serum (Colley et al., 1997b) or mast 
cells with antigen (O'Luanaigh et al., 2002) results in PLD2 relocalization to filopodia and 
membrane ruffles, respectively. Thus, the subcellular localization patterns of PLD2 
suggest functional roles ranging from signal transduction to cytoskeletal reorganization 
(see “Functions of PLD”).  
 
Regulation of PLD 
 
Regulation by lipids 
Phosphoinositides (PI)  
The gold standard in vitro PLD activity assay measures the release of a tritiated 
choline headgroup from an isotopically-labeled PC substrate, typically as part of a 
vesicle containing PC, phosphatidylethanolamine (PE), and phosphatidylinositol 4,5-
bisphosphate (PIP2). The development of this assay required optimization of lipid vesicle 
substrate compositions and PIP2 was absolutely required to detect choline hydrolysis 
from PLD purified from HL-60 membranes (Brown et al., 1993). Recombinant expression 
of mammalian PLD1 (Hammond et al., 1997; Min et al., 1998) and PLD2 (Colley et al., 
1997b; Kodaki and Yamashita, 1997; Lopez et al., 1998) revealed that both enzymes 
require PIP2 for their activity in vitro. Besides PIP2, other phosphatidylinositol species 
can stimulate PLD activity. For example, PI(4,5)P2 and PI(3,4)P2 robustly stimulate 
human PLD1b activity with phosphatidylinositol 3,4,5-trisphosphate (PIP3) able to 
stimulate activity to about half that of the PIP2 species (Hammond et al., 1997; Hodgkin 
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et al., 2000). Similarly, PLD1b displays approximately 2-fold higher binding affinity for 
PIP2 than PIP3. Phosphatidylinositol phosphate (PIP) and PI(3,5)P2 are much less 
effective stimulators of PLD activity and suggests that the position of the phosphates on 
the inositol ring is critical for maximal activity (Hodgkin et al., 2000). For reasons not 
immediately clear, rat PLD1 is stimulated equally by PI(4,5)P2 and PIP3 but not by 
PI(3,4)P2 (Min et al., 1998), suggesting that different species might display some 
selectivity for PIPn species in vivo. 
PIP2 is believed to interact with two distinct sites on PLD; one in the PH domain 
and one between the catalytic domains and each site is believed differentially regulate 
enzyme activity. Multiple groups have shown that the PX and PH domains of PLD1 
(Henage et al., 2006; Sung et al., 1999b) and PLD2 (Sung et al., 1999a) are not required 
for enzyme activity. Since PIP2 is required for PLD activity, investigators reasoned that 
there must be another PIP2 binding site outside of the PH domain. Mutational analysis 
narrowed PIP2 binding to a polybasic region between CRII and CRIII and when arginine 
554 and 558 of PLD2  (corresponding residues are R691 and R695 for human PLD1a) 
were mutated, both the in vitro catalytic activity and PIP2 binding were severely 
compromised (Sciorra et al., 1999). Plant PLDs also require PIP2 and a similar binding 
region was established for plant-PLD1!. Mutation of lysines K437 and K440, also 
between CRII and CRIII ablated PLD! activity in vitro (Zheng et al., 2002). PIP2 binding 
induces a conformational shift in the catalytic domain of plant PLD! that helps recruit PC 
to the active site (Zheng et al., 2002), suggesting that PIP2 binding to the region between 
catalytic domains might influence catalytic activity by promoting PC substrate binding. 
Later studies demonstrated that in the absence of PIP2, PLD was unable to bind PC 
vesicles, further supporting the role of PIP2 in PC binding. 
Although mutation of the PIP2 binding region between CRII and CRIII significantly 
decreases PLD catalytic activity, these mutations do not impact PLD localization as 
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measured by immunofluorescence or subcellular fractionation (Sciorra et al., 1999). PH 
domains are known to bind phosphatidylinositols and regulate subcellular localization 
(Lemmon, 2008). As such, PLD-PH domain binding to PIP2 is a means for regulating 
subcellular localization. Aligning the PH domain from PLD2 with PH domains from other 
proteins revealed several conserved residues believed to mediate PIPn binding. When 
arginine 236 and tryptophan 237 of PLD2 (corresponding residues are R317 and W318 
in PLD1a) were mutated, the resulting protein was catalytically inactive in vivo but 
displayed similar catalytic activity to wild-type protein when PLD2 was 
immunoprecipitated and assayed in vitro (Sciorra et al., 2002). PLD2 resides primarily in 
detergent-insoluble membrane fractions but mutation of R237 and W238 resulted in 
relocalization of PLD2 to detergent-soluble membrane fractions. Mutation of PLD2 also 
resulted in a relocalization from plasma membranes to intracellular localizations (Sciorra 
et al., 2002). Parallel studies with PLD1b also demonstrated mislocalization following 
deletion of the PH domain (Hodgkin et al., 2000). The role of PIP2 in vivo might be to 
recruit PLD to a specific membrane and to enhance catalysis by promoting substrate 
binding to the active site. However, the absolute requirement of PIP2 for PLD activity was 
established in vitro and some debate exists as to the exact nature of PIP2 regulating PLD 
in vivo.  
Several lines of evidence support a role for PIP2 in regulating PLD in vivo. The 
rate-limiting step of PIP2 production is the phosphorylation of PI(4)P by PI(4)P 5-kinase 
(PIP5K) (Ling et al., 1989). When PIP5K was overexpressed in cells to increase levels of 
PIP2, PLD activity also increased, suggesting higher PIP2 levels increase PLD activity in 
intact cells (Divecha et al., 2000).  Modulation of PIP2 levels in the opposite direction 
also influences PLD activity. The antibiotic neomycin has a high affinity for PIP2 and is 
used for cell signaling studies due to its ability to sequester PIP2. As expected, treatment 
of cells with neomycin decreases PLD activity in a manner that is reversed when PIP2 is 
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replenished in the system (Liscovitch et al., 1994). Similarly, synaptojanin, an inositol 
polyphosphate 5-phosphatase capable of dephosphorylating PIP2 (McPherson et al., 
1996), was purified as a cytosolic factor capable of inhibiting PLD activity in vitro (Chung, 
1997). Although the original characterization of PLD inhibition by synaptojanin was 
performed in vitro, synaptojanin might function as a mechanism for terminating PLD 
signaling in vivo. Similarly, the actin and PIP2 binding protein gelsolin inhibits PLD in vitro 
by binding and sequestering PIP2 (Banno et al., 1999). Overexpression of gelsolin also 
inhibits PLD transphosphatidylation activity, further supporting a role for PIP2 regulating 
PLD activity in vivo (Banno et al., 1999).  
These studies create a model where PIs, specifically PIP2, regulate PLD by 
influencing catalysis via an interaction in the PLD catalytic domains and by influencing 
membrane localization via an interaction in the PH domain. Furthermore, PX domains 
are also well-established PI binding domains (Song et al., 2001). The PLD PX domain 
appears to bind PIP3 quite selectively over mono- and di-phosphorylated PIs and 
mutation of PLD1 arginine 179 substantially reduces PIP3 binding (Stahelin et al., 2004). 
Several studies have shown a dependence on PIP3 generation for PLD activation 
following sell surface receptor stimulation. Phosphoinositide 3-kinases (PI3K) produce 
PIP3 by phosphorylating the D3 position of the inositol ring (Cantley 2002) and both PLD 
and PI3K activities are frequently stimulated following receptor tyrosine kinase 
stimulation (see “Cell-surface receptor regulation of PLD”). PI3K inhibitors decrease PLD 
activation following insulin receptor stimulation (Standaert et al., 1996) and mutation of 
the PIP3 binding site on PLD (PLD1-R179) prevents PLD activation and membrane 
recruitment following platelet derived growth factor stimulation (PDGF) (Lee et al., 2005). 
Therefore, membrane recruitment of PLD is precisely regulated by both PIP2 and PIP3 
through interactions with the PH and PX domains, respectively.  
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Fatty acids 
 Purification of various mammalian and plant PLD enzymes revealed activities that were 
stimulated differently by unsaturated fatty acids. Before cloning of the PLD enzymes, a 
PLD was purified from pig lung that was stimulated by unsaturated fatty acids such as 
oleic (18:1), lineoleic (18:2), and arachidonic (20:4) acids (Okamura and Yamashita, 
1994). Several lines of evidence suggest that PLD2 is the isoform stimulated by 
unsaturated fatty acids. PLD activity is highly stimulated by oleate in Jurkat T cells but 
not HL-60 cells (Kasai et al., 1998). mRNA analysis suggests that Jurkat T cells express 
only PLD2 whereas HL-60 cells express PLD1. Likewise, PLD2 is highly enriched in the 
lung (Lopez et al., 1998) where this enzyme was initially purified. Finally, oleate 
stimulates PLD activity in RBL-2H3 mast cells when PLD2, but not PLD1 is 
overexpressed (Sarri et al., 2003). The in vivo relevance of unsaturated fatty acid 
stimulation of PLD2 is not fully understood. 
 
Lipid modifications 
Both PLD1 and PLD2 undergo lipid modification. By feeding tritiated fatty acids to 
cells and then measuring lipid incorporation onto PLD protein, investigators found that 
PLD1 is covalently modified with palmitic acid (Manifava et al., 1999). Later studies 
concluded that cysteine 240 and 241 are the amino acids responsible for attachment 
(Sugars et al., 1999). The exact function of these lipid modifications is not known, but the 
data to date suggest that proper subcellular localization, and not catalytic activity, 
requires these palmitoylation events. In COS-7 cells, PLD1 is normally localized to 
punctate intracellular membranes. However, when the palmitoylated cysteines were 
mutated to alanine, the levels of punctate intracellular PLD1 decreased with a 
concomitant increase in plasma membrane localized protein (Sugars et al., 1999). The 
mutant protein was less active in vivo but showed no differences in activity when 
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compared to wild-type protein in vitro, suggesting that the palmitoylation promotes 
accessibility of substrate lipids to PLD in the cell (Sugars et al., 1999). As discussed 
below, epidermal growth factor (EGF) stimulates PLD activity in a variety of cell lines. 
The cysteine to alanine mutants are much less responsive to EGF stimulation than wild-
type protein, suggesting that palmitoylation is required for cell surface receptor activation 
of PLD1 (Han et al., 2002b). PLD2 is also palmitoylated on C223 and C224 (Xie et al., 
2002a). Similarly to PLD1, mutation of the cysteine residues decreases in vivo activity 
and also results in a smaller fraction of membrane-associated PLD2 (Xie et al., 2002a). 
Therefore, palmitoylation is one of the mechanisms by which PLD is properly localized 
under basal and stimulated conditions. 
 
Phosphorylation 
Serine and theonine phosphorylation 
Many groups have detected phosphorylation of PLD1 and PLD2 at tyrosine, 
serine, and threonine residues, yet the functional significance of these events is not 
always clear and most likely depends on the cell system and stimulus under 
investigation. For example, protein kinase C (PKC) stimulates PLD1 activity through a 
direct protein-protein interaction and not via phosphorylation in fibroblast membranes 
(Conricode et al., 1992). By contrast, PKC" stimulation of PLD in neutrophil membranes 
requires adenosine triphosphate (ATP) and is inhibited by treatment with staurosporine, 
a non-selective protein kinase inhibitor (Lopez et al., 1995), suggesting that PKC" 
phosphorylates PLD directly or phosphorylates an intermediate protein that activates 
PLD. A proteomic analysis revealed that PMA-stimulated PKC phosphorylates S2, T147, 
and S561 on PLD1 (Kim et al., 1999a). When these residues were mutated, the authors 
measured a slight decrease in PMA-stimulated PLD activity in vivo but no changes in in 
vitro activity suggesting that phosphorylation of these residues is not required for 
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catalytic activity (Kim et al., 1999a). Although not required for activity, one study has 
suggested that phosphorylation of S2 is required for association with the actin 
cytoskeleton following cell-surface receptor activation (Farquhar et al., 2007). Similar 
proteomic analyses for PLD2 revealed that phorbol 12-myristate 13-acetate (PMA), a 
PKC activator, stimulation of COS-7 cells increased phosphorylation of S134, S146, 
S243, T72, T99, T100, and T252 and that S243 and T252 were the predominant sites of 
phosphorylation (Chen and Exton, 2005). Mutation of S243 and T252 completely 
inhibited binding of phospho-serine and phospho-threonine antibodies to PMA-
stimulated PLD2, but did not inhibit PMA-stimulated PLD activity (Chen and Exton, 
2005). PMA treatment of COS-7 cells results in rapid increases in both PLD1 (Hu and 
Exton, 2003) and PLD2 (Chen and Exton, 2004) activity. PLD1 (Hu and Exton, 2003) 
and PLD2 (Chen and Exton, 2004) phosphorylation increases only after much longer 
PMA exposure and this correlates to a decrease in PLD activity. The functional 
consequence of PKC phosphorylation of PLD1 and PLD2 is probably to downregulate 
PLD activity in these cells. This hypothesis is substantiated by observations that 
stausporine treatment prolongs PMA-stimulated PLD activity (Hu and Exton, 2003) and 
PKC"/! inhibitors block PLD phosphorylation but not PMA-stimulated PLD activity (Chen 
and Exton, 2004).  
Other lines of evidence suggest that phosphorylation of PLD by PKC might be 
required for cell-surface receptor stimulation of PLD. EGF stimulation of COS-7 cells 
results in a rapid increase in both PLD1 T147 phosphorylation and activity that can be 
ablated by expression of dominant-negative (DN) PKC" or by mutating the PKC 
phosphorylation sites of PLD1 (Han et al., 2002b). The discrepancies between the 
functional consequences of PMA- and EGF-stimulated PLD phosphorylation might be 
explained by differences in PKC isoforms being activated under each condition. For 
example, PMA activates many PKC isoforms and EGF might only activate PKC isoforms 
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that positively regulate PLD activity, such as PKC". In support of this hypothesis, PKC# 
is believed to negatively regulate PLD1 activity in COS-7 cells (Han et al., 2002b). By 
contrast, PKC# is believed to mediate the PMA-activation of PLD2 in PC12 cells (Han et 
al., 2002a) and integrin-stimulated PLD2 activation in COS-7 cells requires 
phosphorylation of S566 by PKC# (Chae et al., 2010). Therefore, the functional role of 
PKC phosphorylation of PLD1 and PLD2 largely depends on the cell background, 
stimulus, and PKC isoform under investigation. 
 In addition to PKC, other serine/threonine kinases are known to regulate 
downstream PLD functions by phosphorylation-dependent mechanisms. For example, 
the p90 ribosomal S6 kinase phosphorylates PLD1 at T147 and this phosphorylation 
event is required for K+ stimulated PLD activity and exocytosis in PC12 neuroendocrine 
cells (Zeniou-Meyer et al., 2008). Additionally, AMP-activated protein kinase (AMPK) 
phosphorylates PLD1 at S505 (Kim et al., 2010). Glucose withdrawal stimulates AMPK 
and PLD activity and the phosphorylation of S505 by AMPK is required for glucose-
stimulated PLD activity in vivo. Mutation of S505 has no effects on basal PLD activity 
suggesting that the phosphorylation is required for catalytic activity (Kim et al., 2010). 
Likewise, PLD2 regulates insulin secretion following EGF stimulation in rat insulinoma 
cells via a mechanism that requires cyclin dependent kinase 5 (Cdk5) phosphorylation of 
PLD2 S134 (Lee et al., 2008). Mutation of S134 to alanine partially decreases EGF 
stimulated PLD2 activity, but does not inhibit basal PLD2 activity (Lee et al., 2008). 
Casein Kinase II (CKII) is found in complex with both PLD1 (Ganley et al., 2001) and 
PLD2 (Ahn et al, 2006) and phosphorylates both isozymes. The exact function of the 
CKII phosphorylation events is unknown, but PLD catalytic activity is unaffected. 
Together, these studies suggest that phosphorylation of PLD most likely functions to 
alter PLD subcellular localization and availability to substrate since basal activity in vivo 
and PLD activity in vitro is not sensitive to mutation of phosphorylation sites. 
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Tyrosine phosphorylation  
Tyrosine phosphorylation as a mechanism of PLD regulation was first proposed 
after the observation that vanadate, a tyrosine phosphatase inhibitor, increased PLD 
activity in HL-60 granulocytes (Bourgoin and Grinstein, 1992). In later studies, PLD was 
shown to be tyrosine phosphorylated as measured by immunoprecipitation (IP) of PLD 
and immunoblotting with a phospho-tyrosine antibody (Gomez-Cambronero, 1995). 
Stimulation of the G-protein coupled receptor (GPCR) for the chemotactic peptide fMLP 
in neutrophils increased PLD activity and tyrosine phosphorylation in a manner that was 
inhibited by general tyrosine kinase inhibitors, suggesting that tyrosine phosphorylation 
directly regulates PLD activity (Gomez-Cambronero, 1995). These studies, however, did 
not discriminate between direct activation of PLD by tyrosine phosphorylation and 
activation of PLD by upstream regulatory proteins. Later studies indicated that tyrosine 
phosphorylation of PLD2 influences catalytic activity to some extent since 
dephosphorylation of immunoprecipitated PLD2 with purified tyrosine phosphatases can 
decrease (Henkels et al., 2009) or increase (Horn et al., 2005) catalytic activity in vitro, 
suggesting that the two phosphatases used in these studies are dephosphorylating 
distinct tyrosine residues. 
EGF stimulation results in tyrosine phosphorylation of PLD2 (Min et al., 2001) at 
Y11 (Slaaby et al., 1998) and Y296 (Henkels et al., 2010), presumably through EGF 
receptor-mediated phosphorylation of PLD2, although the possibility of an intermediate 
kinase was not completely eliminated. When Y11 was mutated to alanine, the authors 
measured a 2-fold increase in EGF-stimulated PLD activity, suggesting that 
phosphorylation of Y11 functions to down-regulate the PLD2 response (Slaaby et al., 
1998). Likewise, mutation of Y296 to phenylalanine also increased in vivo PLD2 activity 
(Henkels et al., 2010), suggesting that like Y11, Y296 also functions to downregulate 
PLD2 activity. Other tyrosine kinases such as JAK3 and Src have been reported to 
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phosphorylate PLD2 at Y415 and Y511, respectively (Henkels et al., 2010). In this study, 
purified JAK3 or Src was incubated with cell lysate and PLD2 was immunoprecipitated to 
determine which tyrosine sites were phosphorylated. The authors did not address the 
possibility that JAK3 or Src might be activating an intermediate kinase that could 
phosphorylate PLD2 and so caution must be exercised when interpreting these results. 
Regardless, the authors suggested that phosphorylation of Y415 stimulates PLD activity 
whereas phosphorylation of Y511 is inhibitory (Henkels et al., 2010). These studies 
suggest that the level of PLD2 activity between various cell lines might result from 
different ratios of tyrosine phosphorylation on both activating and inhibitory residues. 
Besides modulating catalytic activity, tyrosine phosphorylation is known to 
regulate PLD2-protein interactions. As discussed below, PLD2 couples EGF stimulation 
to activation of the small G-protein Ras by binding the adaptor protein Grb2 and 
activating son of sevenless (Sos), a guanine nucleotide exchange factor (GEF) for Ras. 
Grb2 interacts with PLD2 at Y169 and mutation of nearby tyrosine Y179 to 
phenylalanine increases the interaction of Grb2 with Y169 and enhances activation of 
Ras signaling pathways (Di Fulvio et al., 2006). The interaction of Grb2 with Y169 
increases PLD2 catalytic activity and mutation of Y169 to phenylalanine results in a 
catalytically inactive protein (Di Fulvio et al., 2006). Furthermore, Akt kinase was 
suggested to phosphorylate threonine 175 of PLD2 (Di Fulvio et al., 2008). The authors 
used a relatively non-specific Akt-kinase substrate antibody to probe IP’ed PLD2 instead 
of using purified, recombinant Akt kinase. Regardless, mutation of T175 to alanine 
inhibited the Y179F mutant from stimulating Ras, suggesting that T175 and Y179 
function to fine-tune Ras signaling through PLD2 (Di Fulvio et al., 2008). 
As tyrosine kinases are frequently upregulated in cancer, discovering precise 
molecular targets of tyrosine kinases further enhance understanding of cancer biology. A 
recent proteomic study examined changes in global phospho-tyrosine residues in cells 
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overexpressing the constitutively active and transforming nucleophosmin-anaplastic 
lymphoma kinase (NPM-ALK). PLD1 and PLD2 had increased phosphorylation at Y711 
and Y573, respectively, in cells overexpressing NPM-ALK (Wu et al., 2010). Future 
studies will be required to determine the functional significance of these and other novel 
phosphorylation events on PLD.  
 
Protein activators of PLD 
PKC  
Phorbol esters such as PMA potently stimulate PLD activity in many cell lines 
and tissues (Exton, 1999). These compounds function as diacylglycerol (DAG) mimetics 
and potently stimulate the conventional (DAG and Ca2+ responsive; ", !1, !"#! $$! and 
novel (DAG responsive; #, %,!&, ') PKC isoforms (Nishizuka, 1984), thus suggesting that 
PMA stimulates PLD through a PKC-dependent mechanism. In early studies linking 
PMA, PKC, and PLD, investigators separated fibroblast membranes, containing PLD, 
from cytosol, containing PKC, and showed that PMA did not stimulate membrane PLD 
activity unless purified PKC was included in the reaction (Conricode et al., 1992). In the 
same study, PKC was shown to stimulate PLD activity in a kinase-independent manner. 
Additionally, PKC stimulation of PLD was potentiated by PMA, leading to the hypothesis 
that activated PKC stimulates PLD through a protein-protein interaction, independent of 
kinase activity. Multiple groups confirmed a direct interaction using purified proteins (Lee 
et al., 1997b) and by co-immunoprecipitation (co-IP) of PLD and PKC from cell lysates 
(Siddiqi et al., 2000). Interestingly, the interaction is enhanced following PMA 
stimulation, suggesting that activated PKC is a better stimulator of PLD than non-
activated PKC. The requirement for activated PKC suggests that cell surface receptors 
might stimulate PLD through a PKC-dependent mechanism and many reports have 
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indeed demonstrated a requirement for PKC in PLD activation following receptor 
stimulation (see “Cell-surface receptor regulation of PLD”). 
The conventional PKC isoforms, namely ", !1, and !2, but not PKC#, stimulate 
PLD from fibroblast and HL-60 membranes (Conricode et al., 1994; Ohguchi et al., 
1996) and purified PLD from heterologous expression systems (Min et al., 1998). 
Purified conventional PKC stimulates PLD1a and PLD1b indistinguishably in vitro 
(Hammond et al., 1997) whereas PLD2 is unresponsive to PKC stimulation (Colley et al., 
1997b). The interaction between PKC and PLD1 is complex as several lines of evidence 
suggest that at least two sites on PLD1 mediate the interaction with PKC. Expression of 
a PLD1 deletion mutant lacking the first 325 amino acids results in a construct that is 
catalytically active, but unresponsive to PMA stimulation, which suggests that PKC 
stimulates PLD activity through an interaction with the N-terminus (Sung et al., 1999b). 
However, the N-terminally truncated PLD1 still co-IPs with PKC, suggesting another site 
of interaction somewhere in the C-terminus (Sung et al., 1999b). The N-terminal binding 
site was narrowed to a region between amino acids 50-115 (Park et al., 1998; Zhang et 
al., 1999) and the C-terminal binding region on PLD1 was determined to be between 
amino acids 325-582 (Park et al., 1998).   
The mechanism by which PKC stimulates PLD1 activity is also complex and 
requires interaction with both the N- and C-terminal interaction sites. A detailed kinetic 
analysis of the activation of PLD1 by PKC revealed that PKC is a mixed activator of 
PLD1. PKC increases substrate binding (decrease in Km value) and also increases 
catalytic activity (increased kcat value). An N-terminally truncated PLD1 lacking the first 
311 amino acids was much less responsive to PKC stimulation than full-length PLD1 
protein in vitro. The kinetic analysis suggested PKC still increased kcat of the N-terminally 
truncated protein but had no effect on substrate binding (Henage et al., 2006). Thus, 
PKC modulates individual kinetic parameters through distinct interactions on PLD1. The 
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unique kinetic properties of PKC explain how other activators of PLD, such as the small 
GTPase Arf, synergize with PKC to robustly stimulate PLD1 activity (Singer et al., 1996). 
Although PMA and PKC stimulate PLD1 activity in vitro through a direct protein-
protein interaction, the regulation of PLD by PKC in vivo is more complex. As discussed 
above, PKC phosphorylates both PLD1 and PLD2 and these phosphorylation events are 
generally believed to inhibit PLD activity and may function to terminate PLD signaling 
after cell-surface receptor activation. Additionally, PMA stimulation can also increase 
PLD2 activity in vivo (Colley et al., 1997b; Han et al., 2002a; Siddiqi et al., 2000), 
although the fold-stimulation of PLD2 by PMA is much less than the fold-stimulation of 
PLD1. Given the wide range of PKC effectors, PMA-stimulation of PLD2 may be 
explained by other intermediate proteins instead of a direct protein-protein interaction. In 
certain cells such as PC12 cells, PLD2 stimulation by PMA appears to require the 
activity of PKC# as a dominant-negative PKC# construct inhibits PMA-induced PLD2 
activation (Han et al., 2002a). Since purified PKC# did not stimulate PLD1 (Conricode et 
al., 1994), more evidence is needed to determine whether PKC# stimulates PLD2 
directly or through an intermediate protein. In addition to PKC#, PKC% was also shown to 
regulate PLD2 activation following sphingosine 1-phosphate (S1P) stimulation in lung 
epithelial cells (Gorshkova et al., 2008). A direct protein-protein interaction was not 
measured and an intermediate protein is likely mediating the effects of PKC% on PLD2. 
 
Arf  
The ADP-ribosylation factor (Arf) proteins are small molecular weight (Mr=21kDa) 
GTPases first identified as the factors needed for ADP ribosylation of the G"s 
heterotrimeric G-protein by cholera toxin (Kahn and Gilman, 1984). Arfs have since been 
implicated in a variety of cellular events but are predominantly involved in vesicle 
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formation and trafficking along with the cytoskeletal and membrane rearrangements that 
accompany these events (Moss and Vaughan, 1998). Arf was originally identified as a 
cytosolic factor capable of stimulating PLD activity in HL-60 cell membranes. In those 
experiments, the addition of cytosol and a non-hydrolysable GTP analog (GTP$S) to HL-
60 cell membranes robustly stimulated PLD activity. The observation that GTP$S was 
required for this stimulatory activity strongly implicated a GTPase as the activating 
factor. The factor was purified, sequenced, and identified as Arf1/3 (Brown et al., 1993; 
Cockcroft et al., 1994). There are 6 known Arf family members in humans, Arf 1-6, and 
are divided into three classes based on size, sequence, and gene structure; class I 
(Arf1-3), class II (Arf 4-5), and class III (Arf 6) (Moss and Vaughan, 1993). All six Arf 
proteins are capable of directly stimulating PLD activity, although with varying 
efficiencies (Massenburg et al., 1994). Arf proteins also stimulate PLD activity indirectly 
by stimulating PIP5K activity to increase local PIP2 levels (Honda et al., 1999). The Arf-
stimulated increase in PIP2 and PtdOH levels through PIP5K and PLD, respectively, 
might function to terminate Arf signaling as the GAP activities of several ARF-GAPS are 
synergistically stimulated by PIP2 and PtdOH (see “Function of phosphatidic acid”). 
Prior to cloning PLD1 and PLD2, chromatographic separation of PLD activities 
from rat brain revealed two distinct PLD activities where one activity was stimulated by 
Arf and the other by oleate, most likely PLD1 and PLD2, respectively (Massenburg et al., 
1994). In vitro studies using purified proteins later showed that Arf1 and Arf3 are capable 
of stimulating PLD1a and PLD1b between 10-40 fold compared to unstimulated PLD1 
(Hammond et al., 1997; Lopez et al., 1998; Min et al., 1998). PLD2 is either completely 
unresponsive (Colley et al., 1997b) or modestly responsive (approximately 2-fold) 
(Lopez et al., 1998; Sung et al., 1999a), suggesting that Arfs 1 and 3 stimulate PLD1 
specifically. However, as discussed in later sections, Arfs 4 and 6 have been implicated 
in regulating PLD2 activity in vivo (Caumont et al., 1998; Kim et al., 2003b). The sites of 
 22!
Arf-interaction on PLD have not been determined conclusively, although the amino 
terminus of PLD1 is dispensable for Arf stimulation and kinetic analyses of an N-terminal 
deletion mutation revealed that Arf was a catalytic activator of PLD (Henage et al., 2006; 
Sung et al., 1999b). Interestingly, when the amino terminus of PLD2 is deleted, Arf-
stimulates PLD activity nearly as much as PLD1 (Sung et al., 1999a). This suggests that 
sequestration of the PLD2 N-terminus, by lipid or protein binding or by post-translational 
modification, might free an Arf binding site that is otherwise sterically hindered on PLD2. 
As an example, the GM2 ganglioside activating protein binds PLD1 and PLD2 and 
significantly enhances the responsiveness to Arf (Nakamura et al., 1998; Sarkar et al., 
2001). Likewise, proteins such as Arfaptin, which bind and sequester Arf (Tsai et al., 
1998), inhibit PLD activity and emphasize the importance of Arf for regulating PLD 
activity.  
Although the Arf-interaction site has not been determined for PLD, several 
groups have screened Arf mutants that still bind GTP and downstream effectors but do 
not stimulate PLD activity. Deletion of the first 17 amino acids of Arf1 or mutation of 
asparagine 52 to arginine in the switch I region renders the protein unable to stimulate 
PLD (Jones et al., 1999; Liang et al., 1997). The analogous asparagine mutation in Arf6 
(N48R) also inhibits PLD stimulation (Jovanovic et al., 2006) and these mutants have 
been used to discriminate PLD dependent and independent functions of Arf.   
 
Rho 
Rho family members were originally cloned from marine snails as homologues of 
Ras GTPases that shared approximately 35% sequence identity (Madaule and Axel, 
1985). Today, over 20 Rho family members have been identified and the best 
characterized family members include RhoA, Rac1, and Cdc42 (Heasman and Ridley, 
2008). Rho proteins are frequently activated following receptor stimulation and control 
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cytoskeletal dynamics such as formation of stress fibers, lamellipodia, and filopodia 
along with controlling membrane ruffling and cell polarity. Rho proteins have also been 
shown to regulate transcription of certain genes and promote cell proliferation, which 
underscores the importance of Rho proteins in cancer (Ellenbroek and Collard, 2007). 
Like other GTPases, Rho proteins are regulated by GEFs and GTPase-activating 
proteins (GAPs). However, Rho proteins are uniquely controlled by guanine nucleotide 
dissociation inhibitors (GDIs), which promote the inactive, GDP bound state, and prevent 
Rho-membrane association by sequestering their lipid moieties (Ellenbroek and Collard, 
2007).   
For some time, it was known that the combination of cytosol and non-
hydrolyzable guanosine triphosphate (GTP) analogs such as GTP$S, stimulated PLD 
activity from human neutrophil membranes, implicating the participation of small 
molecular weight GTPases (Olson et al., 1991). By including GEFs and GDIs specific for 
Rho proteins in the neutrophil membrane PLD assay, investigators measured stimulation 
and inhibition, respectively of cytosol and GTP$S-stimulated PLD activity (Bowman et al., 
1993; Kwak et al., 1995; Siddiqi et al., 1995). Although these experiments strongly 
suggested that the Rho family of GTPases mediated the cytosol-GTP$S stimulation of 
PLD activity in neutrophils, later studies with rat liver membranes confirmed the 
involvement of RhoA. Treatment with RhoGDI resulted in the loss of membrane-bound 
Rho and inhibition of the cytosol-GTP$S stimulation of rat liver PLD. Reconstitution with 
recombinant RhoA fully restored the PLD response following treatment with RhoGDI 
confirming that Rho proteins stimulate PLD activity (Malcolm et al., 1994). Additional, 
independent studies identified the stimulating factor as Rho due to sensitivity of PLD 
activity to the C3 toxin from Clostridium botulinum, which mediates the ADP-ribosylation 
of Rho proteins (Kuribara et al., 1995). In these studies, other Rho proteins such as 
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Rac1 and Cdc42 were partially able to rescue PLD activity following RhoA depletion or 
inactivation. Rho proteins were also identified as cytosolic factors capable of stimulating 
PLD activity from porcine brain (Brown et al., 1995; Singer et al., 1995).  
Later studies using purified PLD1a and PLD1b demonstrated a direct stimulation 
of PLD1a and PLD1b activity by RhoA and associated family members Rac1 and Cdc42 
(Hammond et al., 1997; Min et al., 1998; Walker and Brown, 2002) where RhoA 
stimulates PLD activity more than other family members. By contrast, PLD2 is relatively 
unresponsive to Rho family members (Colley et al., 1997b; Lopez et al., 1998; Sung et 
al., 1999a). Mutational analysis has mapped Rho-interaction site on PLD1 to the C-
terminus (Sung, 1997; Yamazaki et al., 1999) and mutation of several non-conserved 
residues, K946A, V950A, R955A and K962A, inhibit RhoA binding and stimulation of 
PLD1 activity, potentially explaining the specificity for PLD1 versus PLD2 (Cai and 
Exton, 2001). Additionally, PKC, Arf, and RhoA are believed to bind distinct sites on 
PLD1 and modulate different kinetic parameters. Rho family members are thought to 
function primarily as binding activators and enhance substrate binding (Henage et al., 
2006). As such, PKC, Arf, and Rho synergistically activate PLD1 in vitro (Hammond et 
al., 1997; Ohguchi et al., 1996) and most likely converge on PLD1 to precisely regulate 
activity in vivo. The mechanism by which Rho activates PLD in vivo is complicated by 
observation that Rho also stimulates PIP5K activity to increase PIP2 levels (Chong et al., 
1994). In fact, some studies suggest that the decrease in PLD activity following removal 
of Rho proteins might be due to a decrease in PIP2 as the addition of PIP2 is able to fully 
restore PLD activity in some circumstances (Schmidt et al., 1996). Thus, the role of Rho 
proteins in vivo might be to stimulate PIP2 synthesis via an interaction with PIP5K and 
then to increase PLD substrate binding and subsequent activity as seen in vitro. 
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Ras and Ral 
In addition to Arf and Rho, other small GTPases regulate PLD activity. Early 
investigations into the mechanisms of cellular transformation demonstrated that PLD 
activity was elevated in v-Ras and v-Src transformed fibroblasts compared to non-
transformed cells (Carnero et al., 1994; Song et al., 1991). Maximal PLD activity in v-Src 
transformed fibroblasts required both cytosol and GTP$S and depletion of Ras from 
cytosol significantly decreased PLD activity, suggesting that Ras was required for the v-
Src induced increase in PLD activity (Jiang et al., 1995a). Activated Ras has many 
downstream effectors including the guanine nucleotide dissociation stimulator for RalA, 
Ral-GDS (Hofer et al., 1994; Spaargaren and Bischoff, 1994). As such, later studies 
demonstrated that RalA was required for the v-Src induced increase in PLD activity 
since PLD formed a complex with RalA, but not Ras (Jiang et al., 1995b). The 
stimulatory properties of RalA are not direct, however, and experiments with purified 
proteins demonstrated that RalA does not directly stimulate PLD activity (Kim et al., 
1998). However, RalA potentiates the stimulation of PLD1 by Arf proteins in vitro and Arf 
was found in a ternary complex with PLD1 and RalA when IP’ed from cell lysates (Kim et 
al., 1998). Indeed, inhibition of Arf GEFs in v-Src-transformed fibroblasts reduces PLD 
activity and suggests that Art is a key mediator of the v-Src-Ras-RalA-PLD 
transformation pathway (see “Functions of PLD in cancer”) 
 
Rheb 
 Regulation of the mammalian target of rapamycin (mTOR) pathways is complex 
and involves input signals from many sources. As discussed in the “Functions of PLD in 
cancer” section, PLD and PtdOH positively regulate mTOR (Fang et al., 2001). Rheb, a 
small Ras-like GTPase, also positively regulates mTOR activity through a mechanism 
that was thought to involve direct binding of Rheb to the mTOR complex (Long et al., 
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2005). Rheb co-IPs with PLD1 from cell lysate and stimulates PLD1 activity in vitro (Sun 
et al., 2008) and the investigators proposed that Rheb positively regulates mTOR by 
regulating PLD1 activity. These in vitro experiments used IP’ed PLD1 from human cell 
lysate and bacterially expressed Rheb to demonstrate the regulation of PLD1 by Rheb. 
Follow up studies with highly purified PLD1 from insect cells did not reproduce the 
findings of the original paper suggesting that the regulation of PLD1 by Rheb likely 
involves an intermediate protein (unpublished data, Brown lab). Rheb is negatively 
regulated by the GAP activity of the tuberous sclerosis 2 protein (TSC2), a component of 
the tuberous sclerosis complex (Manning and Cantley, 2003). Cells deficient in TSC2 
show higher PLD and mTOR activity (Sun et al., 2008; unpublished data), consistent 
with the idea of Rheb positively regulating mTOR through PLD.  
 
Non G-protein/PKC regulators of PLD 
 Although PKC and small G-proteins appear to be the major regulators of PLD1 
activity, a small number of additional PLD-stimulating factors have been identified 
although their role in the regulation of PLD is far less studied. 
 PKN. The protein kinase N (PKN) family of kinases are structurally related to 
PKC, yet are calcium-independent and not activated by phorbol esters (Morrice et al., 
1994). These kinases are ubiquitously expressed (Kitagawa et al., 1995) and share 
many of the same intracellular locations as PLD1 (Kawamata et al., 1998). PKN is 
activated by GTP-bound RhoA and participates in cytoskeleton dynamics, cell migration, 
and tumor invasion (Watanabe et al., 1996). PKN directly stimulates PLD1 activity by 
binding to a region between amino acids 228 and 598 (Oishi, 2001). In addition, PtdOH, 
CL, and fatty acids are potent activators of PKN in vitro (Khan et al., 1994; Morrice et al., 
1994). The activation of PKN and PLD by Rho and subsequent activation of PKN by 
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PtdOH presents an interesting positive feedback loop that likely explains some of the 
roles for PLD in regulating processes such as cytoskeleton rearrangement. 
Cofilin. Cofilin proteins sever filamentous actin to generate free actin, an 
important process for cytoskeleton rearrangement (DesMarais et al., 2005). The activity 
of cofilin is regulated through a phosphorylation dependent mechanism where 
phosphorylation by LIM kinases results in cofilin inactivation and a reduction in actin 
severing resulting in actin polymerization. Rho and Rac/Cdc42 activate LIM kinases 
through Rho kinase and p21-activated protein kinase (PAK), respectively (Edwards and 
Gill, 1999; Kaibuchi et al., 1999; Sells and Chernoff, 1997). Phosphorylated cofilin 
stimulates PLD1 activity by directly binding to a region between the loop and CRIII (Han 
et al., 2007). The activation of PLD1 by phospho-cofilin underscores the importance of 
PLD1 in regulating cytoskeletal dynamics since Rho, Rac, and Cdc42 can directly bind 
and stimulate PLD1 and also indirectly activate PLD1 through a LIM kinase-cofilin 
pathway. 
CtBP1. The C-terminal binding protein 1 (CtBP1) is a dual function protein that 
regulates gene transcription in the nucleus and also mediates membrane fission during 
intracellular trafficking events (Corda et al., 2006). CtBP1 specifically co-localizes with 
PLD1 following cell stimulation either with serum or EGF and purified CtBP1 was shown 
to stimulate PLD1 activity in an in vitro activity assay using purified proteins (Haga et al., 
2009). Interestingly, CtBP1 stimulated PLD1 activity in an additive fashion with Arf and 
RhoA, suggesting that CtBP1 binds a distinct site on PLD1. Although further research is 
necessary, the membrane fission functions of CtBP1 might be mediated through PLD 
and PtdOH. 
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PLD inhibitory proteins 
Most cells exhibit low basal PLD activity until stimulated by extracellular agonists 
or cellular stress (Zheng et al., 2006; Chapter III). In vivo, this stimulation most likely 
results from activation of stimulatory proteins and also inactivation of inhibitory proteins. 
As such, a number of PLD inhibitory factors have been purified over the years and a 
surprising number fall into the category of actin binding proteins or proteins involved with 
vesicular trafficking.  
 
Synaptic vesicle proteins 
 Munc-18-1 is a syntaxin binding protein enriched in neurons and plays a critical 
role in synaptic vesicle exocytosis (Harrison et al., 1994; Wu et al., 1998). Munc-18-1 
interacts directly with the PX domain of PLD1 and PLD2 and inhibits PLD activity in vitro. 
When overexpressed in cells, Munc-18-1 and PLD both co-localize and co-IP under 
basal conditions, but dissociate once stimulated with EGF when Munc-18-1 relocalizes 
from plasma membranes to the cytosol and no longer inhibits PLD activity (Lee et al., 
2004). Therefore, cell-surface receptors may activate PLD by dissociating the Munc-18-
1-PLD complex. In addition to Munc-18-1, clathrin assembly protein 3 (AP3) is another 
example of a trafficking protein known to regulate PLD activity. AP3 binds to clathrin 
triskelia and promotes assembly of clathrin-coated vesicles, which are dynamic 
organelles that participate in intracellular membrane trafficking (Ahle and Ungewickell, 
1986; Prasad and Lippoldt, 1988) including recycling of synaptic vesicles. Like Munc-18-
1, AP3 is highly enriched in neuronal tissue (Ahle and Ungewickell, 1990; Keen, 1990) 
and was purified as a factor from rat brain cytosol capable of inhibiting purified PLD1 
activity in vitro (Lee et al., 1997a). Even though AP3 is known to bind PIP2 (Norris et al., 
1995; Ye and Lafer, 1995), AP3 appears to bind and inhibit PLD1 in a PIP2 dependent 
manner, suggesting a direct inhibition of PLD1 activity (Lee et al., 1997a). Like AP3, 
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amphiphysins are nerve terminal proteins that participate in clathrin-mediated synaptic 
vesicle endocytosis. Amphiphysins are believed to function in concert with dynamin to 
promote vesicle budding (Wigge and McMahon, 1998). As with AP3, amphiphysin I and 
II were purified from rat brain cytosol as factors capable of inhibiting purified PLD1 and 
PLD2 activity in vitro and inhibit PMA-stimulated PLD activity when overexpressed in 
cells (Lee et al., 2000). Although the exact physiological relevance of PLD inhibition by 
these synaptic vesicle proteins is unknown, they most likely function to terminate PtdOH 
generation during the early stages of vesicle formation. 
 
Actin binding proteins  
The role of PLD and PtdOH in regulating cytoskeletal dynamics is complicated 
and likely involves many upstream and downstream regulators. A number of actin 
binding proteins, and actin itself, have been identified as inhibitors of PLD activity. 
Stimulation of cytosol with GTP$S results in the association of PLD with detergent 
insoluble fractions, which are highly enriched in actin and actin-binding proteins 
(Hodgkin et al., 1999; Iyer and Kusner, 1999). Actin exists in either monomeric (G-actin) 
or filamentous (F-actin) forms and both have been shown to bind PLD in vitro (Kusner et 
al., 2002). Monomeric G-actin stimulates PLD activity whereas F-actin inhibits PLD 
activity (Kusner et al., 2002; Lee, 2001). The site of interaction between actin and PLD2 
was mapped to a region between CRIII and CRIV for PLD2 (Lee, 2001). Additionally, 
actin binding proteins such as fodrin (Lukowski et al., 1996), spectrin (Lukowski et al., 
1998), "-actinin, and gelsolin (Banno et al., 1999) have also been shown to directly 
inhibit PLD activity. These actin-binding proteins connect microfilaments to give the 
cytoskeleton its characteristic shape. The exact physiological function of PLD inhibition 
by F-actin and actin binding proteins is not known, but the several lines of evidence 
suggest that PLD activity promotes the early stages of actin polymerization. First, 
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inactive-cofilin promotes actin polymerization and PLD activity. Second, monomeric actin 
stimulates PLD activity whereas filamentous actin inhibits PLD activity. Finally, 
interactions with proteins that hold the established actin cytoskeleton together inhibit 
PLD activity. Along with PLD activation by Rho family members, these data strongly 
implicate a role for PLD in cytoskeletal remodeling. 
 
Miscellaneous PLD inhibitors 
In addition to the vesicular and actin-associated PLD inhibitors, several proteins 
have been identified as PLD inhibitors that do not fit into broad categories. Aldolase is a 
glycolytic enzyme that mediates the reversible cleavage of fructose 1,6-bisphosphate 
into dihydroxyacetone phosphate and glyceraldehyde 3-phosphate. Aldolase was 
identified as a cytosolic factor that directly inhibits PLD2. Mutational analysis narrowed 
the site of interaction to the PH domain of PLD2 (Kim et al., 2002). The physiological 
function of the aldolase-PLD2 interaction is unknown, but this interaction might 
contribute to the role of PLD in regulating cellular bioenergetics (Chapter II). Another 
protein known to inhibit PLD is the G!$ subunit from heterotrimeric G-proteins. GPCR 
stimulation results in dissociation of G!$ from G" and G!$ regulates downstream 
effector molecules containing PH domains such as GPCR kinases (GRKs) (Carman et 
al., 2000) and PLC! (Wang et al., 2000). Recombinant G!$ inhibits PLD1 or PLD2 
activity in vitro, presumably through an interaction with PH domain since an N-terminal 
PLD truncation mutant was resistant to G!$ inhibition (Preininger et al., 2006). Thus, G!$ 
inhibition of PLD serves as one of the ways PLD signaling is terminated following GPCR 
stimulation.    
Finally, two neuronal proteins have been identified as PLD2 inhibitors. The first 
protein, "-synuclein, is a small, highly conserved protein of unknown function that is 
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highly enriched in the brain presynaptic terminals. "-synuclein is a major component of 
Lewy bodies and Lewy neuritis, which are neuropathological hallmarks of familial and 
sporadic Parkinson’s disease (Spillantini et al., 1997). "-synuclein was purified as a 
factor capable of inhibiting purified PLD2 activity in vitro (Jenco et al., 1998). This 
observation was later hypothesized as a mechanism by which neurons are protected 
from the toxicity associated with elevated PLD activity (Gorbatyuk et al., 2010). In these 
studies, PLD2 was purified by an immunoaffinity technique and no gels of purity were 
shown. A Later study with highly purified PLD2 was unable to replicate the original 
findings (Rappley et al., 2009), suggesting the presence of an intermediate protein in the 
original paper. Regardless of the interaction between "-synuclein and PLD2, no 
associations have been made in vivo to support a role for PLD2 in the pathophysiology 
of "-synuclein (Ahn et al, 2002). Therefore, the relevance and nature of this interaction is 
still a matter for investigation. The second neuronal protein capable of directly inhibiting 
PLD2 is collapsin response mediator protein-2 (CRMP-2). CRMP-2 is a critical 
component of neuron outgrowth during development and is believed to participate in 
early stages of Alzheimer’s disease (Hensley et al., 2011). Like "-synuclein, CRMP-2 
was purified as a cytosolic brain factor capable of inhibiting purified PLD2 in vitro and is 
believed to directly inhibit activity by binding to the N-terminus (Lee et al., 2002). Future 
studies will no doubt shed light on the role of PLD2 pathologies such as Alzheimer’s 
disease. A table of PLD regulatory proteins is presented below (Table 1). 
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Table 1. PLD regulatory proteins 
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Cell-surface receptor regulation of PLD 
 
Receptor Tyrosine Kinases 
Ligand binding to cell surface receptors is known to stimulate PLD activity in 
many cell lines and tissues. EGF stimulates PLD activity (Fisher et al., 1991) and this 
pathway has been used as a model system for characterizing the intermediate signaling 
events between receptor tyrosine kinases (RTK) and PLD over the past 25 years. EGF 
binding to the EGFR results in receptor dimerization and autophosphorylation of several 
tyrosine residues within the cytoplasmic tails via an intrinsic kinase activity (Schlessinger 
and Ullrich, 1992). These phosphorylated tyrosine residues create high affinity binding 
sites for proteins containing Src-homology 2 (SH2) domains such as PLC-$1, Grb2, the 
p85 subunit of PI3K, Src, SHP-2, and Bruton’s tyrosine kinase, which mediate a variety 
of signaling events including those that regulate DNA synthesis, cell division and 
proliferation, cytoskeletal rearrangements, and a variety of other biological functions 
(Yaffe, 2002). As such, several mechanisms of PLD activation by EGF have been 
described. 
Early studies of PC hydrolysis or phosphatidyl alcohol production following EGF 
stimulation in intact tells did not discriminate between PLD1 and PLD2 activation, 
although later studies have shown that both isoforms couple to EGFR (Slaaby et al., 
1998).  The most-studied EGFR-PLD signaling pathway begins with activation of PLC-$1 
by binding to activated EGFR via its SH2 domain (Anderson et al., 1990; Margolis et al., 
1990). Activation of PLC-$1 results in the rapid hydrolysis of PIP2 into inositol 
triphosphate (IP3) and DAG. IP3 increases intracellular calcium levels, which together 
with DAG, activates PKC (Rana and Hokin, 1990). As discussed in the “Regulation of 
PLD” section, PKC is a well-established activator of PLD and multiple studies have 
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demonstrated an EGFR-PLC-$1-PKC axis for PLD activation. By using small molecule 
PKC inhibitors or by down-regulating PKC levels with prolonged phorbol ester treatment, 
multiple groups have shown decreased EGF-stimulated PLD activation following 
inactivation of PKC in various cell types (Voss et al., 1999; Yeo and Exton, 1995). Later 
studies using mouse embryonic fibroblasts demonstrated compromised EGF stimulation 
of PLD activity in PLC-$1 null cells versus wild-type cells, supporting the requirement of 
PLC-$1 and PKC for EGF stimulation of PLD activity (Hess et al., 1998). Although PKC 
is believed to primarily activate the PLD1 isoform (Colley et al., 1997b; Sung et al., 
1999b), the PX domain of PLD2 interacts with the SH3 domain of PLC-$1 following EGF 
stimulation and is believed to increase PLC-$1 mediated hydrolysis of PIP2 (Jang, 2003). 
When the PLD2-PLC-$1 interaction is disrupted by mutating specific proline residues, 
EGF no longer stimulates PLD2 activity, indicating a complex mode of PLD2 regulation 
by PLC-$1 (Jang, 2003). 
Although EGFR activation stimulates PLD activity through a PLC-$1-PKC axis in 
many cell types, EGFR activation does not always stimulate PIP2 hydrolysis and PKC 
activation in other cell lines (Cook and Wakelam, 1992; Hess et al., 1997). Alternative 
EGFR-PLD coupling mechanisms have been described and usually involve activation of 
small GTPases. Ras participates in a complex regulatory mechanism with RTK-
stimulated PLD. The first step of the canonical Ras activation sequence involves 
recruitment and activation of Sos, which stimulates GDP-GTP exchange on Ras and 
allows Ras to activate downstream effectors (Schlessinger, 2000). GEFs for the small 
GTPase RalA are stimulated by activated Ras (Matsubara et al., 1999) and RalA has 
been implicated in the activation of PLD. RalA interacts with PLD1 (Luo et al., 1997) and 
is believed to enhance PLD catalytic activity in the presence of other activators such as 
Arf GTPase (Kim et al., 1998). As such, PLD stimulation by EGFR requires Ras-
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activated RalA in multiple cell lines (Lu et al., 2000; Voss et al., 1999), although the 
intermediate signaling proteins between RalA and PLD are not fully characterized. In 
addition to RalA, Ras is known to directly activate the p110 subunit of PI3K by binding to 
a Ras binding domain (RBD) (Rodriguez-Viciana et al., 1996). The product of PI3K, 
PIP3, can recruit and activate PLD1 following RTK stimulation via the PLD-PX domain 
(Lee et al., 2005; Standaert et al., 1996). Although speculative, Ras activation of PI3K 
could also influence PLD activity through a PIP3-dependent mechanism. 
By contrast, PLD and PtdOH influence EGF-stimulated Ras activation by 
regulating membrane recruitment and activation of Sos. The adaptor molecule Grb2 
contains two SH3 domains and one SH2 domain. Receptor stimulation recruits Grb2 via 
an interaction with the SH2 domain. Once receptor bound, Grb2 binds Sos via one of the 
SH3 domains and this has been a well-established mechanism for Sos recruitment 
(Schlessinger, 2000). PLD2 binds the other SH3 domain of Grb2 and that this interaction 
was necessary for EGF stimulation of PLD2 activity (Di Fulvio et al., 2006). Interestingly, 
PLD-generated PtdOH also directly binds and recruits Sos to membranes following 
EGFR activation (Zhao et al., 2007). Thus, a potential feed-forward mechanism emerges 
where PLD activates Ras which leads to activation of downstream effectors such as 
RalA, further stimulating PLD activity. The regulation of Ras signaling by PLD has 
important clinical implications and is further discussed in the “Functions of PLD in 
cancer” section. 
In addition to Ras, Arf proteins also participate in PLD1 and PLD2 activation 
following RTK stimulation. RTK activation of PI3K recruits certain GEFs for Arf proteins 
(Venkateswarlu et al., 1998) and results in the formation of an active ArfGEF-RTK 
complex (Li et al., 2003). Studies using Brefeldin A, an inhibitor of certain ArfGEFs  
(Peyroche et al., 1999), demonstrated that the ArfGEF ARNO and Arf1 are required for 
PLD1 activation following stimulation of the insulin receptor in rat fibroblasts (Li et al., 
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2003; Shome et al., 1997). The requirement of Arf in insulin signaling appears to be cell 
line dependent as PLD activation by insulin does not require Arf in CHO-T cells (Emoto 
et al., 2000). Additionally, Arf4 was identified as an EGFR binding partner in a yeast two-
hybrid screen that interacts with EGFR upon agonist stimulation (Kim et al., 2003b). Co-
expression of Arf4 with PLD2 but not PLD1 resulted in a substantial increase in EGF 
stimulated PLD2 activity compared to the expression of PLD2 alone (Kim et al., 2003b). 
Although further studies are required to delineate the role of Arf proteins in RTK-PLD 
activation, these current studies suggest that Arf proteins may play non-redundant roles 
in regulating PLD1 vs. PLD2.  
The Rho family of small GTPases (Rho/Rac/Cdc42) also regulates RTK 
stimulation of PLD activity in some cell systems. Like Ras and Arf, Rho GTPases are 
usually activated by upstream GEFs through a variety of mechanisms (Buchsbaum, 
2007). In fibroblasts, Rac1 and RhoA were required for PLD activation by PDGF and 
EGF, respectively (Hess et al., 1997). However, RTK stimulation of PLD in vascular 
smooth muscle cells requires Arf proteins but not Rho proteins (Shome et al., 2000). 
Rho proteins are particularly important for regulating cytoskeleton rearrangements 
needed for processes such as stress fiber and lamellipodia formation in motile cells 
(Nobes and Hall, 1995). The role of RTK signaling to PLD through Rho family proteins 
may thus be dependent on the motile nature of the cell.  
Recent studies have elucidated new regulators of RTK-PLD signaling in addition 
to the “classic” PLD inhibitors previously discussed. Cyclin dependent kinase 5 (Cdk5) is 
a multifunctional serine/threonine kinase that mediates a variety of signaling events 
including exocytosis of insulin in pancreatic !-cells (Lilja et al., 2004). Upon stimulation 
with EGF in rat insulinoma cells, Cdk5 phosphorylates PLD2 at serine 134 and this 
phosphorylation event was required for EGF stimulated PLD activity and subsequent 
release of insulin from these cells (Lee et al., 2008). Future studies should determine if 
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the phosphorylation of PLD2 by Cdk5 is required for RTK-mediated function in other cell 
types. The multitude of pathways in which RTKs stimulate PLD activity underscores the 
importance of PLD and PtdOH in mediating the biological effects of RTK ligands. 
 
G-protein coupled receptors 
GPCRs represent another large class of cell surface receptors that frequently 
lead to PLD activation. Under inactive conditions, GPCRs bind different classes of 
heterotrimeric G-proteins composed of an alpha subunit and a dimer composed of beta 
and gamma subunits. Ligand binding at the extracellular face of the GPCR leads to a 
conformational change in the receptor that promotes GDP to GTP exchange on the " 
subunit and GTP-bound G" then dissociates from !$ (Oldham and Hamm, 2008). Each 
class of activated G" subunit is associated with a distinct cellular signaling pathway. The 
G"s G-proteins activate adenylyl cyclase (AC) to increase intracellular levels of the 
second messenger cyclic AMP (cAMP), which activates protein kinase A (PKA). The 
G"i/o G-proteins are associated with a decrease in AC activity, however, the liberated 
G!$ dimer has AC-independent roles such as recruiting and activating proteins with PH 
domains (Touhara et al., 1994). G"q/11 G-proteins stimulate PLC activity, which 
subsequently leads to activation of PKC and downstream effectors (McCudden et al., 
2005). Finally, G"12/13
 proteins are associated with activation of Rho proteins and 
effectors by activating Rho GEFs (Kozasa et al., 1998). The list of GPCR ligands that 
activates PLD is quite extensive and GPCRs of all classes have been reported to 
activate PLD (Exton, 1999). Therefore, the known mechanisms of PLD activation by 
each class of G" G-protein are discussed in the following section. 
Once activated, G"q binds and recruits PLC-! to membranes where it hydrolyzes 
PIP2 to generate IP3 and DAG, leading to activation of PKC (Rhee, 2001). Several lines 
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of evidence suggest that PKC mediates the activation of PLD by G"q. Cells that express 
constitutively active G"q have elevated PLD activity (Plonk et al., 1998). Co-expression 
of a PKC-resistant PLD mutant significantly reduces the fold-activation of PLD activity 
due to constitutively active G"q, suggesting that PKC mediates G"q activation of PLD 
(Xie et al., 2002b). Likewise, stimulation of a G"q coupled receptor failed to stimulate 
another PKC-resistant PLD mutant. This mutant was responsive to non-G"q GPCR 
stimuli, confirming proper protein folding and underscoring the importance of PKC in 
mediating G"q-PLD signaling (Zhang et al., 1999). Small-molecule PKC inhibitors block 
PLD activation by a number of GPCR agonists including bradykinin (Pyne and Pyne, 
1995), thrombin (Vasta et al., 1998), and S1P (Meacci et al., 1999) and overexpression 
of PKC-! is known to potentiate the PLD response to endothelin-1 stimulation in Rat6 
fibroblasts (Pai et al., 1991). Similarly, downregulation of PKC with prolonged phorbol 
ester treatment inhibits bradykinin stimulation of PLD in SF3271 fibroblasts (Clark and 
Murray, 1995). Data from our lab suggest that the combination knockdown of PKC" and 
PKC! significantly decreases M1-muscarinic receptor stimulation of PLD in HEK293 
cells (data not shown), confirming the importance of PKC in mediating G"q signaling to 
PLD. However, many G"q-coupled GPCRs couple to additional G-proteins including 
members of the G"12/13 family. 
G"12/13 G-proteins have long been known to stimulate cytoskeletal 
rearrangements through activation of the Rho family of proteins and some GPCRs that 
predominantly couple to G"q also couple to G"12/13. For example, GPCRs such as the 
M3 muscarinic receptor stimulate PLD in a PKC-independent manner in certain cell 
systems. Expression of a dominant negative RhoA construct or treatment with C3 
exoenzyme inhibits M3 stimulation of PLD, suggesting RhoA participates in M3 
activation of PLD (Mitchell et al., 1998; Schmidt et al., 1996). Likewise, expression of a 
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RhoA-resistant PLD mutant is less responsive to M3 stimulation (Du et al., 2000). C3 
exoenzyme treatment inhibits the PLD response to other GPCR agonists such as 
bradykinin (Meacci et al., 2003) and S1P (Meacci et al., 2003). Expression of 
constitutively active G"13, like G"q, stimulates PLD activity. This active G"13 mutant 
stimulates PKC-resistant PLD constructs, suggesting that G"13 stimulates PLD 
independently of PKC. C3 exoenzyme treatment inhibits G"13 activation of PLD (Plonk et 
al., 1998; Xie et al., 2002a), suggesting that RhoA mediates G"13 stimulation of PLD. In 
addition to a direct protein-protein interaction between RhoA and PLD, several other 
activation mechanisms have been proposed. RhoA is known to stimulate synthesis of 
PIP2 (Chong et al., 1994) and exogenous addition of PIP2 following RhoA inactivation is 
known to restore PLD activity (Schmidt et al., 1996). Besides direct stimulation of PLD 
activity and increasing PIP2 levels, a recent study suggested that LIM1 kinase, a RhoA 
effector, stimulates PLD activity following M3 stimulation. As discussed previously, LIM1 
kinase phosphorylates cofilin, and phospho-cofilin stimulates PLD activity downstream of 
M3 activation (Han et al., 2007). Phospho-cofilin depletion had no effect on PMA 
stimulated PLD activity, suggesting a RhoA dependent mechanism. On the other hand, 
several studies suggest that RhoA and PKC synergize to stimulate PLD downstream of 
GPCRs. For example, C3 exoenzyme reduces PLD activity following S1P stimulation in 
C212 myoblasts, but PLD activity is further reduced following with treatment of PKC 
inhibitors (Meacci et al., 2001). Additionally, overexpression of RhoA partially rescues 
M3-mediated activation of PKC-resistant PLD and together these results suggest that 
both RhoA and PKC can mediate signals from the same GPCR to PLD (Zhang et al., 
1999). 
The signaling pathways from G"s coupled receptors to PLD remains somewhat 
elusive. Stimulation of G"s-coupled GPCRs or treatment of cells with AC-activating 
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compounds such as forskolin and dibutyryl-cAMP results in PLD activation (Ginsberg et 
al., 1997). Under these conditions, treatment of cells with PKA inhibitors reduces PLD 
activity, suggesting that PKA somehow mediates PLD activation (Yoon et al., 2005). 
Additionally, transfection of DN-Src and DN-Ras also decreases PLD activation 
downstream of AC, suggesting that Src and Ras participate in G"s coupling to PLD 
(Yoon et al., 2005). Epac1 is a cAMP-activated GEF for small G-proteins such as Rap1. 
Recent studies have shown that depletion of Epac1 inhibits G"s signaling to PLD. Epac1 
also promotes GDP to GTP exchange on R-Ras and this AC-Epac1-R-Ras pathway has 
been implicated in PLD activation (López de Jesús et al., 2006) 
Several GPCRs activate PLD in a pertussis toxin sensistive manner, suggesting 
that G"i/o proteins also stimulate PLD activity. For example, stimulation with fMLP in 
neutrophils or S1P in A549 lung adenocarcinoma cells and in human airway epithelial 
cells results in pertussis toxin sensitive stimulation of PLD (Fensome et al., 1998; Ghelli 
et al., 2002; Meacci et al., 2003). Additionally, known G"i/o receptors such as M2 and M4 
muscarinic receptors stimulate PLD activity in HEK293 cells (Sandmann et al., 1991). 
The pathways by which G"i/o stimulate PLD are relatively uncharacterized, but is thought 
to require the activity of Arf and Rho (Fensome et al., 1998) and participation by tyrosine 
kinases such as Src (Ghelli et al., 2002). Likewise, Arf activity is required for stimulation 
of PLD activity by pertussin toxin insensitive GPCRs (Mitchell et al.,  2003; Mitchell et al., 
1998; Rumenapp et al., 1995). Liberated G!$ subunits are known to activate certain 
PI3Ks and increase local concentrations of PIP3 following receptor activation (Stephens 
et al., 1997). Thus, one potential mechanism for Arf activation appears to be recruitment 
of PI3K-dependent ArfGEFs downstream of G!$ (Touhara et al., 1994). Whether other 
mechanisms besides G!$ stimulation of GEFs mediate G"i/o stimulation of PLD should 
be the subject of future investigations. Additionally, Arf is known to participate in PLD 
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activation by G"q and G"s – coupled receptors (Mitchell et al, 2003; Thibault et al., 
2002).  
The PtdOH derived from GPCR-stimulated PLD may function to terminate GPCR 
signaling by regulating the activity of proteins required for GPCR inactivation. GRKs 
phosphorylate GPCRs and create a high affinity binding site for arrestin proteins, which 
uncouple GPCRs from G proteins and promote receptor internalization and 
desensitization (Moore et al., 2007). PtdOH, along with phosphatidylserine (PS), CL, and 
PI, are stimulators of GRK2/3 activity in vitro as determined by measuring 
phosphorylation of GPCRs in micelles containing phospholipids and purified GPCRs 
incubated with purified GRK. Kinase activity towards muscarinic (DebBurman et al., 
1995) and adrenergic (Onorato et al., 1995) receptors was much higher in the presence 
of PtdOH, suggesting that PLD may promote GPCR internalization and desensitization 
through GRKs.   
Termination of AC signaling requires the activity of cyclic nucleotide 
phosphodiesterases (PDE) that hydrolyze 3’, 5’- cyclic nucleotides to a nucleoside 5’-
monophosphate. Several families of cyclic-AMP specific PDEs have been identified that 
are responsible for terminating signaling events mediated by this important second 
messenger (Conti and Beavo, 2007). As such, multiple variants of the cAMP-specific 
PDE4 family are regulated by phosphatidic acid. Screening recombinant variants of 
PDE4 enzymes for PtdOH sensitivity revealed that PDE4A5, PDE4D3, and PDE4EB1 
were all stimulated by PtdOH in an in vitro enzyme assay (Némoz et al., 1997). PDE4D3 
was shown to bind PtdOH directly and the binding site was mapped to a region enriched 
in basic amino acids from 31-59 (Grange 2002). Another PDE4 family member, PDE4A1 
is not activated in vitro by PtdOH (Némoz et al., 1997), but requires an interaction with 
PtdOH at its amino terminus for proper membrane localization (Baillie et al., 2002). 
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Thus, by activating PDEs, PtdOH may function to terminate G"s signaling by promoting 
metabolism of the cAMP second messenger. 
 
Functions of PLD in cancer 
Over the course of nearly 40 years of research, PLD enzymes have been 
implicated in a variety of pathologies ranging from neurodegenerative diseases (Lindsley 
and Brown, 2012) to blood disorders (Elvers et al., 2010). The best characterized, 
disease relevant roles for PLD relate to the requirement of PLD activity for oncogenesis 
and cancer progression. Early indications of the importance of PLD and PtdOH in cancer 
came from observations that cells transformed by viral oncogenes such as v-Src (Song 
et al., 1991), v-Fps (Jiang et al., 1994) v-Ras (Carnero et al., 1994; Jiang et al., 1995a), 
and v-Raf (Frankel et al., 1999) all showed elevated PLD activity relative to non-
transformed control cells. Furthermore, PLD mRNA and protein analyses from tumors of 
breast (Noh et al., 2000; Uchida et al., 1997), renal (Zhao et al., 2000), colorectal 
(Yoshida et al., 1998), gastric (Uchida et al., 1999), thyroid (Kim et al., 2008), and brain 
(Park et al., 2009) origin show elevated PLD1 and/or PLD2 expression relative to normal 
surrounding tissue. As such, overexpression of PLD isoforms is associated with 
enhanced tumorigenesis in cultured cells as measured by increased anchorage-
independent growth (Ahn et al., 2003; Min, 2001), the most important measure of 
tumorigenicity (Shin et al., 1975). Recent genomic analyses of human cancers have 
revealed several unique PLD mutations in breast (Wood et al., 2007), stomach (Zang et 
al., 2012), and brain (Molenaar et al., 2012; Pugh et al., 2012) cancers although most of 
the reported mutations remain to be functionally characterized. Due to the common 
upregulation of PLD expression and activity along with the growing list of PLD mutations, 
researchers have long assumed that PLD and PtdOH confer growth advantages to 
transformed cells. 
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Definitive characterization of the molecular mechanisms behind these growth 
advantages has been difficult due to the lack of specific, small-molecule inhibitors. The 
three most common techniques for studying PLD function have been the use of primary 
alcohols to produce phosphatidyl alcohols at the expense of PtdOH via the PLD 
transphosphatidylation reaction (Yang et al., 1967), RNA interference (RNAi) to silence 
the expression of PLD mRNA, and expression of catalytically inactive PLD mutant 
proteins that function in a dominant negative manner. Each technique has its own set of 
flaws including non-specific enzyme inhibition, incomplete knockdown of target proteins, 
and retention of lipase-independent activities. The recent development of isoform-
selective PLD inhibitors (Lavieri et al., 2010; Scott et al., 2009) and PLD knockout mice 
(Elvers et al., 2010; Oliveira et al., 2010) are now being integrated into the arsenal of 
tools to study PLD function and will certainly assist in defining the exact roles of PLD in 
cancer. 
 The path to malignancy requires several unique steps. Hanahan and Weinberg 
have proposed eight “hallmarks” of cancer that comprise eight biological capabilities 
acquired during the development of human tumors. These include sustaining 
proliferative signaling, evading growth suppression, activating invasion and metastasis, 
enabling replicative immortality, inducing angiogenesis, resisting cell death, avoiding 
immune destruction, and deregulating cellular energetics (Hanahan and Weinberg, 
2011). Interestingly, PLD has been implicated in almost every hallmark of cancer and the 
following discussion will highlight these various cancer-related PLD functions. 
 
Sustaining proliferative signaling 
 In the absence of growth factors, cells enter a state of quiescence and no longer 
proliferate. This state of cellular quiescence is usually reached following terminal 
differentiation and is critical for maintaining proper tissue function and structure. Cancer 
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cells acquire mutations that allow abnormal proliferation in the absence of normal growth 
signals. Mitogenic signals, or signals that allow passage through cell cycle checkpoints, 
are usually mediated by cell surface receptors such as EGFR and their downstream 
effectors including the mitogen activated protein kinase (MAPK) pathways and 
PI3K/Akt/mTOR pathways. Mutated or overexpressed growth factors receptors including 
the PDGFR and EGFR are commonly observed in malignancies such as glioblastoma 
(GBM) and breast cancer, respectively (Shih and Holland, 2006; Slamon et al., 1987). 
Cancer cells also upregulate and secrete growth factors to stimulate growth in an 
autocrine fashion (Sporn and Roberts, 1985). As discussed previously, PLD is frequently 
activated as a consequence of receptor stimulation and participates in the pathways of 
cellular proliferation. Early evidence that PLD might directly regulate cell proliferation 
came from observations that exogenously added PtdOH or highly active bacterial PLD 
increased levels of c-Fos and c-Myc transcription factors, and stimulated thymidine 
uptake, a marker of DNA synthesis and cell proliferation, when added to cultured cells 
(Moolenaar et al., 1986). Since these early studies, PLD has been shown to participate 
in several cell proliferation pathways. 
 
Mitogen activated protein kinase 
One of the most commonly deregulated proliferative pathways in human cancers is the 
MAPK pathway. Growth factors, hormones, and chemokines activate the MAPK pathway 
by signaling through their cognate receptors and initiating a series of signaling events 
that leads to activation of multiple protein kinases (Shaw and Cantley, 2006). Under the 
canonical activation sequence, receptor activation recruits exchange factors for Ras to 
the membrane, and stimulates GDP to GTP exchange to activate Ras. Raf kinases 
subsequently bind activated Ras at the membrane and phosphorylate an intermediate 
kinase, generally termed mitogen-activated protein kinase kinase (MEK). Activated MEK 
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phosphorylates and activates a terminal MAPK termed extracellular-signal regulated 
kinases 1 and 2 (ERK1/2) (De Luca et al., 2012). Activated ERK1/2 upregulates 
expression of many genes important for cell cycle progression, metabolism, and 
proliferation by activating a plethora of transcription factors such as NFAT, Elk-1, MEF2, 
c-Fos, c-Myc, and STAT3 (Roux and Blenis, 2004). ERK1/2 can regulate protein 
translation by activating p90 ribosomal S6 kinase, MAPK-activated protein kinases, and 
MAPK-interacting kinases, which are known to directly regulate the activity of ribosomal 
translation machinery (Chen et al., 2001). Additionally, ERK1/2 increases expression of 
anti-apoptotic genes and Raf can directly inhibit the apoptotic machinery at the 
mitochondrial membrane, independently of ERK (Alejandro and Johnson 2008). PLD 
and PtdOH have been intricately linked to multiple steps within the MAPK pathway and 
overexpression of PLD has been linked to upregulated ERK activity as measured by 
increased gene transcription downstream of ERK-activated transcription factors such as 
STAT3 (Choi and Han, 2012). 
Ras was one of the earliest identified oncogenes, first discovered as a viral 
protein capable of inducing sarcoma in rats (Malumbres and Barbacid, 2003). Around 
30% of human tumors contain mutations in Ras genes that result in constitutive Ras 
activation (Dunn et al., 2005). A growing body of literature suggests that PLD and PtdOH 
directly regulate Ras activation through several mechanisms. A well-established Ras 
activation pathway involves recruitment of the adaptor protein Grb2 to phosphorylated 
tyrosine residues on RTKs via its SH2 domain (Lowenstein et al., 1992). Grb2 contains 
two SH3 domains (Matuoka et al., 1992) that bind proteins with proline-rich motifs, such 
as the Ras GEF Sos (Chardin et al., 1993; Simon et al., 1991). Ras family members 
undergo farnesylation or geranylgeranylation that results in constitutive membrane 
association. Thus, formation of the RTK/Grb2/Sos complex allows GDP to GTP 
exchange and activation of membrane-associated Ras. In addition to RTKs, Grb2 can 
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bind PLD2 via the Grb2 SH2 domain at PLD2-Y169 and Y179 (Di Fulvio et al., 2006). 
The PLD2-Grb2 complex recruits Sos and stimulates activation of Ras and MAPK 
pathways (Di Fulvio et al., 2006; 2008) in a manner that does not require phospholipase 
activity. Furthermore, the PX domain of PLD2 has been shown to act as a GEF for Ras 
directly (Henkels et al., 2013b), providing an alternative route for lipase independent Ras 
activation. On the other hand, PtdOH directly regulates Ras activation by serving as a 
recruitment signal for the Sos exchange factor. Sos contains a PH domain that binds 
PtdOH, and residues H475 and R479 mediate this interaction. When PtdOH-binding 
residues are mutated, SOS is not longer recruited to the plasma membrane following 
EGFR stimulation. PLD2 was found to co-localize with SOS and genetic silencing of 
PLD2 prevented the EGF-stimulated recruitment of SOS to the membrane and 
subsequent activation of Ras (Zhao et al., 2007). Additionally, PtdOH can inhibit the 
activity of neurofibromin 1 (NF1), a Ras GAP, in vitro. NF1 was identified as one the 
earliest tumor suppressor genes (Cichowski and Jacks, 2001) and while the in vivo 
relevance of PtdOH inhibition of NF1 remains to be established, upregulated PLD 
activity could potentially activate Ras by inhibiting NF1. The diverse mechanisms by 
which PLD can regulate Ras activity certainly underscore the importance of PLD and 
PtdOH for Ras activation.   
On the other hand, Ras can activate PLD via a mechanism involving Ral-GDS, 
RalA, and Arf and the importance of PLD and PtdOH in Ras-mediated tumorigenesis 
was demonstrated in an elegant study where the introduction of dominant negative PLD 
into rat fibroblasts blocked the transforming ability of constitutively active Ras. When the 
Ras-transformed fibroblasts were injected into immunocompromised mice, fibroblasts 
co-expressing DN-PLD failed to form tumors. However, when PtdOH was delivered to 
the mice via osmotic pump, Ras-transformed fibroblasts expressing DN-PLD formed 
tumors similarly to Ras-transformed fibroblasts that did not express DN-PLD (Buchanan 
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et al., 2005). Other studies have also demonstrated the importance of PLD as an 
oncogenic Ras signal-transduction molecule. One of the negative regulators of ERK is a 
small, 15kDa protein known as protein enriched in astrocytes, or PEA15. Originally 
identified as a substrate for PKC in astrocytes (Araujo et al., 1993), it was later identified 
in yeast-two hybrid screen as a binding partner of PLD1 (Zhang et al., 2000). PEA15 
positively regulates PLD activity, potentially by acting as a chaperone protein to increase 
protein stability and decrease degradation (Zhao et al., 2000). PEA15 also directly 
inhibits ERK by sequestration in the cytoplasm and blocking ERK nuclear import 
(Formstecher et al., 2001; Pastorino et al., 2010). On the other hand, when PEA15 is 
phosphorylated at S116 by Akt kinase (Trencia et al., 2003), a downstream effector of 
Ras and PLD (Chapter III), ERK is no longer sequestered by PEA15 and can activate 
downstream targets. PEA15 overexpressed in epithelial cells that express constitutively 
active Ras is hyperphosphorylated at S116 and the overexpression potentiates Ras-
mediated transformation. Interestingly, disruption of the PEA15/PLD1 complex or PLD1 
enzyme inhibition with butanol or small-molecule PLD inhibitors block the PEA15 
potentiation of Ras-mediated tumorigenesis suggesting that the PEA15 enhancement of 
PLD activity in this system drives ERK activation and AIG downstream of Ras 
(Sulzmaier et al., 2011). These studies strongly suggest that PLD and PtdOH transduce 
the signals required for Ras-induced oncogenesis, potentially through downstream 
activation of Raf and the MAPK pathway.      
 There are three members of the Raf family, A-Raf, B-Raf and Raf-1, and all 
activate the MAPK pathway to varying degrees with B-Raf and Raf-1 being the most 
potent stimulators of MEK (McCubrey et al., 2007). Raf mutations have been reported in 
many cancers including colorectal, ovarian, and especially melanoma, with around 60% 
of melanomas containing activating Raf mutations (Pollock and Melzer 2002). As such, 
inhibitors of mutant Raf, such as vemurafenib, are highly efficacious in treating malignant 
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melanoma (Bollag et al., 2012). The activation of Raf kinases is complex and generally 
requires membrane recruitment and subsequent phosphorylation at a number of 
activating residues (Yan et al., 1998). Raf contains a Ras binding domain that allows 
requisite membrane recruitment through interaction with activated Ras. Raf-1 can also 
translocate to membranes by directly interacting with PtdOH (Ghosh and Strum, 1996). 
Through the use of butanol and catalytically inactive PLD mutants, investigators 
determined that PLD-derived PtdOH bound and recruited Raf-1 kinase to facilitate ERK 
activation, but the interaction did not influence Raf-1 activity directly (Rizzo et al., 1999). 
The PtdOH binding domain was narrowed to a region of 35 amino acids and mutation of 
specific arginine residues abolished PtdOH binding to Raf-1. All three Raf family 
members contain this PtdOH binding domain. (Ghosh, 2003; Ghosh and Strum, 1996). 
Although the canonical Raf activation sequence involves membrane recruitment by Ras, 
other studies have suggested that PtdOH mediates the translocation event and Ras 
somehow mediates subsequent Ras activation. Evidence for this claim comes from 
observations that mutation of the PtdOH binding site of Raf-1 completely prevents 
membrane binding whereas expression of a dominant negative Ras construct inhibits 
Raf-1 activation but not translocation (Rizzo et al., 2000). The idea that PtdOH mediates 
Raf-1 translocation and Ras mediates Raf-1 activation is partially substantiated by later 
studies showing that Raf-1 binding to liposomes containing PtdOH is not further 
enhanced by Ras. However, Ras binding to the same liposomes was significantly 
enhanced in the presence of Raf-1, suggesting that Ras binds lipid-bound Raf-1 
(Hekman et al., 2002). Therefore, PtdOH appears to directly recruit Raf-1 to membranes 
and possibly facilitate activation by Ras. 
 In addition to directly regulating Raf translocation to the membrane, PLD may 
indirectly affect ERK activation by regulating receptor endocytosis. Like RTKs, agonist 
binding to many GPCRs leads to a rapid increase in ERK activation and many of the 
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same components that mediate RTK activation of ERK also mediate GPCR activation of 
ERK. However, inhibitors of endocytosis are known to also inhibit GPCR-stimulated ERK 
activation (Daaka et al., 1998; Luttrell et al., 1997). Arrestins are proteins that mediate 
GPCR internalization and serve as scaffolds to nucleate components of the MAPK 
pathways (Shenoy et al., 2006). PLD activity has been shown to regulate receptor 
endocytosis for a variety of cell surface receptors including RTKs, such as EGFR (Shen 
et al., 2001), and GPCRs such as the µ-opioid receptor (Koch et al., 2003) and 
angiotensin II receptor (Du et al., 2004). The cone-shaped PtdOH participates in 
membrane fission events such as endocytosis (Barr and Shorter, 2000). However, a 
recent study suggested that PLD regulates receptor endocytosis independently of 
PtdOH. The small GTPase dynamin is a critical participant in endocytosis and functions 
by circling the neck of an invaginated membrane and pinching off the vesicle by 
constricting the neck in a manner that requires GTP hydrolysis (Ferguson and Pietro De 
Camilli, 2012). PLD1 and PLD2 stimulate GTPase activity of dynamin through a PtdOH-
independent GAP activity in the PLD-PX domain. By using EGFR as an example, 
mutation of the catalytic GAP residue in the PLD-PX domain or overexpression of the PX 
domain fragment decreased and increased EGFR endocytosis, respectively (Lee et al., 
2006). Therefore, in addition to PtdOH regulation of Ras and Raf activation, PLD may 
regulate MAPK signaling through GEF and GAP activities for Ras and dynamin, 
respectively. 
 
Mammalian target of rapamycin 
The mammalian, target of rapamycin (mTOR) is a large serine/threonine protein 
kinase that serves as a sensor of cellular homeostasis and responds to amino acids, 
stress, oxygen, energy levels, and growth factors and in turn regulates cell growth, 
proliferation, survival, and metabolism by phosphorylating a plethora of downstream 
 50!
targets (Laplante and Sabatini, 2012). The activation pathways for mTOR are complex 
and depend on many factors, but a canonical activation pathway involves growth-factor 
receptor activation of PI3K, which activates Akt kinase through a PIP3-dependent 
mechanism. Akt then activates mTOR by phosphorylating and inhibiting an upstream 
inhibitor of mTOR, tuberous sclerosis protein 2 (Manning et al., 2002; Shaw and Cantley, 
2006). In addition to growth factor receptor mutations (Libermann et al., 1985), PI3K 
activity is upregulated in many cancers through inactivation of phosphatase and tensin 
homologue (PTEN), the lipid phosphatase that hydrolyzes PIP3 (Haas-Kogan et al., 
1998), and also though activating mutations in the PI3K catalytic domains (Engelman et 
al., 2006). Thus, cancers that have elevated PI3K activity frequently have elevated 
mTOR activity. 
 Growth factor activation of mTOR results in protein translation through several 
known substrates including p70 S6 kinase 1 (p70S6K1) and eukaryotic translation 
initiation factor 4E binding protein 1 (4E-BP1). mTOR phosphorylates p70S6K1 which in 
turn phosphorylates and activates the S6 ribosomal protein (Chung et al., 1992). 4E-BP1 
interacts with the eukaryotic translation initiation factor 4E and inhibits translation until 
mTOR phosphorylation relieves the repressive function of 4E-BP1 on protein translation 
(Richter and Sonenberg, 2005). The bacterial macrolide rapamycin binds FKBP12 
(FK506 binding protein 12) and the rapamycin-FKBP12 complex binds and inhibits 
mTOR (Koltin et al., 1991; Sabatini et al., 1994) at the FKBP12-rapamycin binding (FRB) 
domain (Choi et al., 1996). PtdOH was shown to bind R2109 in the FRB domain and an 
NMR structure of FRB-bound PtdOH suggested that binding of PtdOH to mTOR 
competes with rapamycin binding (Fang et al., 2001; Veverka et al., 2007). Some have 
suggested that PtdOH stabilizes mTOR complexes and high levels of PtdOH may 
outcompete rapamycin and explain why some systems resist rapamycin-induced cell 
death (Chen et al., 2003; Toschi et al., 2009). Consistent with the importance of PtdOH 
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in mTOR activation, the three PtdOH-generating enzymes, PLD (Fang et al., 2001), 
DAG kinase (Ávila-Flores, 2005), and lysophosphatidic acid acyl transferase (Tang et 
al., 2006) have all been shown to regulate mTOR activity. Although the literature is 
somewhat contradictory, both PLD1 (Fang et al., 2003; Sun et al., 2008) and PLD2 (Ha 
et al., 2006) have been reported as regulators of mTOR. However, small-molecule PLD 
inhibitors do not inhibit mTOR activity in all cells (see Chapter III), which calls into 
question some of the previous studies, which relied on butanol as a PLD inhibitor.  
Although PtdOH can regulate p70S6K1 activity through mTOR, recent studies 
have demonstrated that PtdOH also directly binds and activates p70S6K1 independently 
of mTOR, as measured by recombinant p70S6K1 binding to PtdOH in ELISA and lipid-
sedimentation based assays (Lehman et al., 2007). In order to demonstrate direct 
activation of p70S6K1, the authors treated cells with rapamycin to inhibit mTOR and 
then with PtdOH before IP of p70S6K1 and measurement of activity. Although they 
measured increased p70S6K1 activity after PtdOH treatment, they did not address the 
potential displacement of rapamycin from mTOR by PtdOH, thus calling into question a 
direct stimulation by PtdOH. Further studies must address whether the binding of PtdOH 
to p70S6K1 has physiological relevance.  
 
Evading growth suppression 
 Most cells enter a state of cellular quiescence upon terminal differentiation or 
contact with other cells within a tissue or culture. The signals that prevent cell division 
and replication are diverse and complex, but are largely mediated by soluble factors and 
cell-surface proteins that activate inhibitors of cell cycle progression through restriction 
points into S (DNA synthesis) or M (mitosis) phases (Fagotto and Gumbiner, 1996). As 
discussed in the previous section, mitogenic signals, such as those from growth factor 
receptors, evoke passage through cell cycle checkpoints to replicate DNA, undergo 
 52!
mitosis, and ultimately divide. In order to establish a transformed primary cell line in 
culture, at least two cooperating oncogenes or tumor suppressors must be mutated. 
These include, for example, mutations allowing constitutive mitogenic signaling, 
mutations that allow cells to overcome restrictions on cell cycle checkpoints, or 
mutations that allow cells to overcome programmed cell death (Land et al., 1983). As 
such, excessive proliferative signaling alone often leads to cell cycle arrest as a normal 
cellular response to preventing neoplastic growth. Overexpression of Raf (Woods et al., 
1997) and oncogenic Ras (Serrano et al., 1997) proteins in non-immortalized, primary 
cells leads to cell cycle arrest. Likewise, oncogenic Ras, which does not normally 
transform primary cells, transforms cells with the introduction of a protein that sequesters 
and inactivates cell cycle checkpoint proteins (Hahn et al., 1999; Serrano et al., 1997). 
While PLD overexpression alone does not appear to be transforming, PLD 
overexpression cooperates with overexpressed proto-oncogenes such as c-Src or EGFR 
in rat fibroblasts (Joseph et al., 2001), suggesting that PLD might also function at the 
level of cell cycle progression. 
The transcription factor p53 is one of the most important tumor suppressors 
involved in cell cycle control and over 50% of human tumors contain inactivating 
mutations in the p53 gene (Hollstein et al., 1994). As cells pass through the cell cycle, 
DNA integrity is constantly monitored. Cellular stressors such as DNA damage can 
activate a number of proteins including ataxia telangiectasia mutated (ATM), a well-
known activator of p53 (Xu and Baltimore, 1996). Once activated, p53 either initiates a 
series of events triggering a cell-cycle arrest or events triggering programmed cell death. 
By enforcing a G1 checkpoint, p53 prevents entry into the S, phase allowing time for 
DNA repair to proceed. If DNA damage is sufficient, p53 can initiate programmed cell 
death to prevent replication and passage of damaged genes (Evan and Littlewood, 
1998). p53 enforces a cell cycle arrest by upregulating a number of genes that prevent 
 53!
cell cycle progression. Although there are many, the p21 cyclin-dependent kinase 
inhibitor (p21Cip1) is one of the best-characterized p53 targets (el-Deiry et al., 1993). 
p21Cip1 binds to cyclin dependent kinases and blocks their activity to enforce a G1 cell 
cycle arrest. p53 can initiate apoptosis by upregulating pro-apoptotic genes such as Bax 
(Miyashita and Reed, 1995) and death receptors (Owen-Schaub et al., 1995), and p53 
can stimulate apoptosis independently of its transcriptional activity by directly activating 
the mitochondrial apoptotic machinery (Chipuk et al., 2004). Therefore, inactivation or 
suppression of p53 is often times a key step in neoplastic growth and PLD has been 
linked to the p53 pathway in several studies. 
In normal proliferating cells, DNA damaging agents cause apoptosis through a 
mechanism that involves increased expression of p53. In rat fibroblasts and MDA-MB-
231 breast cancer cells, overexpression of PLD1 results in decreased p53 levels and 
decreased apoptosis following treatment with DNA damaging agents, suggesting that 
PLD activity promotes p53 degradation (Hui et al., 2006; 2004). p53 levels are usually 
low as the protein is continuously degraded via a mechanism that involves ubiquitination 
and proteasomal degradation. The E3 ubiquitin-protein ligase MDM2 functions as a 
negative regulator of p53 by targeting the protein for proteasomal degradation (Moll and 
Petrenko, 2003). Overexpression of PLD correlates with increased levels of MDM2 in rat 
(Hui et al., 2004) and human (Hui et al., 2006) cells, potentially explaining the 
mechanism by which PLD decreases p53 levels. Furthermore, the possibility that PLD 
activity promotes p53 degradation was later supported in etoposide-treated HCT116 
colorectal cancer cells when siRNA knockdown of PLD1 or treatment of cells with 
exogenous PtdOH increased and decreased p53 levels, respectively (Jang et al., 
2008a). Additionally, overexpression of PLD1 and PLD2 inhibits etoposide-induced 
increase in p53 expression (Hui et al., 2004; Kwun et al., 2003). Similar results were 
observed in fibroblasts with high-intensity Raf signaling, normally prone to cell cycle 
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arrest (Woods et al., 1997). Overexpression of either PLD1 or PLD2 in these cells led to 
a dramatic decrease in p21Cip1 (Joseph et al., 2002). In one study, PLD2 controlled 
p21Cip1 expression independently of p53, raising the possibility that the PLD1 may 
regulate p21Cip1 levels through p53 while PLD2 may regulate p21Cip1 levels through 
other transcription factors such as Sp1 (Kwun et al., 2003). The molecular mechanism 
by which PLD regulates p53 and p21Cip1 levels largely remains to be determined. 
However, MAPK pathways are known to regulate p53 (Wu, 2004) and inhibitors of ERK 
partially negate the effects of PLD overexpression on p53 degradation (Hui et al., 2004), 
potentially implicating a PLD-MAPK pathway. 
The retinoblastoma protein (pRB) is another frequently mutated tumor 
suppressor protein that functions as cell cycle restriction point guardian to allow passage 
from the G1 gap phase into S phase. Accordingly, loss of pRB allows unrestricted 
passage from G1 to S phase. pRB normally binds E2F transcription factors that, when 
liberated from pRB, upregulate genes necessary for G1 to S phase transition (Dyson, 
1998). The regulation of pRB is complex, but multiple phosphorylation events determine 
whether pRB restricts S phase entry. Before cells reach the G1 restriction point, pRB is 
hypophosphorylated and levels of phosphorylated pRB increase during the last few 
hours of the G1 phase. Hyperphosphorylated pRB then allows passage through the G1 
checkpoint (Weinberg, 1995) and hyperphosphorylated pRB is associated with cell cycle 
progression. Cyclins of the D class regulate pRB activity (Ewen et al., 1993; Kato et al., 
1993) by activating cyclin-dependent kinases, which phosphorylate and activate pRB 
(Tamrakar et al., 2000). Although current literature does not directly implicate PLD in 
pRB activation, several putative links exist. First, when PLD1 or PLD2 are 
overexpressed in mouse fibroblasts, Cyclin D3 levels increase and a greater population 
of cells enter S phase relative to cells that do not overexpress PLD (Min, 2001). 
Additionally, p21Cip1 is a potent inhibitor of cyclin dependent kinases that phosphorylate 
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pRB (Harper et al., 1993), offering another mechanism by which PLD may regulate pRB 
activation since PLD activity is negatively correlated with p21Cip1 expression. Finally, 
protein phosphatase 1 (PP1), a serine/threonine phosphatase, dephosphorylates pRB 
and can inhibit the G1 to S phase transition (Rubin et al., 1998). PP1 is a ubiquitously 
expressed phosphatase in all eukaryotic cells with a broad spectrum of functions 
including cell division, apoptosis, protein synthesis, metabolism, cytoskeletal 
reorganization, and regulation of membrane receptors (Shi, 2009). PP1 is a holoenzyme 
consisting of catalytic and regulatory subunits that confer phosphatase specificity. PP1 
activity is regulated by inhibitory proteins in vivo (Cohen, 2002) and PtdOH was shown 
to inhibit the catalytic subunit of PP1! with an IC50 value of 15nM (Jones and Hannun, 
2002). The PtdOH binding site was mapped to a small stretch of amino acids between 
274 and 299 and mutation of serine 292 reduced PtdOH binding by about 50% (Jones et 
al., 2013). Theoretically, PLD activity could inhibit PP1 leading to hyperphosphorylated 
pRB and G1 cell cycle arrest since PP1-induced hypophosphorylation of pRB, is 
associated with a G1 arrest (Kwon et al., 1997) and conditions that favor pRB 
phosphorylation favor cell proliferation (Cobrinik et al., 1992). 
 
Resisting cell death 
Apoptosis  
Along the journey to malignancy, cancer cells must overcome intrinsic 
programmed cell death mechanisms that exist to destroy genetically unstable or cells 
undergoing deregulated, autonomous proliferation. DNA damaging agents, death 
receptor stimulation, inhibition of oncogenic kinases, and nutrient deprivation are 
established stimuli of apoptotic cell death (Kelly and Strasser, 2011). As cells 
proliferate within a solid tumor, the nutrient supply temporarily decreases until cells can 
stimulate angiogenesis and restore blood flow via neovascularization. In cell culture, 
 56!
viability is normally compromised following serum, or nutrient withdrawal. PLD activity is 
frequently upregulated in cultured cells following serum withdrawal (Zheng et al., 2006) 
and many cancer types require PLD and its product, PtdOH, for sustained survival under 
stress conditions (Foster and Xu, 2003). Several groups have thus proposed the idea 
that PLD and PtdOH provide some sort of survival signal to prevent programmed cell 
death. For example, when serum is withdrawn in rat fibroblasts overexpressing the 
proto-oncogene c-Src, cells undergo apoptosis unless PLD1 or PLD2 is co-
overexpressed (Zhong et al., 2003). Interestingly, the same rat fibroblast line 
transformed with oncogenic v-Src has elevated basal PLD activity and does not undergo 
apoptosis following serum withdrawal, illustrating a correlation with PLD activity and cell 
survival. Established cancer cell lines also require PLD activity for survival in the serum 
withdrawal paradigm. For example, when PLD activity is inhibited in T24 bladder, Calu-1 
lung, 786-O renal, HCT116 colorectal and MDA-MB-231 breast cancer cells following 
serum withdrawal, the established cancer lines undergo apoptosis (Kang et al., 2008; 
Shi et al., 2007; Toschi et al., 2008; Zhong et al., 2003). These studies utilized butanol, 
DN-PLD, and PLD siRNA to inhibit PLD activity and expression. The importance of PLD 
in the serum-withdrawal survival pathway has since been corroborated obtained using 
small-molecule PLD inhibitors in MDA-MA-231 cells (Lavieri et al., 2010). 
Although the molecular mechanisms by which PLD protects against apoptotic cell 
death are not fully understood, several mechanisms have been proposed. The first 
mechanism involves upregulation of anti-apoptotic proteins. B-cell lymphoma 2 (Bcl-2) is 
an anti-apoptotic protein that prevents apoptosis by binding pro-apoptotic proteins such 
as Bax and Bak (Cheng et al., 2001; Tsujimoto et al., 1984). Not surprisingly, 
overexpression of Bcl-2 is associated with apoptosis resistance in many cancers (Adams 
and Cory, 2007). Several cell types increase Bcl-2 expression as a function of PLD 
activity. PLD overexpression and exogenous PtdOH treatment in HeLa cells increases 
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Bcl-2 transcription (Choi and Han, 2012). H19-7 rat embryonic hippocampal cells 
increase Bcl-2 expression when stimulated by FGF. DN-PLD and PLD siRNA inhibit the 
FGF-induced increase in Bcl-2, suggesting PLD activity is required for Bcl-2 expression 
(Yoon et al., 2012). Both studies demonstrate that Bcl-2 transcription increases through 
the STAT3 transcription factor in a mechanism that requires MAPK activity. Therefore, 
Bcl-2 expression by PLD may be a byproduct of PLD-induced MAPK activation.  
 Another mechanism by which PLD may protect against apoptosis involves the 
regulation of mTOR. Several cell types undergo apoptosis when treated with the mTOR 
inhibitor rapamycin (Woltman et al., 2001). As mentioned previously, PtdOH is believed 
to bind and stimulate mTOR directly in a manner that competes with rapamycin binding 
(Chen et al., 2003). Along these lines, the pro-survival transcription factor c-Myc (Dang, 
2012) is translated downstream of mTOR (Gera et al., 2004). Inhibition of PLD using 
butanol or DN-PLD is associated with a decrease in c-Myc protein in MCF7 cells and it 
has been suggested that PLD promotes c-Myc expression through mTOR activation 
(Rodrik et al., 2005). In some circumstances, c-Myc overexpression can force the cell to 
initiate apoptosis in a manner that requires the early growth response protein 1 (Egr1) 
transcription factor (Boone et al., 2011; Sherr, 2001). Egr1 is a tumor suppressor 
involved in differentiation, proliferation, and apoptosis (Boyle et al., 2009; Yu et al., 2007) 
and enhances expression of PTEN (Virolle et al., 2001). Apoptotic stimuli increase Egr1 
expression in NIH3T3 and C6 glioma cells. However, PLD overexpression or treatment 
with exogenous PtdOH prevents Egr1 induction and subsequent apoptosis (Kim, 2006). 
These results suggest that PLD may regulate apoptosis by regulating expression of pro- 
and anti-apoptotic proteins, potentially through MAPK and mTOR pathways, although 
determination of the exact pathways should be the subject of future investigation. 
 Apoptosis initiation is a stepwise process involving mitochondrial 
permeabilization, cytochrome c release and activation of several caspase proteases 
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(Parrish et al., 2013). As such, treatment of cells with apoptotic stimuli such as small-
molecule PLD inhibitors is associated with an increase in caspase activity (Lavieri et al., 
2010). PLD1 and PLD2 are targets for activated caspases and are cleaved at several 
sites. PLD1 is cleaved at D545 and PLD2 is cleaved at D13, D16, and D28 (Jang et al., 
2008b; Riebeling et al., 2008). Caspase cleavage of PLD1, but not PLD2, disrupts 
catalytic activity. Interestingly, the cleavage product of PLD1 inhibits uncleaved PLD1. 
Overexpression of this fragment inhibits endogenous PLD activity and renders cells 
more susceptible to apoptosis-inducing agents (Jang et al., 2008a). Likewise, expression 
of a caspase-resistant mutant, D545A, renders cells resistant to apoptotic stimuli (Jang 
et al., 2008a). These studies suggest that caspase cleavage of PLD1 leads to 
generation of protein fragments that enable apoptosis by inhibiting PLD activity. These 
studies link the intrinsic apoptotic machinery to PLD activity and further underscore the 
importance of PLD as a survival factor.  
 
Autophagy 
Eukaryotic cells encounter a variety of environmental stressors ranging from 
nutrient and growth factor deprivation to chemical stressors and infectious agents. 
Macroautophagy (hereafter referred to as autophagy) is an evolutionarily conserved 
process whereby cytoplasmic constituents are enveloped in double-membrane vesicles 
called autophagosomes and delivered to lysosomes for degradation and nutrient 
recycling in times of stress (Yang and Klionsky, 2010). Autophagy is the only mechanism 
to degrade large bulky structures, such as organelles, and serves a housekeeping 
function, under non-stress conditions, to clear the cell of damaged and potentially toxic 
components (Rabinowitz and White, 2010). In addition to providing recycled nutrients, 
such as amino acids and nucleic acids, autophagy is critical for immune function 
(Puleston and Simon, 2013) and preventing neurodegenerative diseases such as 
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Huntington’s and Parkinson’s disease by clearing toxic protein aggregates (Sarkar et al., 
2007; Wang and Mandelkow, 2012). The relationship between autophagy and cancer is 
more complex and autophagy has been shown to serve tumor suppressing and tumor 
promoting roles. Mice with genetic deletions for essential autophagy genes have 
increased incidences of cancer, most likely due to increased genotoxic stress following 
buildup of damaged organelles (Edinger and Thompson, 2003). On the other hand, 
autophagy is required for the metabolic shift towards aerobic glycolysis in Ras-
transformed fibroblasts (Kim et al., 2011b) and autophagy inhibitors decrease Ras-
induced transformation (Kim et al., 2011c). Autophagy also supports tumor cell growth 
by clearing damaged organelles and toxic metabolites following chemotherapy 
treatment, thus pharmacological modulation of autophagy is clinically important 
(Rubinsztein et al., 2012).    
Autophagy is a multi-stage process coordinated by distinct protein complexes. In 
yeast, approximately 30 autophagy-related (ATG) genes control the various autophagic 
stages, which include initiation, elongation, and maturation. Approximately half of these 
genes are conserved in mammals (Xie and Klionsky, 2007). Autophagosome initiation 
begins with the budding of a preautophagosomal structure (PAS) from a membrane 
within the cell. Although some debate exists as to the membrane of origin, 
autophagosomes may contain membrane components from the endoplasmic reticulum 
(Axe et al., 2008), mitochondria (Hailey et al., 2010), and plasma membrane (Ravikumar 
et al., 2010). PAS formation requires recruitment of several proteins including Vps34, 
Vps15, Atg14L, and beclin1 (Itakura et al., 2008). Atg14L targets the complex to PAS 
structures (Matsunaga et al., 2010) where beclin1 can stimulate the activity of the class 
III phosphatidylinositol 3-kinase Vps34 to increase local concentrations of PI(3)P 
(Kihara, 2001; Liang et al., 1999). Increased concentrations of PI(3)P contribute to the 
negative curvature of the PAS isolation membrane and recruit proteins containing 
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PI(3)P-binding domains, such as PX domains (Knævelsrud and Simonsen, 2012). Vps34 
activity results in the formation of another complex containing Atg5, Atg12, and Atg16 to 
promote the elongation phase. Atg5 and Atg12 are conjugated to each other through the 
actions of Atg7 and Atg10, which function similarly to E1 and E2 ubiquitin-activating and 
ubiquitin-carrier proteins, respectively (Mizushima et al., 1998; Shintani, 1999). As the 
nascent autophagosomes elongates, Atg7, Atg3, and Atg5-Atg12 function as E1, E2, 
and E3 ubiquitin-like conjugation proteins to covalently attach PE to microtubule-
associated protein/light chain 3 (LC3) to facilitate LC3 attachment to autophagosomal 
membranes (Hanada et al., 2007; Noda et al., 2011). Once LC3 attaches to the 
autophagosome, the Atg5-Atg12-Atg16 complex dissociates and LC3 assists in the final 
fusion of the PAS membranes into an autophagosome containing the engulfed 
cytoplasmic constituents (Nakatogawa et al., 2007). As autophagosomes mature, they 
fuse with endosomes to create amphisomes before ultimately fusing with lysosomes. 
The maturation process is less understood, but is partially mediated by the formation of 
beclin1-comples distinct from those formed during autophagosome initiation (Matsunaga 
et al., 2009; Zhong et al., 2009) and by components of the endosomal and lysosomal 
membranes such as Rab7 and LAMP-2 (Eskelinen, 2005).  
 mTOR is a classic negative regulator of autophagy and inhibits autophagosome 
formation by directly inhibiting components of the autophagosome initiation complex 
(Chang et al., 2009; Jung et al., 2010). When nutrients are widely available, mTOR 
inhibits autophagosome initiation by directly regulating components of the autophagy 
initiation complex. The formation of the Vsp34/Beclin1 complex and the subsequent 
autophagosome initiation is subject to regulation by proteins such as Atg1/ULK (Unc-51-
like kinase), another key component of the autophagosome initiation complex 
(Mizushima, 2010). When nutrients are abundant, mTOR phosphorylates and binds the 
ULK complex, preventing autophagosome initiation (Ganley et al., 2009; Hosokawa et 
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al., 2009). When nutrients become limiting or cells are treated with rapamycin, mTOR 
activity decreases and dissociates from the ULK complex, enabling autophagosome 
formation. ULK is also regulated by the AMPK when AMP levels increase due to 
metabolic demand (Hardie, 2007; Kim et al., 2011a). In addition to mTOR and AMPK, 
PLD is emerging as an important, multifaceted regulator of autophagy. Vps34 directly 
regulates PLD1 localization and activity in response to amino acid availability or 
deprivation (Xu et al., 2011; Yoon et al., 2011). PLD binds to PI(3)P-containing 
membranes via the PX domain where it co-localizes with mTOR and promotes mTOR 
activity in the presence of amino acids. Amino acid deprivation decreases PLD activity 
(Yoon et al., 2011) and could trigger an increase in autophagosome biogenesis through 
decreasing mTOR activity. As such, PLD knockout mice produce fewer 
autophagosomes in liver slices and in embryonic fibroblasts following autophagic stimuli 
compared to wild-type littermates (Dall'Armi et al., 2010). Furthermore, Arf6, which is 
known to localize to the plasma and endosomal membranes (D'Souza-Schorey and 
Chavrier, 2006; Donaldson, 2003), stimulates autophagosome biogenesis from plasma 
membranes in a manner that requires PLD activity (Moreau et al., 2012). These 
observations were not directly correlated with mTOR and follow-up studies suggest PLD 
may independently regulate autophagy. In cells derived from polycystic kidney disease, 
which show upregulated mTOR activity, PLD inhibitor treatment results in a large 
increase in autophagosome numbers. However, rapamycin treatment of the same cells 
does not increase autophagosome numbers and suggests that PLD may be uncoupled 
from mTOR in these cells (Liu et al., 2013). Increased autophagosome numbers can 
result from increased biogenesis or decreased degradation, and the investigators of this 
study did not perform the experiments to make the distinction. 
Agents that inhibit lysosomal acidification prevent autophagosome fusion and 
ultimate degradation. By pretreating cells with lysosomal proton pump inhibitors such as 
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bafilomycin A1, investigators can clamp autophagosome degradation and determine if a 
compound increases autophagosome biogenesis or inhibits autophagic flux (Yamamoto 
et al., 1998b). PLD inhibitor treatments induce a robust increase in autophagosome 
numbers in GBM cells, but do not increase autophagosome numbers more than 
bafilomycin treatment alone (chapter III). These results suggest that PLD promotes 
autophagosome flux and degradation. Similarly, when HeLa cells are cultured in 
balanced saline solutions lacking amino acids, PLD1 localizes with LC3-containing, late 
endosomal/lysosomal structures, but not PAS membranes suggesting that PLD 
promotes the later stages of autophagy as opposed to the initiation stages (Dall'Armi et 
al., 2010). Furthermore, PLD inhibitors increase levels of autophagy substrates in both 
nutrient-deprived CHO (Dall'Armi et al., 2010) and serum-deprived GBM cells (chapter 
III), consistent with a blockade in autophagosome degradation. Beclin1 promotes 
autophagosome maturation and degradation by interacting with a variety of partners 
throughout the process. Rubicon is a Beclin1-interacting protein that inhibits 
autophagosome maturation by inhibiting Vps34 lipid kinase activity (Matsunaga et al., 
2009; Sun et al., 2011; Zhong et al., 2009). Akt phosphorylates Beclin1 and promotes 
autophagic flux by preventing the interaction with Rubicon (chapter III). PLD promotes 
Akt activity in GBM cells and promotes autophagic flux by preventing the binding of 
Rubicon to Beclin1 (chapter III).  
Although most of the current data is consistent with PLD promoting autophagic 
flux, PLD may function to promote autophagosome biogenesis in some systems. For 
example, the decrease in autophagosome numbers in PLD1 KO mice is consistent with 
a role of PLD in biogenesis and contradicts the data seen with PLD inhibitors (Dall'Armi 
et al., 2010; Liu et al., 2013; Chapter III). These differences may be explained by the 
various treatment paradigms or by differences in the cell lines or tissues under 
investigation. Another possibility is that the PLD protein provides a non-lipase function 
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that is required for autophagosome biogenesis. Additionally, data obtained from 
knockout animals may expose the non-lipase functions that small-molecule inhibitors 
may obscure. PLD may also promote autophagy through production of other lipids such 
as DAG. Autophagy is upregulated when pathogens such as S. typhimurium infect cells. 
PLD-derived DAG was recently shown to be required for autophagy following infection 
(Shahnazari et al., 2010). Since PLD was only recently discovered to modulate 
autophagy, future studies are needed clarify the exact mechanism of autophagy 
regulation by PLD. 
 
Activating invasion and metastasis 
 Once a tumor reaches a certain size, nutrient availability and space become 
limiting factors for continued tumor growth. The solution usually involves invasion of 
surrounding tissues and metastasis to distant sites where nutrients and space are not 
initially limiting (Hanahan and Weinberg, 2000). Invasion is a multistep process involving 
dissolution of the extracellular matrix (ECM) and surrounding tissue by protease 
secretion, detachment from neighboring cells and ECM, and finally cellular migration into 
the surrounding tissue. Many studies have implicated PLD in the promotion of cancer 
cell invasion. In early studies investigating invasive properties of human small-cell lung 
cancer cells, a pro-invasion role for PLD was suggested following observations that 
exogenously added bacterial PLD or PtdOH dramatically stimulated lung cancer cell 
invasion in vitro (Imamura et al., 1993). Later studies revealed a positive correlation 
between PLD activity and invasive potential. Overexpression of PLD in breast, GBM, or 
lymphoma cells stimulates invasion (Knoepp et al., 2008; Park et al., 2009; Zheng et al., 
2006) whereas expression of DN-PLD prevents invasion (Zheng et al., 2006). Similarly, 
small-molecule PLD inhibitors and PLD siRNA decrease breast cancer cell invasion and 
further implicate the importance of PLD in invasive processes (Scott et al., 2009). 
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Prior to leaving their tissues of origin, cancer cells must degrade ECM 
components and surrounding tissues to provide a path for migration and intravasation. 
This process is usually mediated by production and secretion of 
collagenases/gelatinases termed matrix-metalloproteinases (MMP) (Rao, 2003). MMP 
activity is the best predictor of invasiveness in some cancers, such as GBM (Wild-Bode 
et al., 2001) and PLD activity is highly correlated with increased MMP activity in many 
cancer types. Simulation of HT1080 fibrosarcoma cells with activators of PLD such as 
laminin (Reich et al., 1995) or PMA (Williger et al., 1999) resulted in increased MMP2 
and MMP9 secretion, respectively. By using primary alcohols and exogenously added 
PtdOH to decrease and increase MMP secretion, respectively, the investigators 
established a role for PLD in MMP secretion (Reich et al., 1995; Williger et al., 1999). 
Since these original studies, the requirement of PLD in MMP secretion has been 
established for multiple cell types including melanoma (Kato, 2005), colorectal (Kang et 
al., 2008), GBM (Park et al., 2009) and breast (Kang et al., 2011) cancer cells. To date, 
a combination of primary alcohol, DN-PLDs, PLD siRNA, and small-molecule PLD 
inhibitors have been used to block MMP secretion form cancer cells, firmly supporting 
the requirement for PLD activity. The most widely accepted mechanism for PLD 
regulation of MMP secretion is through a transcription-dependent mechanism. A Ras-
MAPK dependent pathway likely mediates MMP transcription as DN constructs or 
inhibitors of multiple proteins within the MAPK-pathway block MMP secretion in 
response to stimuli such as PDGF, EGF, and PMA. Nuclear factor kappa-light-chain-
enhancer of activated B cells (NF(B) is a transcription factor downstream of ERK 
(Kurland et al., 2003) and has been named as the ERK-dependent transcription factor 
responsible for inducing MMP2 and MMP9 transcription (Kang et al., 2008; 2011; Kato, 
2005; Park et al., 2009).   
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Once the surrounding tissue environment has been appropriately remodeled to 
permit tumor cell escape, the cells must detach from their surrounding cells and ECM 
before beginning the process of migration. In epithelial cells, this process is usually 
termed the epithelial-mesenchymal transition (EMT) where cells lose polarity and cell-
cell adhesion and transition into migratory mesenchymal-like cells (Hanahan and 
Weinberg, 2000). During EMT, cells reorganize adhesion proteins that promote 
interaction with the ECM. E-cadherin is a cell-surface protein that couples to the actin 
cytoskeleton, regulates adhesion-dependent signaling, and interacts with other cells to 
transmit anti-growth signals (De Craene and Berx, 2013). Downregulation of E-cadherin 
is one the earliest steps in EMT, usually achieved through transcriptional regulation by a 
variety of pathways. Growth factors such as EGF, FGF, PDGF stimulate EMT through a 
Ras-MAPK pathway leading to activation of transcription factors such as SLUG, which 
represses E-cadherin and promotes expression of EMT genes (Bolós et al., 2003; 
Savagner et al., 1997; Yang and Weinberg, 2008). As PLD is intimately involved in RTK-
Ras-MAPK signaling, it stands to reason that PLD may also regulate EMT and loss of 
cell-adhesion. Indeed, a positive correlation between PLD activity and loss of E-cadherin 
exists in certain cells. Wounded corneal epithelial cells undergo an EMT as cells migrate 
at the leading edges of the wound. Treatment of these cells with exogenous PtdOH or 
overexpression of PLD2 caused a dramatic reduction of cell-surface E-cadherin in these 
cells (Mazie et al., 2006). However, butanol did not decrease EGF stimulation of ERK in 
this system, suggesting that PLD may regulate E-cadherin through different means. In 
addition to the Ras-ERK pathway, the Wnt/!-catenin pathway also promotes EMT 
(Sánchez-Tilló et al., 2011; Yang and Weinberg, 2008). The Wnt pathway is critical in 
tissue development and is frequently mutated in many cancers (Kikuchi, 2003). Recent 
studies have shown that PLD1 is a transcriptional product of Wnt activation and 
participates in a feed-forward mechanism where PLD activity is required for transcription 
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of a number of Wnt-responsive genes (Kang et al., 2010). Although EMT gene 
expression was not measured in the study, PLD may potentially regulate EMT and loss 
of adhesion through Wnt. Small-molecule PLD inhibitors block Wnt-mediated 
transformation of NIH3T3 cells and underscore the importance of PLD in Wnt-signal 
transduction (Kang et al., 2010). Whether or not PLD directly participates in EMT and 
loss of cell-cell and ECM adhesion should be the subject of future studies. 
After ECM remodeling and loss of adhesion, invading cells must migrate into 
surrounding tissues. Migration events occur under normal conditions such as the 
chemotaxis of cells towards chemical stimuli during infection and development. The 
process of migration requires significant cytoskeletal rearrangements and PLD is an 
important regulator of these events. PLD activity is required for neutrophil migration 
towards chemotactic peptides and cytokines such as fMLP and interleukin-8 (IL-8) 
(Carrigan et al., 2007; Lehman et al., 2006) and for macrophage migration towards 
colony stimulating factor 1 (Knapek et al., 2010). Cancer cells can secrete 
chemoattractants to recruit immune cells into tumors where they produce MMP and 
other factors that promote invasion (Condeelis and Pollard, 2006). Additionally, PLD 
activity is required for fibroblast migration towards LPA (Pilquil et al., 2006) and 
endothelial cell migration towards S1P (Gorshkova et al., 2008). Like non-transformed 
cells, cancer cells such as MDA-MB-231 also require PLD activity for migration (Scott et 
al., 2009; Zheng et al., 2006). Cellular migration is a multistep process consisting of 
cycles of cells protrusion, attachment to the ECM, and retraction. The first step of the 
cycle requires polarization of the cell into leading and retracting edges with the 
development of protrusions such as lamellipodia or filopodia at the leading edges. These 
protrusions must then be stabilized by formation of focal adhesions to the surrounding 
matrix, and finally, the trailing edge of the cell must detach and contract in order to move 
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the cell forward (Ananthakrishnan and Ehrlicher, 2007; Manneville, 2004). PLD and 
PtdOH have been linked to each step of the process.  
PLD enzymes, especially PLD2, are frequently localized to the leading edge of 
motile cells in membrane ruffles and lamellipodia, depending on the cell type (Colley et 
al., 1997b; Nagasaki et al., 2008; O'Luanaigh et al., 2002). PLD activity is required for 
leading edge formation (Santy and Casanova, 2001) and overexpression of PLD 
promotes leading edge characteristics (Shen et al., 2002). Actin-rich leading edge 
formation requires a series of cytoskeletal rearrangements coordinated by members of 
the Rho family such as RhoA, Cdc42, and Rac (Ridley et al., 2003) along with other 
proteins such as non-receptor tyrosine kinases (NRTKs) of the Src family (Kanda et al., 
2007). Rac proteins appear to control lamellipodia formation while Cdc42 controls 
filopodia formation (Manneville, 2004). As discussed previously, the RhoA family 
members stimulate PLD1 activity by a direct protein-protein interaction. Several studies 
have proposed mechanisms where Arf6 and Rac1 converge on PLD1 to promote PtdOH 
production and membrane ruffling in epithelial cells and mast cells (Powner et al., 2002; 
Santy and Casanova, 2001). However, the PLD2 isoform is perhaps more important for 
cell migration and an intriguing mechanism of Rac regulation by PLD2 is emerging. 
 In endothelial cells, Rac activation appears to require PLD2 activity as RNAi 
silencing of PLD2 decreased Rac activation and cell migration in response to S1P 
(Gorshkova et al., 2008). The PH domain of PLD2 encodes a putative CRIB (Cdc42/Rac 
interactive binding) domain that directly interacts with Rac proteins, located between 
amino acids 255-269 (Mahankali et al., 2011; Peng et al., 2011). In vitro, purified PLD2 
potently stimulates GDP-GTP exchange on Rac2 and silencing of PLD2 leads to 
decreased Rac2 activation and chemotaxis in neutrophils (Mahankali et al., 2011). PLD2 
also stimulates GEF activity on Rac1, although the rate of PLD2-catalyzed GDP-GTP 
exchange for Rac1 is less than for Rac2 (Henkels et al., 2013b). Although these studies 
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describe a lipase-independent mechanism of Rac activation by PLD2, other studies 
suggest that PLD catalytic activity is required for Rac activation (Gorshkova et al., 2008) 
and several lipase-dependent mechanisms have been described. In one mechanism, 
PtdOH directly binds the C-terminal polybasic motif of Rac1 and promotes membrane 
translocation (Chae et al., 2008). In the description of the PLD2-GEF activity, inclusion of 
PtdOH in the reaction mixture increases GEF activity (Mahankali et al., 2011), 
suggesting a putative mechanism where PtdOH recruits Rac1 binding to the membrane 
and the combination of PtdOH and PLD2-GEF activity stimulates Rac activation. Another 
mechanism for PtdOH mediated Rac activation involves direct modulation of the Rac 
GEF, dedicator of cytokinesis 2 (DOCK2). DOCK2 contains a DOCK homology region 
that binds PIP3 and controls membrane localization. Full recruitment of DOCK2 to 
leading edges of migrating cells was shown to require PtdOH in addition to PIP3 and the 
PtdOH binding site was narrowed to a polybasic amino acid stretch in the C-terminus 
(Nishikimi et al., 2009). DOCK2 translocation required PtdOH generated by PLD as 
expression of catalytically inactive PLD, treatment with butanol, and treatment with 
small-molecule PLD inhibitors all reduced DOCK2 accumulation at the leading edges of 
neutrophils undergoing chemotaxis (Nishikimi et al., 2009). In non-activated neutrophils, 
Rac is sequestered by GDIs. Upon activation, Rac dissociates and allows GEFs to 
stimulate GDP-GTP exchange leading to membrane ruffling. In vitro, PtdOH and other 
lipids such as arachidonic acid and PIPn’s stimulate dissociation of Rac from the Rac-
GDI (Chuang et al., 1993). The number of mechanisms by which PLD and PtdOH 
stimulate Rac activity certainly highlights Rac as an important mediator of PLD-mediated 
leading edge formation. 
 Just beneath the plasma membrane lies a region rich in cortical actin known as 
the cortex. During leading edge formation, the cortical cytoskeleton undergoes a series 
of events that requires de novo synthesis of F-actin filaments, which provide structure 
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and force to the protruding end of the cell (Small et al., 1999). A complex network of 
actin-binding proteins sever, cap, and nucleate actin monomers to promote formation of 
F-actin filaments. Cortactin is an actin-binding protein that promotes nucleation and 
branching of actin filaments (Ammer and Weed, 2008). Cortactin is subject to regulation 
by NRTKs and phosphorylated cortactin promotes polymerization of actin filaments (Kim 
and Wong, 1998; Wu et al., 1991). In pulmonary epithelial cells, Src phosphorylation of 
cortactin requires PLD activity as PLD siRNA prevented Src and cortactin redistribution 
to the cell periphery (Usatyuk et al., 2009). In addition to Src, PLD has been shown to 
regulate the activity of Fer. The NRTK Fer is a cytosolic protein implicated in cell 
adhesion and cell migration (Greer, 2002). Cortactin is the best-characterized substrate 
of Fer and this phosphorylation is critical for fibroblast migration (Sangrar et al., 2007). 
Recently, PtdOH was shown to bind and activate Fer by binding to R417 (Itoh et al., 
2009). Activation of Fer was inhibited by butanol but not DGK inhibitors suggesting that 
PLD-produced PtdOH was critical for Fer activation. Migration of rat kidney epithelial 
cells was inhibited by butanol or by genetic knockdown of PLD1/PLD2. Knockdown of 
Fer in addition to PLD1/PLD2 did not result in further reduction of migration suggesting 
PLD is a critical upstream regulator of Fer and cortactin phosphorylation (Itoh et al., 
2009). Fes is NRTK that shares structural similarity to Fer and is also implicated in cell 
migration (Kanda et al., 2007). PLD2 interacts with Fes and overexpression of PLD2 
increases Fes activity (Di Fulvio et al., 2012). Treatment of cells with exogenous PtdOH 
stimulates Fes activity, possibly through a direct interaction, based on sequence 
homology to Fer kinase (Ye et al., 2013). In addition to NRTKs, other upstream kinases 
such as PAK and MAPKs can activate cortactin (Campbell et al., 1999; Webb et al., 
2006). 
The PAKs are serine/threonine protein kinases that are activated by the small G-
proteins Cdc42 and Rac. PAKs mediate many intracellular functions including 
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cytoskeleton rearrangement (Sells and Chernoff, 1997), stress signaling through the 
p38/Jun N-terminal kinase (JNK) pathways (Zhang et al., 1995), and regulation of 
NADPH oxidase activity by direct phosphorylation of p47phox (Knaus et al., 1995). 
Although the PAKs were originally identified based on the ability of Cdc42/Rac to 
stimulate autophosphorylation and kinase activity, sphingosine and PtdOH also potently 
stimulate PAK1 in vitro (Bokoch et al., 1998). The activation of PAK1 by Cdc42/Rac and 
sphingosine or PtdOH is not additive or synergistic, suggesting a common binding site 
on PAK1. In vivo, PAK1 activity is inhibited following butanol treatment, which suggests 
PLD-derived PtdOH regulates PAK1 activity (Chae et al., 2008). Along with Src, Fer, and 
MAPK, PAK1 provides another potential downstream effector of PLD capable of 
activating cortactin.  
 One of the ways in which cortactin promotes actin nucleation is to bind and 
activate the actin-related protein complex 2/3 (Arp2/3), which binds to a preexisting actin 
filament and nucleates branching of a new filament (Ammer and Weed, 2008; Weed et 
al., 2000). The The Wiskott-Aldrich syndrome protein (WASp) family of proteins 
cooperates with cortactin to activate Arf2/3 (Martinez-Quiles et al., 2004; Mizutani et al., 
2002). As mentioned previously, PLD2 forms a complex with the Grb2 adaptor protein 
(Di Fulvio et al., 2006). WASp forms a complex with Grb2 and PLD2 and this protein 
complex promotes the formation of phagocytic cups in macrophages, a process 
requiring similar actin rearrangements to lamellipodia formation (Kantonen et al., 2011). 
When the Grb2 site on PLD2 is mutated, the complex fails to form properly and 
phagocytosis is decreased. Although a direct relationship between the PLD2-Grb2-
WASp complex and cancer cell migration remains to be established, PLD is poised as a 
central regulator of several proteins that cooperate to promote cortical actin 
poymerization. 
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As cell protrusions extend forward, focal adhesions are formed that serve as 
mechanical anchors to the ECM and provide contractile forces that propel the cell 
forward. These adhesions are mediated in large part by the integrin family of proteins 
that bind ECM components and relay information about the cellular environment to 
intracellular components (Hood and Cheresh, 2002). Integrins attach to the cytoskeleton 
through a complex set of adaptor proteins including vinculin (Geiger, 1979) and talin 
(Burridge and Connell, 1983) and induce F-actin polymerization. Integrins are known to 
stimulate PLD and the integrin-induced increase in F-actin requires PLD activity. As 
such, butanol treatment or knockdown of PLD is associated with defects in the ability to 
form adhesions (Aguirre Ghiso et al., 1997; Iyer et al., 2006). The speed of migration is 
largely controlled by the speed at which cells form and detach from these adhesions 
(Lauffenburger and Horwitz, 1996) and PLD regulates migration speed in wound healing 
assays (Mazie et al., 2006). PLD activity is associated with an increase in vinculin levels 
(Mazie et al., 2006) and also activation of focal adhesion kinase (FAK), a key regulator 
of focal adhesion turnover (Knoepp et al., 2008; llić et al., 1995). Mechanistically, PLD 
can regulate adhesion dynamics by regulating the activity of integrin adaptor proteins. 
PIP2 binding to the adaptor protein talin enables bindings to the integrin !-subunit and 
changes integrin conformation to a high affinity state for ECM components (Calderwood 
et al., 2002; García-Alvarez et al., 2003; Tadokoro et al., 2003). PLD can enhance 
binding of talin to integrins through regulation of PIP2 levels by activating PIP5K. Early 
investigations revealed that PtdOH stimulated PIP5K activity from bovine brain 
membranes (Moritz et al., 1992) and later investigations revealed that only the class I 
PIP5Ks are stimulated by PtdOH (Jenkins et al., 1994). In vivo regulation of PIP5K by 
PtdOH has been documented as a significant decrease in PIP2 levels in lysosomal 
membranes following butanol treatment (Arneson et al., 1999) and a decrease in PIP5K-
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dependent actin stress fiber formation following PLD inhibition in murine fibroblasts 
(Pardo and Fitzpatrick, 2007). Recent studies have demonstrated reduced PIP5K activity 
following treatment with small-molecule PLD inhibitors (Roach et al., 2012), further 
underscoring the importance of PtdOH in PIP5K regulation. In mast cells, PLD inhibition 
was associated with decreased PIP2 levels and reduced binding of talin to integrins 
(Powner et al., 2005). Thus, by regulating PIP5K and PIP2 levels, PLD is directly able to 
control cell adhesion. 
 After protruding forward and forming focal adhesions, the retracting edge of a 
migrating cell must detach from the ECM and contract. This process is assisted by the 
formation of actin stress fibers in some systems (Kovac et al., 2013), which connect to 
focal adhesions (Geiger et al., 2009; Parsons et al., 2010). Stress fibers are bundles of 
actin filaments that provide contractile force for actively moving cells (Pellegrin and 
Mellor, 2007). Agents that elevate PLD activity frequently result in stress fiber formation. 
These include thrombin stimulation of fibroblasts (Ha and Exton, 1993), LPA stimulation 
of porcine aortic endothelial cells and rat fibroblasts (Cross et al., 1996; Kam and Exton, 
2001), and S1P stimulation of human airway epithelial cells (Porcelli et al., 2002). In 
these cases, inhibition of PLD activity with butanol or DN-PLD expression prevented the 
agonist-mediated stress fiber formation and exogenous PtdOH stimulated stress fiber 
formation in the absence of agonist. Overexpression of PLD is able to induce stress fiber 
formation in L6 myoblasts (Komati et al., 2005) and expression of DN-PLD prevents 
LPA-stimulated stress fiber formation in fibroblasts (Kam and Exton, 2001). RhoA is a 
master regulator of stress fiber formation in many cells (Kaibuchi et al., 1999; Mackay 
and Hall, 1998) and RhoA-stimulated PLD activity has been implicated in stress-fiber 
formation. The observations that butanol and DN-PLD inhibit stress fiber formation and 
exogenous PtdOH stimulates stress fiber formation strongly implicate a PtdOH-
dependent mechanism for stress fiber formation. Recently, however, the PX domain of 
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PLD2 was shown stimulate GDP-GTP exchange for RhoA directly, offering a lipase-
independent mechanism for stress-fiber formation (Jeon et al., 2011). In this study, 
overexpression of the isolated PX domain was sufficient to trigger stress fiber formation. 
Therefore, PLD appears to regulate stress fiber formation through lipase dependent and 
independent mechanisms. 
 
Inducing angiogenesis 
 Angiogenesis is the process of sprouting new blood vessels from existing vessels 
and is required to provide nutrients, remove metabolic waste, and promote metastasis. 
In this process, vascular endothelial cells are either recruited into the tumor mass or 
undifferentiated tumor stem cells already present undergo differentiation into epithelial-
like cells to contribute to the formation of new blood vessels (Hanahan and Folkman, 
1996; Wang et al., 2010b). Initiation of angiogenesis usually begins with secretion of pro-
angiogenic factors that interact with cell surface receptors on endothelial cells and 
stimulate migration into the tumor (Colville-Nash and Willoughby, 1997; Ferrara and 
Alitalo, 1999). Many of these factors such as VEGF (Seymour et al., 1996), EGF, FGF, 
HGF (Adachi et al., 1996), and interleukin-8 (Sozzani et al., 1994) stimulate PLD activity, 
and PLD activity is required for VEGF induced angiogenesis (Zhang et al., 2011). In 
zebrafish, PLD activity is required for angiogenesis during embryonic development of 
vasculature (Zeng et al., 2009), further emphasizing the importance of PLD in the blood 
vessel devlopment. 
 PLD may contribute to angiogenesis in several ways. As a downstream effector 
of angiogenic growth factors, PLD and PtdOH may mediate growth factor signaling. 
Cells with elevated Raf activity demonstrate elevated VEGF expression (Akula et al., 
2005). Similarly, oncogenic Ras can upregulate VEGF expression (Rak et al., 1995) and 
PLD may contribute to the Ras-MAPK signaling cascades in these cells. Latent forms of 
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VEGF can be sequestered in the extracellular matrix and become bioavailable following 
proteolytic processing by proteases such as MMP9 (Bergers et al., 2000; Kessenbrock 
et al., 2010). As such, PLD regulation of MMP9 activity may directly contribute to VEGF 
secretion.  
Angiogenesis requires migration of endothelial cells, and PLD likely regulates the 
migratory processes required during angiogenesis. When mouse melanoma or lung 
cancer cells were implanted into WT or PLD1 KO mice, tumors in PLD1 KO mice 
showed a much lower density of microvascular cells (Chen et al., 2012). When VEGF-
coated matrigel plugs were inserted into the same mice, endothelial cells failed to 
migrate to the plugs in the PLD1 KO mice, suggesting inherent defects in the migration 
of PLD1 KO-derived endothelial cells. Consistent with this observation, PLD1 KO mice 
showed impaired integrin signaling as manifested by a failure to properly adhere to ECM 
integrin ligands such as fibronectin, vitronectin, and collagen (Chen et al., 2012; Elvers 
et al., 2010). Therefore, the role of PLD in angiogenesis is most likely to mediate 
endothelial cell migration. 
 
Deregulating cellular energetics 
 In the 1920’s, the German physiologist Otto Warburg pioneered the study of 
cancer metabolism by characterizing fundamental differences in glucose utilization 
between tumors and normal tissue. These differences included avid glucose 
consumption and lactate production by tumor cells resulting in increased ATP production 
via the less efficient glycolysis pathways compared to the highly efficient mitochondrial 
oxidative phosphorylation pathways, even in the presence of ample oxygen (Warburg, 
1956). This surprising discovery, termed the “Warburg effect,” violated the established 
ideas of the Pasteur effect where O2 was known to suppress glucose consumption and 
glycolysis (Krebs, 1972). Subsequent studies have confirmed and broadened Warburg’s 
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initial discoveries and most cancer cells today have altered metabolic profiles consistent 
with the Warburg effect (Hanahan and Weinberg, 2011). When tumors outgrow the 
diffusion limits of nutrients and oxygen from the blood supply, a metabolic shift occurs 
where glycolytic gene expression increases along with increases in cell surface 
expression of glucose transporters. Thus, oxygen dependence is reduced compared to 
the more vascularized surrounding tissue. This glycolytic shift is advantageous for the 
cancer cell as it allows for growth and survival in the tumor microenvironment (Hsu and 
Sabatini, 2008). Proliferating cells must accumulate biomass such as lipids and 
ribosomes, and the high rate of glucose and glutamine (DeBerardinis et al., 2007) 
uptake provides anabolic carbons for pathways such as the pentose phosphate pathway 
and Krebs cycle (Vander Heiden et al., 2009). Therefore, deregulated cellular energetics 
is emerging as a fundamental process in tumorigenesis. 
 The molecular mechanisms behind the Warburg effect are not entirely 
characterized, but several key components have been identified including established 
oncogenes. For example, expression of oncogenic Ras or Myc results in an upregulation 
of glucose transporter activity and glycolytic gene expression (Ahuja et al., 2010; Dang 
and Semenza, 1999; Osthus et al., 2000; Ramanathan et al., 2005). Activation of the 
PI3K/Akt pathway stimulates glucose uptake and a shift toward aerobic glycolysis by 
regulating the activities of multiple glycolytic enzymes (Deprez et al., 1997; Elstrom et 
al., 2004; Majewski et al., 2004). As PLD is a signaling component in these pathways, 
the aerobic glycolysis induced by Ras, Myc, or PI3K may require PLD activity. As such, 
PLD can participate in the development of the Warburg phenotype through several 
different mechanisms. PLD1 is phosphorylated at S505 and activated by AMPK, a 
protein responsible for sensing and responding to changes in cellular energy status 
(Hardie, 2007; Kim et al., 2010). Glucose deprivation stimulates PLD1 activity via AMPK 
activation (Kim et al., 2010), suggesting PLD may be one of the early responders to 
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energetic perturbations as seen in a growing tumor. Glycolytic enzymes such as 
aldolase and GAPDH also directly regulate PLD activity, supporting the idea that PLD 
may serve as sensor of cellular energy homeostasis (Kim et al., 2002; 2003a). The 
downstream effect of AMPK-mediated PLD activation is an increase in glucose 
transporters at the plasma membrane (Kim et al., 2010) to facilitate glucose uptake. 
Likewise, several studies have shown a requirement for PLD activity for glucose 
transporter translocation to the plasma membrane following insulin stimulation 
(Bandyopadhyay et al., 2001; Huang et al., 2005; Sajan et al., 2002). PtdOH is a key 
component of the glucose transporter vesicular membrane and the authors 
demonstrated that PtdOH contributes to the late-stage fusion events. The role of PLD in 
exocytic events is well established in neuroendocrine cells (Vitale et al., 2001; Zeniou-
Meyer et al., 2008) and similar mechanisms may be at play for glucose transporter 
vesicle fusion. Besides directly contributing to the biophysics of glucose transporter 
translocation, PLD also controls expression of glycolytic genes. 
 The hypoxia-inducible factors (HIF) are transcription factors that control 
expression of many glycolytic enzymes (Kaelin and Ratcliffe, 2008). HIF regulation is 
complex and involves several upstream components.  Prolyl hydroxylases sense O2, and 
hydroxylate residues on the alpha subunit of HIF in the presence of O2 (Dann and 
Bruick, 2005). Ubiquitin is then coupled to these modified residues by the Von Hippel-
Lindau (VHL) E3 ubiquitin ligase and HIF is targeted for proteasomal destruction 
(Schofield and Ratcliffe, 2005). Thus, loss of the VHL tumor suppressor leads to 
constitutively high HIF expression resulting in upregulation of glycolytic gene 
transcription seen in many cancers (Zhong et al., 1999). For example, 786-O renal 
carcinoma cells are VHL null and have constitutively high HIF levels. Butanol, PLD 
siRNA, and small-molecule inhibitors suppress HIF expression in these cells (Garcia et 
al., 2008; Toschi et al., 2008). After restoring VHL function in these cells, HIF expression 
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decreases and can be induced again by treatment with hypoxia mimetic compounds. 
PLD inhibition blocks the hypoxia mimetic-induced HIF expression and the authors 
attribute these results to PLD regulating HIF expression through mTOR (Toschi et al., 
2008). However, as discussed in chapter II, PLD may serve an mTOR independent role 
as a general sensor of cellular bioenergetics. 
 
Functions of phosphatidic acid 
Phosphatidic acid is a multifunctional lipid that is generated by two other 
pathways besides PC hydrolysis by PLD. In the first pathway, PtdOH is synthesized de 
novo by a two-step mechanism involving the transfer of two fatty acyl chains to the sn-1 
and sn-2 positions of glycerol 3-phosphate, situating PtdOH as the precursor to all other 
glycerophospholipids (Kennedy, 1987). In addition to de novo synthesis and PC 
hydrolysis by PLD, diacylglycerol kinase can transfer a phosphate group to DAG to 
generate PtdOH, although these PtdOH species are believed to be distinct in acyl 
composition compared to PLD derived PtdOH (reviewed in (Shulga et al., 2011). Once 
generated, PtdOH can mediate signaling events by indirect mechanisms through 
metabolism into other bioactive lipids such as LPA by phospholipase A (Aoki, 2004) and 
DAG by lipid phosphate phosphatase (Brindley, 2004). The most relevant functions of 
PtdOH for this dissertation, however, are the signaling functions mediated by PtdOH 
directly.  
 Many signaling cascades begin with the generation of bioactive lipids such as 
PtdOH or phosphorylated PIs that recruit or modulate enzymatic activities of 
downstream effectors. These transient protein-lipid interactions are mediated by families 
of lipid-binding domains that share some degree of sequence or structural homology 
(Lemmon, 2008). The C1 and C2 domains (conserved regions 1 and 2) were first 
identified in protein kinase C and are responsible for binding DAG and Ca2+/PS, 
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respectively (Cho and Stahelin, 2006; Colón-González and Kazanietz, 2006). PH 
domains were identified as PIPn binding domains from pleckstrin, the major substrate for 
PKC in platelets (Lemmon, 2008). Proteins with PH domains show some degree of 
specificity for PIPn species. For example, the PH domain of Akt kinase has a high affinity 
for PIs phosphorylated at the D3 and D4 positions such as PI(3,4)P2 and PI(3,4,5)P3 but 
has much weaker affinity for PI(4,5)P2 (Thomas et al., 2002). The PH domain of PLC#1, 
on the other hand, has a high affinity for PI(4,5,)P2 and this interaction is required for its 
catalytic activity (Ferguson et al., 1995). Monophosphorylated PI(3)P is recognized by 
several binding motifs including FYVE and PX domains, named after the phagocyte 
NADPH oxidase (Kanai et al., 2001; Kutateladze, 2006). Although most FYVE and PX 
domains bind PI(3)P, some have affinity for PIP2 and PIP3 (Song et al., 2001). Annexin 
domains are calcium dependent phospholipid-binding domains that are thought to 
predominantly bind PS, although binding to other phospholipids has been reported 
(Gerke et al., 2005). Besides interacting with specific lipids, other domains are known to 
detect or promote membrane curvature.  Domains such as F-BAR, BAR, ENTH, and 
ANTH domains participate in functions that require membrane deformation such as 
endocytosis and cytokinesis (Itoh and De Camilli, 2006). The specificity and 
conservation of these lipid-binding domains has helped to identify proteins involved with 
lipid-mediated signal transduction.  However, no specific domain has been identified for 
PtdOH binding and thus the identification of proteins modulated by PLD-generated 
PtdOH has been especially challenging (Stace and Ktistakis, 2006). Many of the known 
PtdOH binding proteins have already been described in relevant sections of this 
introduction. Thus, a survey of other known PtdOH-binding proteins along with the 
functional significance of the interactions is presented in the following section and a table 
summary of all PtdOH-binding proteins described in this introduction is included at the 
end of this section (Table 2).   
 79!
Kinases 
SPHK1. Sphingosine kinase phosphorylates sphingosine to produce the 
bioactive S1P. A family of GPCRs, known as Edg receptors, bind S1P and mediate a 
variety of functions including cell growth, cytoskeleton rearrangement, and vascular 
maturation (Spiegel and Milstien, 2002). Membrane recruitment of SPHK1 to perinuclear 
regions requires PtdOH (Delon et al., 2004). The translocation of SPHK1 is enhanced by 
overexpression of PLD or stimulation with phorbol esters and inhibited by treatment with 
butanol, thus suggesting that PtdOH derived from PLD regulates SPHK1 membrane 
localization (Delon et al., 2004).  
PKC!. The epsilon isoform of PKC is a member of the calcium independent, 
DAG-dependent PKC family. PKC% has been implicated physiological functions such as 
neurite outgrowth, inflammatory or immune responses, tumorigeneis, myocardial 
development, and protection against ischemic damage (Akita, 2002). Membrane 
recruitment of PKC% requires DAG and PLD-generated PtdOH, as determined by the 
use of butanol (Jose Lopez-Andreo et al., 2003). In order to address the possibility that 
PtdOH was metabolized to DAG and did not directly influence membrane recruitment of 
PKC%, the authors demonstrated synergistic PKC% activation by co-stimulation with DAG 
and PtdOH (Jose Lopez-Andreo et al., 2003).  
PKC". Like PKC%, the delta isoform belongs to the novel PKC family of calcium-
independent, DAG-dependent PKCs. The PKC# isoform shares partial functional 
redundancy to other PKC isoforms, but PKC# mediates specific roles in apoptosis, cell 
cycle progression, and transcriptional regulation (Steinberg, 2004). PtdOH can stimulate 
PKC# in vitro although the fold stimulation is much less than PS, suggesting a general 
requirement for anionic phospholipids (Aris et al., 1993). In vivo relevance of PtdOH 
regulation of PKC# remains to be determined.  
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PKC#. The zeta isoform of PKC is a member of the atypical family of PKCs that 
do not respond to calcium or DAG and appear to regulated by PIP3 and by protein-
protein interactions (Hirai and Chida, 2003; Ways et al., 1992). PKC) is believed to 
participate in the MAPK cascade, NF(B transcription, the p70S6-kinase cascade, and 
development of cell motility (Hirai and Chida, 2003). In vitro, PKC) is activated by PtdOH 
(Limatola et al., 1994; Nakanishi and Exton, 1992). However, mono- and 
polyunsaturated fatty acids, PS, and CL, also stimulate PKC) in vitro (Nakanishi and 
Exton, 1992) and an in vivo regulation of PKC) by PLD-derived PtdOH remains to be 
established.  
PKC$. The alpha isoform of PKC belongs to the conventional family of PKCs and 
requires both calcium and DAG for full activation. PKC" is activated by many 
extracellular stimuli and plays important roles in proliferation, apoptosis, differentiation, 
motility, and inflammation (Nakashima, 2002). PtdOH has been shown to regulate PKC" 
in multiple studies. PtdOH added to PKC"-transfected COS-7 cells results in a 
significant upregulation of PKC" autophosphorylation (Limatola et al., 1994). 
Additionally, PtdOH stimulates PKC" kinase activity when added to bovine brain cytosol 
(Yokozeki et al., 1998). Neither study ruled out the possibility of an intermediate PtdOH-
stimulated protein or metabolism of PtdOH to DAG as a potential explanation for the 
increase in PKC" activation following PtdOH treatment. Therefore, the exact role of 
PtdOH remains unclear. 
Akt. A recent study demonstrated that Akt could be phosphorylated at tyrosine 
176, distinct from the canonical activating phosphorylation sites of threonine 308 and 
serine 473. When phosphorylated at tyrosine 176, the lipid binding profile of Akt changed 
such that the kinase preferred to bind PtdOH, yet no functional consequence of Akt-
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PtdOH binding was determined (Mahajan et al., 2010). Binding of PtdOH to Akt will be 
further discussed in chapter III. 
 
Phosphatases 
SHP1. The Src homology region 2 domain-containing phosphatase-1 (SHP1) is a 
non-receptor tyrosine phosphatase, mainly expressed in hematopoietic cells, with a wide 
spectrum of substrates (Soulsby and Bennett, 2009). SHP1, but not SHP2, was 
activated by PtdOH in vitro (Tomic et al., 1995). Additionally, PtdOH enhanced the 
association between SHP1 and EGFR and increased EGFR dephosphorylation. The 
high affinity PtdOH binding site on SHP1 was later mapped to the carboxy-terminal 41 
amino acids (Frank et al., 1999). Although PLD was not directly shown to participate in 
the modulation of SHP1, PLD-generated PtdOH could act as part of a negative feedback 
loop involving SHP1 to terminate receptor tyrosine kinase signaling. 
Lipin1%. Lipin1! is a type-1 (magnesium dependent and N-ethylmaleimide 
sensitive) PtdOH phosphatase that plays important roles in adipocyte differentiation by 
regulating triacylglycerol production and storage. Mutations in Lipin1! lead to 
lipodystrophy in mice (Péterfy et al., 2001). In addition to its phosphatase activity, 
Lipid1! translocates to the nucleus to activate a subset of peroxisome proliferator-
activated receptor $ coactivator 1a (PGC-1a) target pathways including fatty acid 
oxidation and mitochondrial oxidative phosphorylation (Finck et al., 2006). Recently, a 
PtdOH binding site was mapped to a polybasic motif of Lipin1!, independent of the 
catalytic site. Interestingly, when these residues were mutated or when cells were 
treated with small-molecule PLD inhibitors, Lipin1! localized to the nucleus, suggesting 
that PLD and PtdOH may serve to modulate specific gene transcription (Ren et al., 
2010). 
 82!
Phospholipase C 
PLC%1. PI-specific PLC enzymes hydrolyze PIP2 to generate IP3 and DAG, which 
increase intracellular calcium stores and activate PKC. PtdOH directly binds purified 
PLC!1 and stimulates its activity in vitro. The activation of PLC!1 is unique to PtdOH as 
other phospholipids were unable to stimulate PIP2 hydrolysis (Litosch, 2000). 
Additionally, primary butanol significantly rightward shifts muscarinic receptor-stimulated 
PIP2 hydrolysis, implicating a role for PLD regulating in PLC in vivo (Litosch et al., 2009). 
Tyrosine 952 and isoleucine 955 mediate PtdOH binding, suggesting distinct modes of 
PLC regulation by PtdOH and G"a (Litosch et al., 2009). PLC! stimulation by PtdOH is 
unique to PLC!1 as other ! isoforms were unresponsive to PtdOH stimulation (Litosch, 
2003). 
PLC&1. Receptor tyrosine kinase stimulation increases PIP2 hydrolysis through 
the activation of PLC$ (Meisenhelder et al., 1989) and PtdOH was shown to stimulate 
the activity of PLC$1 in vitro (Jones and Carpenter, 1993). The hypothesized mechanism 
for PtdOH regulation of PLC$1 is through allosterically increasing enzyme activity rather 
than increasing the equilibrium dissociation constant, Ks (Jones and Carpenter, 1993). 
PLC!. The epsilon isoform of PLC is activated through the actions of small G 
proteins such as Ras and through heterotrimeric G proteins such as G"12 and G"13 
(Song et al., 2001). When purified to homogeneity, PLC% had very low basal activity that 
was stimulated by arachidonic acid, PtdOH, and to a lesser extent by PS and LPA 
(Murthy et al., 2013). Interestingly, PtdOH was a more potent stimulator of PLC% 
hydrolysis of PI than PIP2 whereas arachidonic acid stimulated PLC% activity to wards 
both substrates equally. These results suggest that lipids may regulate substrate 
specificity of PLC%. 
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PLC"3. The delta isoforms of PLC are activated by increased Ca2+, which 
promotes association with PIP2 (Rhee, 2001). Purified PLC#3 was shown to bind PtdOH 
vesicles through its PH domain (Pawelczyk and Matecki, 1999) and the interaction with 
PtdOH increased PLC#3 activity in vitro.  
 
G protein regulatory proteins 
RA-RhoGAP. As key regulators of cytoskeleton dynamics, Rho GTPases are 
known to control neurite development and decreased Rho activity is associated with 
enhanced neurite sprouting, extension, and branching (Luo, 2000). RA-RhoGAP is a 
Rho GAP that binds PtdOH via its PH domain (Kurooka et al., 2011). As with several 
other PtdOH-protein interactions, mutation of a basic residue, arginine 399, abolished 
PtdOH binding. The interaction of RA-RhoGAP with PtdOH stimulated GAP activity in 
vitro (Kurooka et al., 2011). Overexpression of DAG kinase increased neurite length in a 
manner that depended on PtdOH binding to RA-RhoGAP. Contributions of PLD-derived 
PtdOH were not measured in this study. 
Arf GAPs. Several Arf GAPs have been identified that are modulated by PtdOH 
in vitro. Two of the earliest ArfGAPs discovered, ArfGAP1 and ArfGAP2, are both 
stimulated by phospholipids. ArfGAP1 activity is stimulated about 7-fold by PIP2, PtdOH, 
and PS. ArfGAP2 is stimulated 2-fold by PIP2, but not by PtdOH or PS. However, PIP2 
and PtdOH synergize to stimulate ArfGAP2 activity about 20-fold (Randazzo, 1997). 
ASAP1, like ArfGAP2, is weakly stimulated by PtdOH alone, but synergistic activity is 
observed in the presence of PtdOH and PIP2. Like ArfGap2, PtdOH and PIP2 synergize 
to activate another Arf-GAP, ASAP1. ASAP1 contains a PH domain that most likely 
mediates the phospholipid interactions (Brown et al., 1998b). AGAP1 is another PH 
domain-containing Arf-GAP that is synergistically stimulated by PIP2 and PtdOH. 
Although the synergy was most robust with PtdOH, other anionic lipids such as PS and 
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PI also synergized with PIP2 (Nie et al., 2002). Arf6 specific GAPs, ACAP1 and ACAP2, 
display similar synergy with PIP2 and PtdOH (Jackson et al., 2000). The requirement of 
PIP2 for PLD and Arf-GAP activities along with the ability of Arf to stimulate PLD 
presents a potential negative feedback loop whereby PLD-generated PtdOH may serve 
to terminate Arf signaling. 
n-chimaerin. n-chimaerin was identified as a phorbol ester binding GAP for the 
small G protein Rac. n-chimaerin is stimulated by PtdOH and, to lesser extent, PS. 
Interestingly, arachidonic acid inhibits n-chimaerin GAP activity (Ahmed et al., 1993). 
RGS4. The G" subunits are regulated by a special class of GAPs known as 
regulators of G protein signaling (RGSs) (Ross and Wilkie, 2000). RGS proteins function 
to attenuate GPCR signaling by stimulating G" GTP hydrolysis. When M1 muscarinic 
acetylcholine receptors were reconstituted in lipid vesicles and incubated with RGS4, 
vesicles containing PtdOH inhibited RGS4 GAP activity following M1-agonist stimulation. 
PtdOH was then determined to directly bind the first 57 amino acids of RGS4 (Ouyang et 
al., 2003). As discussed in chapter II, M1 stimulation activates PLD1 and thus, the 
inhibition of RGS4 activity by PLD-generated PtdOH might potentiate M1 signaling. 
 
Miscellaneous proteins 
NADPH oxidase. Host defense systems against invading pathogens involve 
phagocytosis and subsequent destruction by the generation of superoxide anions, 
hydrogen peroxide, and hypochlorous acid via the NADPH oxidase complex in 
phagocytes. This complex contains multiple membrane (p22Phox and gp91Phox) and 
cytosolic subunits (p47Phox, p40Phox, p67Phox, and Rac1/2) that are subject to regulation by 
PLD and PtdOH (DeLeo and Quinn, 1996). Upon engagement of cell surface receptors 
by pathogens, cytokines, or chemoattractants, PLD activity and PtdOH production 
increase (McPhail et al., 1999). PtdOH stimulates an unknown kinase that 
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phosphorylates the p47Phox and p22Phox subunits (McPhail et al., 1995; 1999). Later 
studies demonstrated that PtdOH was able to stimulate NADPH oxidase activity by 
directly interacting with different subunits of the complex (Palicz et al., 2001). Crystal 
structures of the p47Phox subunit revealed a high affinity binding site for PIP2 and 
separate binding site for anionic phospholipids such as PtdOH. Binding of p47Phox to PIP2 
vesicles was synergistically increased when PtdOH was also as a vesicle component, 
suggesting that PtdOH increases p47Phox association to PIP2 (Karathanassis et al., 
2002). Recently, studies with small-molecule PLD inhibitors have confirmed the 
involvement of PLD in regulating NADPH oxidase (Chang et al., 2011). 
Neurogranin. Neurogranin (Ng) is a protein originally identified as a PKC 
substrate in brain and is involved in synaptic plasticity (Baudier et al., 1991). Ng 
specifically binds PtdOH in vitro in a site that overlaps with its calmodulin-binding motif. 
Overexpression of PLD increased localization of Ng at dendritic spines, suggesting PLD-
generated PtdOH regulates Ng localization. 
Sin1. mTOR exists in two distinct complexes (mTORC1 and mTORC2) 
distinguished by different binding partners and unique substrate specificities. Sin1 is an 
essential component of the mTORC2 complex and is required for complex stability and 
kinase activity towards downstream effectors (Yang et al., 2006). Sin1 contains a PH 
domain that binds PIPns and PtdOH in vitro (Schroder et al., 2007). The relevance of 
Sin1-PtdOH binding is unknown, but PLD may regulate mTORC2 activity by activating or 
localizing Sin1. 
ADP/ATP translocase. The ADP/ATP translocase (ANT) is an inner mitochondrial 
membrane protein that transports newly synthesized ATP from the mitochondria to the 
cytosol (Klingenberg, 2008). When purified from bovine heart and analyzed for bound 
lipids, PtdOH was tightly bound to the ANT protein (Epand et al., 2009). The 
physiological relevance of this interaction is unknown. 
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%-coatmer, Arf, N-ethylmaleimide-sensitive factor (NSF), and Kinesin. In an 
attempt to isolate novel PtdOH binding proteins, investigators coupled PtdOH or PIP2 to 
affinity beads to isolate proteins specifically bound to PtdOH from brain cytosol. !-
coatmer, Arf, NSF, and kinesin, all traffic related proteins, were identified as specifically 
binding PtdOH beads. Recombinant Arf and NSF were shown to directly bind PtdOH, 
but the physiological relevance remains unknown (Manifava et al., 2001). 
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Table 2. Phosphatidic acid proteins. 
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Research purpose 
 
 The lipid-hydrolyzing PLD enzymes respond to diverse extracellular stimuli and 
mediate a large number of cellular events. As such, excessive PLD activity contributes to 
the progression of several pathologies including cancer. The research described within 
this dissertation investigates the composition and functions of PLD signaling networks in 
order to further understand the regulation of PLD and the molecular mechanisms by 
which PLD promotes cancer cell survival. In chapter II, we establish model cell systems 
expressing either GPCRs or RTKs with affinity tagged PLD1 or PLD2 and use proteomic 
analyses to identify novel PLD-protein interactions. The main questions investigated in 
chapter II are: What are the common and unique binding partners between PLD1 and 
PLD2? What are the common and unique binding partners of PLD1 and PLD2 following 
stimulation by a GPCR or RTK? Our preliminary proteomic analysis of PLD2 complexes 
revealed putative interactions between PLD2 and several metabolic enzymes. 
Therefore, chapter II also discusses the questions of: What circumstances does PLD 
regulate intracellular ATP? Which types of cells require PLD activity to maintain ATP 
levels? What is the molecular mechanism of bioenergetic regulation by PLD? We 
present data to support a novel function of PLD to regulate intracellular ATP levels in 
certain PTEN-null GBM and breast cancer cells following serum stimulation, potentially 
by serving as a bioenergetic sensor. 
 In chapter III, we investigate a novel interaction between PLD2 and Akt kinase 
and determine the mechanism by which PLD2 promotes GBM cell survival by regulating 
the activation of Akt. The main questions addressed in chapter III are: How does PLD2 
control activation of Akt kinase? How do PLD2 and Akt promote GBM cell survival? 
What are the molecular targets for PLD2-stimulated Akt activity? We present a 
mechanism by which the cell stressor of serum withdrawal stimulates PLD2 activity 
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leading to PtdOH-mediated membrane recruitment and activation of Akt, which promotes 
autophagic flux and ultimately cell survival in GBM cells. We demonstrate PLD to be a 
clinically relevant target in GBM as PLD inhibitors decrease Akt activation, autophagic 
flux, and ultimately GBM cell viability.  
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CHAPTER II 
 
IDENTIFICATION AND CHARACTERIZATION OF NOVEL PLD COMPLEXES 
 
Rationale 
 At the beginning of this project, the molecular mechanisms for the cellular 
functions of PLD were not well characterized, partially due to incomplete characterization 
of the PLD interactome. The majority of PLD-interacting proteins were purified and 
identified from extracts of tissues and cells based on their ability to stimulate or inhibit 
PLD activity and were limited to a relatively small number of proteins. Since their 
identification, proteins such as Arf, Rho, and PKC have been extensively characterized 
for their ability to activate PLD downstream of cell-surface receptors. Given the 
ubiquitous nature of PLD activation by diverse extracellular stimuli, it seems likely that 
additional unidentified proteins also participate in receptor-mediated PLD activation. 
Once activated, PLD mediates diverse cellular functions such as proliferation, migration, 
secretion, trafficking, protein synthesis, and cytoskeletal rearrangements depending on 
the stimulus and type of cell. Investigators have attempted yeast two-hybrid studies to 
yield insight into the molecular mechanisms for these PLD-mediated functions, but these 
studies have only identified a small-number of PLD interacting proteins (Koch et al., 
2003; Zhang et al., 2000). To date, no studies have been published that used an 
unbiased systems biology approach to identify binding partners of PLD enzymes. 
Therefore, we utilized proteomic approaches to identify and characterize novel PLD 
complexes formed after various receptor stimulations and we believed this approach 
would allow us to answer several important questions. The first question concerns 
determination of proteins that are common and unique for activation of PLD1 and PLD2 
following GPCR and RTK stimulation. The second question concerns identification of 
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PLD-effector complexes that form following unique receptor stimulations. By answering 
these questions, we hoped to further understand the protein components of PLD 
signaling networks.  
 
Development of model systems 
This project began with the goal of identifying novel regulators and effectors of 
the individual human PLD isoforms and to further understand the role of PLD in 
intracellular signaling. HEK293-TREx cells were chosen as a model system due to their 
low levels of endogenous PLD activity and their high transfection efficiency. The M1 
muscarinic receptor, a typical GPCR, and EGFR, a typical receptor tyrosine kinase, are 
known to activate PLD following receptor stimulation (Fisher et al., 1991; McKenzie et 
al., 1992). Preliminary data indicated that the M1 receptor coupled exclusively to PLD1 
whereas the EGFR coupled to both PLD1 and PLD2. In these studies, PLD1 or PLD2 
was overexpressed in HEK293 cells, which stably expressed either M1 or EGFR, and 
PLD was stimulated using an agonist for each receptor.  Expression of PLD1, but not 
PLD2, potentiated M1 stimulation of PLD activity (Figure 1A). On the other hand, 
stimulation of the EGFR resulted in activation of both PLD1 and PLD2 (Figure 1B). The 
specificity of receptor-PLD signaling was then confirmed genetically using small 
interfering RNA (siRNA).  Silencing of endogenous PLD1 abolished the M1 response 
whereas silencing of both PLD1 and PLD2 was required to completely inhibit the EGFR 
response (data not shown). These model systems thus provided a unique background 
for studying isoform-specific PLD signaling. 
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Figure 1. PLD1 and PLD2 activity following EGF or M1 receptor stimulation. A. HEK293-
M1 stable cells were transiently transfected with the indicated human PLD isoform or 
vector control for 48 hours prior to assay. Cells were stimulated with 1 µM M1 agonist 
TBPB (Bridges et al., 2008) in the presence of n-butanol-d10 for 30 min prior to 
glycerophospholipid extraction and subsequent phosphatidylbutanol (PtdBuOH) 
quantification. B. HEK293-EGFR cells were stably transfected with tetracycline-inducible 
PLD1 or PLD2 to generate monoclonal cell lines. Cells were induced with tetracycline for 
PLD1a or PLD2 overexpression 72 hours prior to assay. Cells were serum starved 
overnight and stimulated with 100 ng/ml EGF for 15 min before measuring PLD activity 
as in (A). Error bars – standard error of the mean (SEM) of triplicate samples 
 
After establishing a model cell system, we developed a method for isolating PLD 
complexes from agonist-stimulated cells and the general experimental scheme is 
presented in Figure 2. Epitope-tagged PLD constructs were expressed in either the M1 
or EGFR HEK293 cells, stimulated with appropriate agonist, and isolated using 
immunoprecipitation or other affinity capture techniques. Several epitope tags were 
tested for immunoprecipitation suitability including myc, HA, FLAG, and hexahistidine. All 
epitope tags were fusted to the amino-terminus as any modification to the carboxy-
terminus results in a catalytically inactive PLD enzyme (Liu et al., 2001). All constructs 
expressed at similar levels, and we used the myc-tagged PLD construct for initial 
proteomic analyses.  
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Figure 2. Experimental scheme for identifying receptor-stimulated PLD complexes. 
Parental HEK293-TREx cells were stably transfected to overexpress either the M1 
muscarinic or EGF receptor. HEK293-EGFR or HEK293-M1 cells were then transfected 
with epitope tagged PLD1 or PLD2 and stimulated with the appropriate agonist. Epitope-
tagged PLD was immunoprecipitated and submitted for proteomic analysis to compare 
binding partners in the presence and absence of agonist stimulation. 
 
An example myc-PLD1 IP experiment can be seen in Figure 3. Several problems 
arose from this original approach: high levels of non-specific binding in control 
conditions, contamination from the heavy and light chain immunoglobulins (IgG) (55 kDa 
and 30 kDa bands), and low levels of expression for myc-PLD1. As such, our first 
proteomic analysis of M1-stimulated PLD1 complexes confirmed that the majority of 
proteins were present in both PLD1 and vector controls, consistent with high levels of 
non-specific binding and weak expression of myc-PLD1.  
 
HEK293-receptor HEK293-receptor 
Agonist Vehicle 
Isolate tagged PLD1 or PLD2 from lysate 
Compare binding partners 
(+/- Agonist, PLD1 vs PLD2) 
Identify bound proteins (proteomics) 
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Figure 3. Immunoprecipitation of PLD1a-myc. HEK293-M1 stable cells were transfected 
with myc tagged PLD1a for 48 hours before stimulation with 1 µM TBPB for 5 min. Cells 
were lysed and PLD1 immunoprecipitated with an anti-myc antibody. Complexes were 
eluted in SDS loading buffer, separated on SDS-PAGE gels, and  silver stained to 
assess PLD1-protein complex formation. Numbers indicate molecular weights of 
standards in kDa. 
 
Tandem affinity purification of PLD2 
In order to circumvent the problems associated with high levels of non-specific 
protein binding, we created new PLD constructs expressing a tandem affinity purification 
(TAP) tag that binds affinity resin and can be gently eluted using small molecules. The 
TAP procedure generally consists of two different affinity tags separated by a TEV 
protease cleavage site (Rigaut et al., 1999).  This technique has been widely used in 
yeast as well as mammalian proteomics due to the drastic reduction in non-specific 
proteins and from the lack of heavy and light chain IgG contaminants (Knuesel et al., 
2003; Rigaut et al., 1999). We chose a TAP tag consisting of the IgG binding domain of 
protein-A from Staphylococcus aureus and the strepII tag, which binds strep-tactin 
affinity resin, to create the ProteinA-TEV-StrepII (PtS) tag (Giannone et al., 2007). 
Amino-terminal, PtS-tagged PLD constructs were ligated into the pcDNA5/TO vector 
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backbone, which encodes tetracycline operator sequences in the promoter region that 
allows for transcriptional control in cells that express the tetracycline repressor protein. 
The HEK293-TREx line was engineered by the manufacturer to stably express the 
tetracycline repressor protein. We created stable cell lines for PtS-PLD1 or PtS-PLD2 in 
each receptor background, and determined that PtS-PLD2 expression levels were much 
higher than PLD1. Therefore, the remaining effort was focused on isolating PLD2 
complexes. 
In the TAP procedure, cell lysates are applied to IgG agarose, washed 
extensively, and then incubated with TEV protease overnight to liberate the strepII-
tagged PLD2 from the IgG agarose. Proteolyzed strep-PLD2 is then applied to strep-
tactin affinity resin, washed extensively, and eluted with biotin. Given the multiple rounds 
of affinity purification in the TAP procedure, final eluates should contain fewer non-
specific proteins. However, the multiple rounds of affinity purification also provide more 
opportunities for protein loss. Therefore, we determined the capture efficiency and 
protein loss at each step (Figure 4). Protein expression was induced in HEK293-EGFR-
PtS-PLD2 cells for 48 hours prior to cell harvest and detergent lysis. Lysate was clarified 
by centrifugation at 500 ! g for 10 minutes and the supernatant was saved as the 
detergent soluble lysate (Figure 4A, lane 2). The insoluble pellet was boiled in 1% SDS 
and saved as the insoluble fraction (Figure 4A, lane 1). We noted that the TAP tag 
seemed to enhance PLD detergent solubilization more than any of the small epitope 
tags. To capture the protein-A tag, lysate was incubated with IgG-agarose for 3 hours in 
a Bio-Rad disposable poly-prep column.  After incubation, lysate was allowed to flow 
through the column (Figure 4A, lane 3).  Resin was washed three times with 10 ml lysis 
buffer and once with TEV cleavage buffer (Figure 4A lanes 6-9). Beads were 
resuspended in TEV cleavage buffer, transferred to 1.5 ml centrifuge tubes, and 50 units 
of TEV protease were added overnight.  Aliquots of IgG agarose, before and after TEV 
!96!
cleavage, were saved to determine proteolysis efficiency (Figure 4A lanes 4 and 5). 
TEV-cleaved PLD2 was then applied to strep-tactin resin (Figure 4A, lane 10) and 
allowed to incubate for 3 hours before centrifugation of resin and collection of non-bound 
material (Figure 4A, lane 11).  Resin was washed three times (Figure 4A, lanes 12-14) 
and then PtS-PLD2 was eluted in three 500 µ! fractions in buffer containing biotin 
(Figure 4A, lanes 16-18). In order to determine biotin elution efficiency, an aliquot of 
strep-tactin resin post-elution was probed for PLD2 (Figure 4A, lane 15). Proteins were 
precipitated from the large wash and elution volumes using trichloroacetic acid (TCA), 
allowing for a quantitative measure of protein levels between fractions. 
Tracking the capture efficiency and protein loss for PtS-PLD2 allowed us to draw 
several important conclusions. First, the majority of PtS-PLD2 is captured by the IgG and 
strep-tactin resins although some material remains unbound. Second, TEV proteolysis 
yields two PtS-PLD2 immunoreactive bands corresponding to the full-length PLD2 and 
PLD2 lacking the protein-A tag (Figure 4A, lanes 4 and 5). The strong presence of these 
two bands indicates that a large percent of PLD2 was not proteolyzed by TEV and that 
the cleaved product either binds non-specifically to the IgG resin or forms a dimer with 
the uncleaved PLD2. Finally, the final yield of PLD2 from strep-tactin is a small fraction 
of the PLD2 starting material as measured by immunoreactivity in the lysate before IgG-
agarose incubation. Thus, although the final eluates were much less contaminated than 
in IP immunoprecipitation (Figure 4B), the use of the TAP procedure for large-scale 
protein purification would likely result in minimal protein yield. However, since mass 
spectrometry is a highly sensitive method of identifying even low abundance peptides, 
we proceeded to analyze PtS-PLD2 complexes from HEK293-EGFR cells. 
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Figure 4. Determination of capture efficiency and purity of PtS-PLD2 tandem affinity 
purification. A. Fractions from PtS-PLD2 purification were immunoblotted for PLD2. Lane 
1: 20 mg of insoluble pellet following cell lysis. Lane 2: 20 mg of cell lysate before 
incubation with IgG beads. Lane 3: Flowthrough after IgG incubation (same volume as 
lane 2). Lane 4: Aliquot of IgG beads before TEV cleavage (5% of total IgG volume). 
Lane 5: Aliquot of IgG beads after TEV cleavage (5% of total IgG volume). Lane 6:  
Wash 1 (25% of total wash material). Lane 7: Wash 2 (~25% of total wash material). 
Lane 8:  Wash 3 (25% of total wash material). Lane 9: Wash 4 (25% of total wash). Lane 
10: 10% of TEV-cleaved PLD2 products. Lane 11: 25% of flowthrough after strep-tactin 
incubation. Lane 12: Strep-tactin wash 1 (25% of total wash material). Lane 13: Strep-
tactin wash 2 (25% of total wash material). Lane 14: Strep-tactin wash 3 (25% of total 
wash material). Lane 15: Strep-tactin resin after elution with biotin (boiled in SDS loading 
buffer, (33% of resin material). Lane 16: Elution 1 (50% of total elution). Lane 17: Elution 
2 (50% of total elution). Lane 18: Elution 3 (50% of total elution). B. Silver-stained gel of 
final eluates from TAP procedure. HEK293-EGFR-Pts-PLD2 cells were induced with 
tetracycline for 48 hours before stimulation with EGF and tandem affinity purification of 
PLD2 complexes. Numbers indicate molecular weights of standards in kDa. 
 
 
 
 
130 
95 
130 
95 
Strep (short exposure) 
Strep (long exposure) 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
A 
130 
250 
95 
72 
55 
36 
28 
B 
Tetracycline - + + 
EGF - - + 
PtS-PLD2 
!98!
Proteomic analyses of PLD2 complexes from EGFR stimulated HEK293 cells 
Our second proteomic experiment contained three conditions: non-induced 
HEK293-TREx-EGFR-PtS-PLD2 cells as a negative control, tetracycline-induced cells 
stimulated with 100 ng/ml EGF for 5 minutes, and tetracycline-induced cells with no EGF 
stimulation. Cells were harvested and PtS-PLD2 isolated using the full TAP procedure. 
Biotin eluates were pooled, precipitated with TCA, and the entire TCA precipitate run on 
denaturing SDS-PAGE gels, which were delivered to the Vanderbilt proteomics core. 
Peptides were identified after in-gel trypsin digestion and separation on a one-
dimensional high-performance liquid chromatography (HPLC) column by tandem mass 
spectrometry. Although the list of identified interactions was small, the second proteomic 
analysis was much more successful than the first attempt since several proteins were 
identified in the tetracycline-induced samples that were not present in the non-induced 
samples.  Briefly, these included known interacting proteins such as tubulin (Chae et al., 
2005) and novel potential interactions such as the small GTPase Rab11 and various 
components of the ATP synthase holoenzyme. We concluded that the full TAP 
procedure resulted in the loss of weakly interacting proteins and most likely prevented 
identification of interesting PLD2 interactions. Therefore, we abandoned the full TAP 
procedure and isolated PLD2 complexes using strep-tactin resin alone. 
By using a single affinity step to isolate PtS-PLD2, we captured greater quantities 
of PLD2 with visible bands that were not present in non-induced controls (Figure 5). 
Therefore, we repeated the proteomic analysis using the single strep-tactin affinity 
capture. HEK293-EGFR-PtS-PLD2 cells were induced with tetracycline and stimulated 
with EGF as in the second proteomic experiment. We included another set of cells 
transfected with an empty vector to account for any leakiness of the tetracycline-
induction system. PtS-PLD2 was isolated using strep-tactin, eluted in three fractions per 
condition, and proteins were precipitated from pooled fractions with TCA. Proteins were 
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delivered to the proteomics core as a dried film to improve detection of proteins that 
might not be efficiently extracted from acrylamide gels. The third proteomic analysis also 
used a multi-dimensional HPLC approach (MudPIT; multi-dimensional proteomic 
identification technology) to improve resolution and identification of peptides (Washburn 
et al., 2001). Trypsin-digested peptide mixtures were resolved by strong cation and 
reversed phase chromatography before peptide fragmentation and identification by 
tandem mass spectrometry. Our third proteomic analysis identified many more novel 
PLD2 interactions compared to the previous two attempts. These PLD2-protein 
interactions can generally be grouped into five functional categories including 
metabolism, heat shock or chaperone, transport, signal transduction, and trafficking. A 
table of these results can be found in Table 1. Although we identified many proteins in 
the PLD2 samples not present, or in low abundance, in the vector control samples, we 
were surprised to find no unique proteins in the EGF-stimulated conditions. One 
explanation is that overexpressed PLD2 already has significant basal activity (Figure 1) 
and that EGF stimulation only yields about a two-fold activation. The proteins required to 
activate PLD2 following EGF treatment might constitutively bind PLD2 in this 
overexpression system and mask differences between basal and agonist-stimulated 
conditions. Another explanation is that the PLD2-protein interactions following EGF 
treatment might be transient or low affinity interactions and dissociate following cell lysis 
and protein capture. Future studies should use chemical cross-linking reagents to 
capture these low affinity interactions. Due to the lack of unique proteins identified in 
EGF-stimulated conditions, we shifted the focus to investigating a role for PLD2 in 
cellular bioenergetics, based on the large number of metabolic enzymes identified as 
potential PLD2 binding partners. 
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Figure 5. Strep-tactin affinity capture of PtS-PLD2 complexes. HEK293-EGFR-PtS-
PLD2 cells were induced with tetracycline for 48 hours prior to EGF stimulation. PtS-
PLD2 complexes were captured using strep-tactin affinity resin and eluted with biotin. 
Eluates were precipitated with TCA, run on SDS gels, and stained with coomassie blue.   
 
 
 
 
 
 
 
 
130 
250 
95 
72 
55 
36 
28 
Tetracycline - + + 
EGF - - + 
PtS-PLD2 
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Table 1. Proteomic analysis of PLD2 complexes. 
 
 
 
Proteins listed in this table were identified predominantly in PLD2 samples and not in 
vector controls. If peptides were present in the vector control samples, only peptides with 
a ratio greater than 4:1 PLD2:vector were included in the table of putative PLD2 
interacting partners. Note, no proteins were identified that were unique to EGF 
stimulated conditions. 
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Validation of the interaction of PLD2 with ATP synthase 
The most predominant hits from the second and third proteomic analyses were 
enzymes associated with metabolism, and especially components of the ATP synthase 
complex. This 500-kDa complex functions to drive synthesis of ATP from ADP and 
inorganic phosphate in the mitochondrial matrix. ATP synthase contains an inner 
mitochondrial membrane-associated component (FO) that forms a pore through which H
+ 
ions can flow down their electrochemical potential gradient previously established by the 
electron transport chain. The energy from the flow of H+ through the FO component 
provides the energy needed to drive rotational catalysis of the F1 catalytic component. 
The FO and F1 components each contain multiple subunits that are remarkably 
conserved among species ranging from plants and bacteria to humans: a, b, and c for FO 
and ", #, $, %, and & for F1 (Boyer, 1997). The majority of these subunits were identified in 
the PLD2 proteomic screen (Table 1). Since these are highly abundant proteins that 
frequently present as false-positives in proteomic analyses, we validated the interaction 
with immunoprecipitation experiments from HEK293-TREx cells.  
In the first experiment, myc-PLD2 was transfected into HEK293-TREx-EGFR 
cells and cells were stimulated with 100 ng/ml EGF as in the experiments for proteomic 
analysis. By using myc-PLD2 instead of the PtS-PLD2, we were able to exclude non-
specific binding of proteins to the PtS tag. Myc-PLD2 was immunoprecipitated with a 
myc antibody and the complexes were probed for co-IP of endogenous ATP synthase 
alpha. To exclude non-specific interactions of ATP synthase with the protein-G agarose 
or the myc antibody, we immunoprecipitated non-specific proteins from an empty-vector 
transfected set of HEK293-TREx-EGFR cells. As can be seen in Figure 6A, we detected 
specific binding of endogenous ATP synthase alpha to myc-PLD2. Next, we performed 
the reverse IP experiment where we immunoprecipitated endogenous ATP synthase 
alpha and probed for co-IP of myc-PLD2. HEK293-TREx cells were transfected and 
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stimulated as in Figure 6A. To exclude non-specific binding of myc-PLD2 to protein-G or 
to mouse IgG, we immunoprecipitated non-specific proteins from myc-PLD2 transfected 
cells using an antibody of the same isotype as the ATP synthase alpha antibody. As can 
be seen in Figure 6B, myc-PLD2 co-immunoprecipitated specifically with ATP synthase 
alpha. The proteomic analysis of PLD2 identified no proteins that uniquely interacted 
with PLD2 following EGF stimulation, and the forward and reverse immunoprecipitation 
experiments with PLD2 and ATP synthase alpha confirmed the constitutive, EGF-
independent interaction.  
Along with the alpha subunit, we confirmed the interaction of PLD2 with the beta 
subunit of ATP synthase. A PLD2 construct containing the strepII tag was created to 
remove the bulky Protein-A tag component of the TAP tag. StrepII-PLD2 or empty vector 
was transfected into HEK293-TREx-EGFR cells and PLD2 complexes were isolated 
using strep-tactin as in the proteomics experiment. StrepII-PLD2 was eluted from resin 
by boiling in 2x SDS-PAGE loading buffer and complexes probed for ATP synthase beta. 
Although the commercial ATP synthase beta antibody was not as robust as the alpha 
antibody, a faintly immunoreactive band can be detected for ATP synthase beta in the 
strepII-PLD2 sample (Figure 6C). Together these results confirm the proteomic 
identification of ATP synthase as a bona fide PLD2-interacting protein. 
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Figure 6. Validation of the PLD2 interaction with ATP synthase. A. myc-PLD2 or vector 
was transfected into HEK293-EGFR cells for 48 hours prior to stimulation with EGF. 
Cells were subsequently lysed and myc-PLD2 complexes were immunoprecipitated with 
a myc-specific antibody. Complexes were probed for co-IP of endogenous ATP synthase 
". B. Endogenous ATP synthase " was immunoprecipitated from myc-PLD2 transfected 
HEK293-EGFR cells and complexes were probed for co-IP of myc-PLD2. Non-specific 
proteins were immunoprecipitated by an antibody of the same isotype as the ATP 
synthase " antibody. C. HEK293-EGFR-strep-PLD2 cells were induced with tetracycline 
for 48 hours prior to cell lysis. Strep-PLD2 complexes were captured with strep-tactin 
affinity resin and complexes were immunoblotted for ATP synthase #. 
 
Validation of other proteins identified in the PLD2 proteomic analysis 
Similar IP and pull-down experiments were used to validate two other protein 
interactions. For the first interaction, we attempted to confirm the binding of PLD2 to the 
ADP/ATP translocase 2 (ANT2) by immunoprecipitating PLD2 and probing for co-IP of 
ANT2. Unfortunately, the commercially available antibodies for ANT2 were not sensitive 
enough to detect co-IP of endogenous levels of protein (Figure 7). For the second 
interaction, we attempted to confirm the binding of PLD2 to heat shock protein 90 
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(HSP90). HEK293-TREx-EGFR cells were transfected with myc-PLD2 and PLD2 
immunoprecipitated using a myc antibody to probe for endogenous HSP90. No 
interaction was detected using myc-PLD2 as bait. To test the possibility that the either 
the protein-A or strepII tags non-specifically interacted with HSP90, we transfected either 
the full-length TAP tagged PLD or the strepII tagged PLD2 into HEK293-TREx cells and 
isolated PLD using strep-tactin affinity resin. As can be seen in Figure 7, binding of 
HSP90 was only detected using the full-length TAP tagged PLD2, confirming that 
HSP90 interacts with the Protein-A tag and not PLD2. Since the identification and 
validation of the PLD2-ATP synthase interaction provided a completely novel path for 
interrogation of PLD function, other proteomic identifications were not validated.  
 
 
 
Figure 7. Validation of HSP90 and ANT2 as PLD2-interacting partners. HEK293-TREx-
EGFR cells were transfected with PLD2 containing an N-terminal strepII tagor PtS tag 48 
hours prior to cell lysis and capture of PLD2 using strep-tactin affinity resin.  Complexes 
were probed for HSP90 and ANT2. Binding partners of strep-PLD2 were compared to 
PtS-PLD2 to control for non-specific protein binding to the PtS tag. 
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Regulation of cellular bioenergetics by PLD 
 
Growth factor stimulation of intracellular ATP 
The robust interaction between PLD2 and ATP synthase prompted us to 
investigate a potential role for PLD in the regulation of bioenergetics. The previously 
discussed IP experiments suggested that PLD2 and ATP synthase interact, but did not 
indicate whether the interaction was direct or part of a larger protein complex. 
Conclusive experiments to determine direct protein interactions require purified proteins 
and since ATP synthase is a multiunit complex of over 500 kDa with multiple, genetically 
independent subunits, purification is impractical (Boyer, 1997). Therefore, we focused on 
investigating a physiological role for PLD in regulating intracellular ATP.  
In order to measure intracellular ATP, we optimized the use of a luciferase-based 
bioluminescence assay. Luciferin is a substrate for the luciferase enzyme and in the 
presence of ATP, luciferase oxidizes luciferin to produce oxyluciferin, adenosine 
monophosphate (AMP), and light (Deluca and McElroy, 1978). Cells are lysed in a buffer 
compatible with luciferase activity and lysate is added to a reaction mixture containing 
luciferase and saturating concentrations of luciferin. Therefore, the amount of light 
emitted during the reaction, as measured by a luminometer, is proportional to the 
concentration of ATP in the sample and can be quantified using a standard curve of 
known ATP concentration.  
Our initial experiments examined the effects of small-molecule PLD inhibitors on 
ATP levels in HEK293-TREx-EGFR cells. Under normal growth conditions, treatment of 
HEK293-TREx-EGFR cells with PLD inhibitors failed to reproducibly alter ATP levels at 
various time points tested. Since PLD activity remains low in most non-tumorigenic, non-
stimulated cells, we decided to investigate whether conditions known to stimulate PLD 
activity also stimulate changes in intracellular ATP in a PLD-dependent manner. Multiple 
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cell lines were screened for an increase in intracellular ATP following EGF stimulation 
and included various GBM, renal, breast, and lung cancers along with HEK293 cells. For 
the screen, cells were seeded in complete growth media and allowed to attach for 24 
hours. The following day, cells were washed and cultured in serum-free media to remove 
traces of EGF present in serum. Cells were treated with 100 ng/ml EGF for time points 
ranging from 30 minutes to 4 hours to determine an optimal time point for measuring 
changes in intracellular ATP. EGF stimulated an increase in intracellular ATP in multiple 
cell lines with one of the most robust increases measured in the U87MG cell line (Figure 
8). In order to determine if PLD activity was required for the EGF stimulation of PLD 
activity, U87MG cells were pretreated with the VU0359595 PLD inhibitor for 30 minutes 
and then stimulated with 100 ng/ml EGF for 4 hours. PLD inhibition prevented the 
increase in intracellular ATP following EGF stimulation (Figure 9), suggesting that PLD 
activity is required for EGF-stimulated increases in ATP. Unfortunately, the U87MG cells 
were highly variable in this response, and EGF failed to increase intracellular ATP levels 
in several experiments. When EGF did elicit an ATP response, PLD inhibition 
consistently prevented the EGF-stimulated increase in intracellular ATP. Due to the 
highly variable nature of the EGF-response, we assayed other growth factors including 
PDGF, insulin, and insulin-like growth factor 1 using the same paradigm as EGF. None 
of the other individual growth factors elicited an ATP response in the U87MG cells  (data 
not shown). 
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Figure 8. Screen of various cell lines for EGF-stimulated changes in intracellular ATP. 
Indicated cell lines were seeded to achieve approximately 60% confluency 24 hours 
after plating. Cells were deprived of serum overnight and stimulated with 100 ng/ml EGF 
for the indicated lengths of time before cell lysis and ATP quantification. * p < 0.05, ** p < 
0.01, unpaired Student’s t-test comparing vehicle to EGF stimulation for each time point.  
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Figure 9. PLD mediates the EGF-stimulated increase in intracellular ATP. U87MG cells 
were serum-starved overnight and treated with 10 µM VU0359595 for 30 min before a 4-
hour stimulation with 100 ng/ml EGF. ATP levels were quantified following EGF 
stimulation and normalized to total cellular protein in each sample. Shown is a 
representative experiment with triplicate samples. ** p < 0.01, NS – not significant, 
unpaired Student’s t-test. 
 
Serum stimulates increased intracellular ATP 
 Since we were unable to elicit a reproducible change in ATP levels with individual 
growth factors, we considered other stimulators of PLD activity. Serum contains many 
components including growth factors, cytokines, and amino acids that may function 
individually or synergistically to stimulate PLD activity and ATP synthesis. As such, 
previous studies have shown that serum stimulates PLD activity (Fang et al., 2001) and 
ATP synthesis (Hahn-Windgassen et al., 2005) in model systems. Various cell lines 
were screened for ATP changes following serum stimulation. Representative 
glioblastoma, breast, lung, and renal cancer lines along with HEK293-TREx cells were 
cultured in serum-free media overnight and stimulated with 20% fetal bovine serum 
(FBS) for durations ranging from 30 minutes to 4 hours. Multiple cell lines responded to 
serum stimulation by increasing intracellular ATP and the 4-hour serum stimulation time 
point resulted in the most robust ATP stimulation among the cell lines assayed (Figure 
10).  
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Figure 10. Screen of various cell lines for serum-stimulated changes in intracellular 
ATP. Indicated cell lines were seeded to achieve approximately 60% confluency 24 
hours after plating. Cells were deprived of serum overnight and stimulated with 20% FBS 
for the indicated lengths of time before cell lysis and ATP quantification. * p < 0.05, ** p < 
0.01, *** p < 0.001 unpaired Student’s t-test comparing vehicle to serum stimulation for 
each time point. 
 
PLD mediates the serum-ATP response in glioblastoma and breast cancer lines 
In order to determine if the serum-induced ATP increase required PLD activity, 
we pretreated cells with PLD inhibitors for 30 minutes before stimulating with FBS and 
measuring ATP. Three cell lines demonstrated a dependence on PLD for the serum-
induced ATP increase: U87MG and U118MG glioblastoma cells and BT549 breast 
cancer cells (Figure 11A-C). In these cell lines, PLD inhibitors suppressed the serum-
stimulated ATP increase but did not change basal ATP levels. The parental HEK293-
TREx line also responded to serum stimulation, but demonstrated a different pattern of 
ATP changes following PLD inhibition. Unlike the GBM and breast cancer lines, basal 
ATP levels consistently decreased following PLD inhibitor treatment in HEK293-TREx 
cells whereas the fold increase in the serum-stimulated ATP response remained 
unchanged (Figure 11D). The differences in ATP responses between the various cell 
lines suggested that PLD activity is required to meet the metabolic demands required for 
serum-induced proliferation in certain cancer cells. 
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Figure 11. Serum stimulation of intracellular ATP requires PLD activity in multiple cancer 
lines. A-C. Cells were deprived of serum overnight, pretreated with 10 µM VU0359595 
for 30 minutes, then stimulated with 20% FBS for 4 hours before ATP extraction and 
quantification. Data is presented as the fold change in ATP over non-stimulated controls 
for n=6 independent experiments for each cell line. * p < 0.05, *** p < 0.001, NS – not 
significant, paired Student’s t-test. D. HEK293-TREx cells were treated as in (A-C). 
Shown is a representative experiment with triplicate samples. ** p < 0.01, *** p < 0.001, 
unpaired Student’s t-test. 
 
To further support a role for PLD in regulation of cancer cell bioenergetics, we 
extended our analysis to a more relevant model system. Although the U87MG and 
U118MG cells are well-established GBM lines, we wanted to extend our study of the 
regulation of cancer cell bioenergetics by PLD in a more disease relevant system. As will 
be further discussed in chapter III, stem cells can be isolated from patient biopsies by 
sorting for the CD133 surface antigen and these stem cells phenocopy the patient’s 
original tumor when injected into nude mice (Singh et al., 2004). Unlike the other cell 
lines discussed previously, these cells require growth in media containing a serum 
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substitute (B27) and a cocktail of EGF and FGF. In order to mimic the experimental 
paradigm established with the other GBM lines, we deprived the stem cells of B27 and 
growth factors overnight before pretreating with PLD inhibitors and stimulating with 
complete media containing B27, EGF, and FGF for 4 hours. The growth factor cocktail 
stimulated an increase in intracellular ATP in the GBM stem cells as in the established 
cell lines in a PLD-dependent manner (Figure 12). The dependence on PLD in a cancer 
model system that more closely resembles a primary tumor further supports a cancer-
dependent role for PLD in regulating bioenergetics. 
 
 
 
Figure 12. PLD activity is required for the serum-induced increase in intracellular ATP in 
CD133+ glioma stem cells. CD133+ glioma stem cell clone 4302 was seeded onto tissue 
culture plates coated with 0.5% laminin in complete growth media. Cells were cultured in 
neurobasal medium lacking growth supplements for approximately 16 hours prior to a 30 
minute pretreatment with 10 µM VU0359595. Cells were subsequently stimulated with 
complete growth media containing B27, EGF, and FGF for 4 hours before ATP 
measurement. 
 
Excluding off-target effects of VU0359595 on the serum-ATP response 
In order to exclude off target effects of VU0359595, we first titrated the 
concentration of inhibitor needed to fully inhibit the serum-ATP response. VU0359595 is 
a PLD1-preferring compound with a cellular IC50 value of 3.7 nM for PLD1 and 6.4 µM 
for PLD2 (Lewis et al., 2009). In the previous assays, VU0359595 was used at a 
relatively high concentration of 10 µM, a concentration that would completely inhibit 
PLD1 and partially inhibit PLD2. To determine the concentration of VU0359595 needed 
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to completely inhibit the serum-ATP response in U118MG cells, cells were deprived of 
serum overnight and then pretreated with various concentrations of PLD inhibitors before 
a serum stimulation the following day. VU0359595 concentrations as low as 100 nM 
completely inhibited the serum-ATP response in U118MG cells (Figure 2-13). Although 
the concentration response curves remain to be generated for the serum stimulation of 
PLD activity in the U87MG cells, the concentration response curve for PLD inhibition of 
the serum-ATP stimulation in the U118MG remarkably resemble the curve for PLD1 
inhibition in our Calu-1 model system (Lewis et al., 2009). Although not conclusive, the 
low concentration of VU0359595 needed to inhibit the serum-ATP response argues 
strongly for specific inhibition of PLD as the mechanism for VU0395595 inhibition of the 
serum-ATP response. 
 
 
 
Figure 13. VU0359595 concentration response curve for the serum-ATP response in 
U118MG cells. Cells were deprived of serum overnight and then pretreated with the 
indicated concentration of VU0359595 for 30 minutes before a 4-hour stimulation with 
20% FBS. Data is presented as the percent inhibition of the serum stimulated ATP 
response due to PLD inhibition relative to vehicle control.  
 
After establishing the specificity of our PLD inhibitor in the serum-ATP response, 
we silenced expression of either PLD1 or PLD2 to determine if ablation of PLD protein 
mimicked the small molecule inhibitor effect. U118MG or U87MG glioblastoma cells 
were transfected with PLD1, PLD2, or a combination of PLD1 and PLD2 siRNA at a final 
concentration of 100 nM. Forty-eight hours after transfection, cells were washed and 
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cultured in serum-free media overnight and cells were stimulated with 20% FBS for 4 
hours approximately 72 hours after the siRNA transfection. Silencing of either PLD1 or 
PLD2 significantly decreased the fold increase in intracellular ATP following serum 
stimulation (Figure 2-14). Together, these data suggest that both PLD1 and PLD2 are 
required to mediate the signaling events necessary to increase ATP levels following 
extracellular stimuli and that the effects of VU0359595 on ATP production are due to 
inhibition of PLD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!116!
 
 
 
Figure 14. siRNA silencing of PLD1 and PLD2 decreases the serum-induced increase in 
intracellular ATP in GBM cells. A. U87MG cells were transfected with 100nM siRNA 
targeting either PLD1 or PLD2 as indicated. 48 hours after transfection, cells were 
deprived of serum for an additional 24 hours. Cells were then stimulated with 20% FBS 
for 4 hours before lysis and ATP measurements. B. Representative immunoblot of 
siRNA knockdown of PLD1 or PLD2. Note, the commercial PLD2 antibody recognizes a 
non-specific band immediately below PLD2 in the U87MG cell line. C and D. U118MG 
cells were treated as in (A) and (B). ** p < 0.01, *** p < 0.001, one-way analysis of 
variance (ANOVA) with Dunnett’s multiple comparisons test comparing FBS-stimulated 
ATP levels in the siRNA treated samples to the non-targeting controls. 
 
Characterization of the molecular mechanisms for bioenergetic regulation by PLD 
 The increase in intracellular ATP following serum stimulation could result due to 
an increase in ATP synthesis or a decrease in metabolic demand. Given the mitogenic 
and proliferative properties of serum, the increase in ATP is likely due to increased 
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biosynthesis of ATP to fuel processes required for cell growth. Multiple pathways exist to 
generate requisite ATP including glycolysis and mitochondrial oxidative phosphorylation. 
In order gain insight into the pathways modulated by PLD, we used chemical tools to 
dissect the two ATP-generating pathways. 2-deoxyglucose (2-DG) is a glucose analog 
that lacks a hydroxyl group in the 2 position of the glucose ring. Therefore, 2-DG passes 
through the glucose transporter and is phosphorylated by hexokinase but cannot 
continue into the glycolysis pathway since the next enzymatic step is isosomerization of 
glucose to fructose 6-phosphate by phosphoglucose isomerase. Thus, the charged 2-
deoxyglucose 6-phosphate is trapped within the cell and inhibits further glycolysis by 
product inhibition of hexokinase, the rate-limiting step of glycolysis (Wick et al., 1957). 
Oligomycin is a bacterial macrolide that blocks the function of ATP synthase in the 
mitochondria and inhibits mitochondrial ATP production (Guerrieri et al., 1976). By 
binding to and occupying the pore of the FO component of ATP synthase, oligomycin 
inhibits electron-transport-chain derived H+ ions from passing down their electrochemical 
gradient through the ATP synthase complex and the energy source for ATP catalysis 
from ADP and inorganic phosphate is thus uncoupled.  
To determine which pathways generated serum-stimulated ATP, we treated 
serum-starved U118MG or HEK293 cells with 2-DG or oligomycin for 2 hours before a 
30-minute VU0359595 pretreatment. After pretreatments, cells were stimulated with 20% 
FBS for 4 hours as in previous experiments. Cells were collected for ATP analysis, and 
media was saved for lactate analysis as a measurement for glycolytic activity. Lactate is 
produced when the end product of glycolysis, pyruvate, is reduced by the lactate 
dehydrogenase complex (LDH). Lactate production is frequently used as a measure of 
glycolytic activity. A common method for measuring lactate concentrations in cell media 
uses a two-step enzymatic reaction. In the first reaction, lactate is oxidized to pyruvate 
by LDH in the presence of NAD+. In the second reaction, a diaphorase enzyme reduces 
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a tetrazolium salt such as INT (2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-
tetrazolium chloride) using the newly produced NADH to generate a formazan dye which 
absorbs light at 490 nM (Wolterbeek and van der Meer, 2005). Thus, the absorbance of 
the formazan dye is directly proportional to the amount of lactate present in the sample. 
Measurement of mitochondrial oxygen consumption is more difficult and investigators 
have historically used a Clark electrode to measure oxygen levels in a sample containing 
actively respiring mitochondria. As samples must be constantly stirred to maintain 
equilibrium, this technique becomes impossible for most monolayer cell cultures. New 
techniques, such as the use of oxygen-sensitive fluorescent probes, show promise for 
measuring mitochondrial respiration in cultured cells. Cells are grown on microtiter plates 
and loaded with a fluorescent dye that is quenched by O2. As cells respire and O2 levels 
decrease, fluorescence increases (Hynes et al., 2005). In our hands, these dyes were 
not sensitive enough to detect respiration in U118MG or HEK293 cells so measurement 
of metabolic activity attributable to individual pathways was limited to lactate production 
and glycolysis. 
The ATP measurements following 2-DG or oligomycin treatment were highly 
variable in all of the cell lines tested. In some experiments, 2-DG dramatically decreased 
overall ATP levels whereas oligomycin had little to no effect. In other experiments, 
individual inhibitor treatment did not alter basal ATP levels. Additionally, serum 
stimulated an increase in ATP even in the presence of individual metabolic inhibitors. 
Together these results indicate that these cells are capable of using both ATP-
generating pathways and that serum-stimulation engages both glycolysis and oxidative 
phosphorylation.  
Although the ATP results were inconclusive for determining the pathway 
regulated by PLD, the lactate measurements were much more reproducible and 
provided several insights into the ATP biosynthetic pathways engaged by serum 
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stimulation (Figure 15). First, 2-DG treatment abolished lactate generation in both cell 
lines as would be expected from glycolysis inhibition and oligomycin treatment increased 
lactate production, presumably by inducing an upregulation of glycoloytic activity. 
Second, lactate levels did not increase following serum stimulation in either cell line, 
suggesting that glycolysis was not the predominant pathway of ATP generation following 
serum stimulation. We observed divergent responses to basal lactate levels between 
HEK293-TREx and U118MG cells where VU0359595 selectively decreased basal 
lactate only in the HEK293-TREx cells (Figure 15A). The decrease in basal lactate levels 
in HEK293-TREx cells following VU0359595 treatment correlates with the decrease in 
basal ATP we measured following PLD inhibitor treatment (Figure 11D) and suggests 
that HEK293-TREx cells utilize glycolysis for basal ATP production more than U118MG 
cells. Finally, VU0359595 completely inhibited the elevation in oligomycin-induced 
lactate production in both cell lines, which suggests that PLD may somehow function to 
promote the switch from oxidative phosphorylation to glycolysis. In order words, PLD 
may serve to act as a sensor of cellular energy homeostasis at the level of the 
mitochondria.  
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Figure 15. Serum stimulation of lactate production in the presence of metabolic and PLD 
inhibitors. A. HEK293-TREx cells were deprived of serum overnight before treatment 
with either 1 µM oligomycin or 10 mM 2-DG for 2 hours. Cells were treated with 10 µM 
VU0359595 for the final 30 minutes of the 2-hour pretreatment. Cells were finally 
stimulated with 20% FBS for 4 hours before media was collected for lactate 
measurement. B. U118MG cells were treated similarly to HEK293-TREx cells. Shown 
are representative experiments with triplicate samples. * p < 0.05, *** p < 0.001, one-way 
ANOVA with Tukey’s multiple comparison test comparing indicated sample conditions. 
### p < 0.001, unpaired Student’s t-test comparing vehicle to VU0359595 treatment 
within the oligomycin condition. NS – not significant. 
 
Investigation of PLD as a sensor of bioenergetic homeostasis 
 Treatment of cells with oligomycin would likely decrease intracellular ATP and 
upregulate compensatory pathways for ATP generation and the experiment in Figure 15 
suggested that PLD was a required component of those compensatory signaling 
pathways. We therefore hypothesized that PLD was acting as a sensor of cellular 
bioenergetic status and transduced signals in response to intracellular energy 
fluctuations. In order to test this hypothesis, we performed exogenous PLD activity 
assays using recombinant, purified PLD2 in the presence of various concentrations of 
ATP, ADP, and AMP to determine if PLD activity was directly regulated by adenine 
nucleotides. High concentrations of ATP and ADP inhibited PLD2 activity whereas AMP 
had no effect on PLD2 activity at the same concentrations (Figure 16). Although the 
concentrations of ATP and ADP required to inhibit PLD activity were in the millimolar 
range, the concentrations of intracellular ATP are similarly high (Beis and Newsholme, 
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1975). These results suggest that high basal levels of intracellular ATP might inhibit PLD 
activity. As ATP levels decrease, either through metabolic poison or through increased 
metabolic demand such as proliferation following serum stimulation, PLD activity would 
increase and initiate signaling cascades to generate ATP. 
 
 
 
Figure 16. Concentration response curves for adenine nucleotides on PLD2 activity. 
PtS-PLD2 was purified from Sf21 insect cells and activity was measured as choline 
release from [3H]PC in the presence of the indicated concentrations of ATP, ADP, or 
AMP. Data is presented as the percent PLD2 activity remaining in the adenine 
nucleotide samples relative to vehicle control. 
 
Characterization of serum factors responsible for stimulating ATP in GBM cells 
 Serum is a complicated mixture of growth factors, cytokines, fatty acids, and 
other nutrients such as amino acids and carbohydrates including the individual growth 
factors we assayed for ATP stimulating activity. Determining the component(s) of serum 
responsible for stimulating PLD activity and increasing intracellular ATP has potential 
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therapeutic value if a specific signaling pathway can be targeted in cancer cells. In order 
to determine if low molecular weight factors such as glucose or amino acids were 
stimulating the ATP response, we dialyzed FBS using a 3500 molecular weight cutoff 
membrane against phosphate buffered saline overnight. Successful dialysis was 
confirmed by measuring lactate concentrations in FBS before and after dialysis. Both 
dialyzed and non-dialyzed FBS stimulated an ATP increase in the U118MG cell line, but 
VU0359595 did not inhibit the serum-ATP response when cells were stimulated with 
dialyzed FBS (Figure 17A). Additionally, stimulation with non-dialyzed FBS did not 
increase lactate production in HEK293-TREx or U118MG cells, in agreement with 
previous experiments (Figure 15). By contrast, dialyzed FBS stimulated a robust 
increase in lactate production in the U118MG cell line (Figure 17B). 
 
 
 
Figure 17. ATP and lactate production in response to dialyzed and non-dialyzed FBS in 
U118MG cells. Cells were deprived of serum for approximately 16 hours before a 30 
minute pretreatment with 10 mM VU0359595. Cells were subsequently stimulated with 
20% non-dialyzed FBS or FBS dialyzed overnight using a 3500 molecular weight cutoff 
dialysis membrane. After 4 hours, media was saved for lactate measurements and cells 
were lysed for ATP measurements. Shown is a representative experiment with triplicate 
samples. ** p < 0.01, *** p < 0.001, NS – not significant, one-way ANOVA with Tukey’s 
multiple comparisons test comparing indicated conditions. 
 
Several conclusions can be drawn from analyzing the effects of dialyzed FBS on 
the ATP and lactate levels in U118MG cells. Both normal and dialyzed serum treatments 
stimulated ATP to the same magnitude. However, the elevation in lactate following 
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dialyzed FBS treatment suggests that glycolysis is the primary pathway for ATP 
generation under this treatment condition. PLD inhibition does not block the ATP 
response to dialyzed FBS, supporting the notion that PLD regulates bioenergetics at the 
level of the mitochondria and not through regulating glycolysis. One potential explanation 
for the switch from oxidative phosphorylation to glycolysis following dialysis of FBS is the 
removal of lactate from FBS following the dialysis procedure. LDH is known to 
demonstrate product inhibition where high concentrations of lactate reduce LDH activity 
(Karlsson et al., 1974). With lactate removed from FBS, glycolytic activity would increase 
with LDH no longer inhibited due to high levels of extracellular lactate. Taken together, 
the data in this chapter suggest that PLD enzymes interact with metabolic enzymes and 
regulate ATP production, and may possibly govern the fluctuation between oxidative 
phosphorylation and glycolysis to provide requisite energy needed during times of cell 
proliferation. Elucidating the exact molecular mechanisms of the PLD-ATP pathways 
should be the subject of future investigations. 
 
Materials and methods 
 
Cell culture 
U87MG, U118MG, and BT549 cells (ATCC) and HEK293-TREx (Life 
Technologies) were maintained in Dulbecco's modified eagle's medium (DMEM) (Life 
Technologies) + 10% FBS (Atlanta Biologicals) + 1% Penicillin/Streptomycin (P/S) (Life 
Technologies). Inducible, HEK293-TREx derived cell lines were maintained in DMEM + 
10% tetracycline-free FBS (Atlanta Biologicals) + 1% P/S. CD133+ glioma stem cells 
were cultured as described (Wang et al., 2010a). Stem cells were maintained in 
neurobasal media containing glutamine, B27, sodium pyruvate (all from Life 
Technologies), 20 ng/ml fibroblast growth factor and epidermal growth factor 
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(Peprotech). All human cells were maintained at 37 °C in a humidified incubator with 5% 
CO2. 
 
Plasmid production 
myc-PLD2 was created by PCR amplification of the PLD2 open reading frame 
(PLD2 cDNA was a generous gift from Dr. David Lambeth at Emory University) primer: 
5'- ataagaatgcggccgccatggaacaaaaactcatctcagaagaggatctgATGACGGCGACCCCTGAG 
-3', reverse primer: 5'- gctctagaCAACTATGTCCACACTTCTAG -3').  myc-PLD2 was 
ligated into the NotI/XbaI restriction sites of pcDNA5/TO (Life Technologies). See 
chapter III for details on the construction of all other plasmids. 
 
Transfection 
 Mammalian cells were transfected using Fugene 6 (Roche) according to the 
manufacturer’s instructions using the standard volumes of transfection reagent and DNA 
quantities. Cells were harvested approximately 48 hours post transfection. Stable 
HEK293-TREx cell lines were generated by transfection of indicated construct as per the 
manufacturer’s instructions. 48 hours after transfection, cells were split into media 
containing 100 µg/ml hygromycin B (Life Technologies). Cells were grown until colonies 
developed. Individual colonies were harvested by aspiration into a 200 µ! pipette tip 
under a microscope and expanded as monoclonal colonies. Cells were eventually 
screened for stable transfection by immunoblotting. 
 
Immunoblotting  
 Lysates were prepared by incubating cell pellets in lysis buffer (50 mM Tris pH 
8.0, 150 mM NaCl, 0.5% Nonidet P-40, 40 mM #-glycerophosphate, 20 mM sodium 
pyrophosphate, 1 mM Na3VO4, 2 mM EDTA, 2 mM EGTA, 5 mM NaF, 1 mM DTT, and 
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Roche complete protease inhibitor cocktail for 30 minutes at 4 °C. Protein concentrations 
were measured using the Bio-Rad protein assay reagent. Myc antibody (clone 9E10) 
was from AdD Serotec). PLD1, ATP synthase, HSP90, and ANT2 antibodies were from 
Santa Cruz. Strep-tag antibodies were from Qiagen. PLD2 antibody was from Abgent. 
 
Immunoprecipitation 
 Cells were resuspended in lysis buffer (see Immunoblotting section) and lysed 
with three freeze/thaw cycles in dry ice/ethanol, drawing lysate through a 25G syringe 
needle between cycles.  Clarified (10,000 ! g for 10 min) lysates were pre-cleared with 
protein-G agarose (Millipore) and immunoprecipitating antibodies were incubated with 
lysate overnight. Complexes were captured using protein-G agarose, washed three 
times in lysis buffer, then eluted by boiling in 2! SDS-PAGE loading buffer. 
 
Proteomic analysis 
 Proteins were delivered as TCA precipitates to the Vanderbilt proteomics core 
and peptides were resolved and fragmented according to previously established 
methods (Link et al., 1999; McDonald et al., 2002). Peptide sequences were assigned to 
tandem mass spectra using the IDpicker software (Ma et al., 2009). 
 
ATP measurement 
Cells were seeded to achieve approximately 60% confluence the next day. After 
allowing cells to adhere for 24 hours, cells were washed twice in phosphate buffered 
saline (PBS) and then cultured for approximately 16 hours in serum free DMEM. Where 
indicated, metabolic inhibitors or PLD inhibitors were added 2 hours or 30 minutes, 
respectively, before stimulation with growth factors (all from Life Technologies) or 20% 
FBS. Cells were washed once then scraped in ice-cold PBS. Cells were collected by 
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centrifugation at 1,000 ! g at 4 °C for 5 minutes. Pellets were resuspended in 60 µl 
extraction buffer (50 mM Tris pH 7.75, 4 mM EDTA) and boiled for 5 minutes. After 
boiling, extracts were cooled on ice then centrifuged at 18,000 ! g for 5 minutes. 40 µl of 
extract was transferred to a new tube and protein concentrations were measured from 
undiluted extracts using the Bio-Rad protein assay. Extracts were then diluted 1:10 in 
extraction buffer and 50 µl of the dilution loaded into 96-well plates. Luciferase activity 
was measured by automated injection of 50 µl luciferase reagent (Roche, ATP 
Bioluminescence Assay Kit CLS II) per well and then luminescence was measured for 
10 seconds in 0.1 second intervals following a 2 second delay after the addition of 
luciferase reagent. Luminescence was integrated over the 10-second collection time and 
used to calculate [ATP] based on the luminescence of a standard ATP curve. ATP was 
calculated as nanomoles ATP per microgram protein in each sample. 
 
Lactate measurement 
Following experimental manipulation of cells for ATP measurement, media was 
saved and frozen at -80°C until time of assay. Samples were diluted in DMEM to obtain 
values within the linear range of the assay. Lactate measurements were performed 
using the L-Lactate Assay Kit I from Eton Biosciences and [lactate] determined from a 
standard curve. Blank samples containing 20% FBS or DMEM alone were used for 
background subtraction from stimulated and non-stimulated samples, respectively. 
 
Exogenous PLD activity assay 
In vitro PtS-PLD2 activity was measured as choline release from [3H]PC-
containing phospholipid vesicles as described previously (Brown et al., 1993). Stock 
concentrations of adenine nucleotides were made from powder in PLD activity assay 
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buffer and diluted to the final concentration indicated in the figures. ATP was obtained 
from Avanti Polar Lipids. ADP and AMP were obtained from Sigma. 
 
Purification of PLD2 
Detailed methods for purification of PLD2 are found in chapter III. 
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CHAPTER III 
 
PHOSPHOLIPASE D2 MEDIATES SURVIVAL SIGNALING THROUGH DIRECT 
REGULATION OF AKT IN GLIOBLASTOMA CELLS 
 
Introduction 
Glioblastoma multiforme, the most common and aggressive glioma, is a highly 
lethal type of brain tumor with poor patient prognosis. Despite advances in imaging and 
neurosurgery over the past 30 years, GBM remains one of the most difficult tumors to 
manage with a median survival time of approximately 14 months following diagnosis 
(Stupp et al., 2005). Treatment options are limited and invasive, typically including a 
combination of surgical resection, radiotherapy, and adjuvant chemotherapy (DeAngelis, 
2001). Less invasive, small molecule therapies for GBM have been met with limited 
success due, in part, to the poor blood-brain-barrier penetrance of current 
chemotherapeutics that limits their access to GBM tumors. Moreover, the aggressive 
nature of GBM, its genetic variability, and antineoplastic drug resistance further curbs 
the effectiveness of small molecule inhibitors to treat the disease. The combination of 
these clinical obstacles contributes to the comparatively short survival times and patient 
death rate (Eramo et al., 2006). Thus, the field requires a more thorough understanding 
of GBM signaling and metabolic pathways to develop novel treatment options. 
Among the most frequently deregulated pathways in GBM are components of the 
PI3K/Akt pathway (Cheng et al., 2009). Activated PI3K, either by cell-surface receptor 
stimulation or mutation to a constitutively active form, results in PIP3 production and 
subsequent initiation of signaling cascades by recruiting a variety of molecules 
containing lipid-binding domains to membranes (Cantley, 2002). The serine/threonine 
kinase Akt was identified as the eukaryotic homolog of the retroviral oncogene v-Akt, 
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which becomes activated following PI3K generation of PIP3 (Bellacosa et al., 1991; 
Franke et al., 1995). Akt mediates a variety of intracellular functions critical to oncogenic 
processes, including cell growth, proliferation, metabolism, and survival (Manning and 
Cantley, 2007). Mutations that result in PI3K activation, such as constitutive growth 
factor receptor activation (Libermann et al., 1985) or inactivation of PTEN (Haas-Kogan 
et al., 1998), the lipid phosphatase that hydrolyzes PIP3, are common in GBM. While 
small-molecule inhibitors of the PI3K/Akt pathway hold promise in clinical trials for GBM 
(Furnari et al., 2007), global inhibition of the Akt isoenzymes results in side effects that 
limit their clinical potential (Yap et al., 2011). 
In addition to PIP3, other lipids such as PtdOH are known to mediate intracellular 
signaling events that are required for oncogenic processes. Multiple cancer types 
including breast, gastric, and renal cancers show elevated PLD activity compared to 
normal tissue (see Chapter I). Cells overexpressing PLD demonstrate increased AIG 
(Min, 2001), invasiveness (Park et al., 2009), and tumorigenesis in nude mice 
(Buchanan et al., 2005). Mechanistically, PLD and PtdOH regulate cytoskeletal 
rearrangement (Henkels et al., 2013a), angiogenesis (Chen et al., 2012), and expression 
of matrix metalloproteases (Park et al., 2009), which are all requirements for invasion 
and metastasis. The development of small molecule PLD inhibitors that decrease cancer 
cell invasiveness (Scott et al., 2009), along with the development of PLD knockout mice 
that show no overt negative phenotypes (Elvers et al., 2010; Oliveira et al., 2010), 
makes PLD a promising therapeutic target.  
Recent reports have suggested a possible relationship between PLD and Akt 
involving both direct (Di Fulvio et al., 2008; Patel et al., 2010) and indirect (Toschi et al., 
2009) mechanisms. Interestingly, PLD from Neisseria gonorrhoeae regulates human Akt 
kinase activity upon infection of cervical epithelial cells (Edwards and Apicella, 2006). In 
this chapter, we investigate the regulation of Akt by human PLD and demonstrate a 
 130!
novel mechanism by which PtdOH activates Akt and mediates survival signaling in GBM 
cells. By targeting PLD, we explore novel treatment options for regulating Akt kinase 
activity for the treatment of human brain cancers. 
 
Results 
!
PLD2 activity is required for glioma viability following serum-withdrawal !
Multiple cancer types require PLD and its product, PtdOH, for sustained survival 
under stress conditions (Foster and Xu, 2003). Serum-withdrawal, a known stimulus of 
PLD activity in multiple cancer cell lines (Zheng et al., 2006), is frequently used to 
simulate the harsh growth environments encountered by neoplastic cells prior to 
vascularization and restoration of nutrient supply within the tumor mass. Viability is 
compromised when normal cells are cultured in serum-depleted conditions. Cells with 
elevated PI3K/Akt activity, however, continue to proliferate under these harsh culture 
conditions (Sun et al., 1999). To investigate the role of PLD in GBM survival, we 
measured PLD activity following serum-withdrawal in the PTEN-null U87MG GBM cell 
line. Cells were grown overnight in complete growth media (DMEM with FBS) before 
growth in media lacking FBS for times ranging from 1 to 24 hours. Serum-withdrawal 
resulted in a time-dependent increase in PLD activity with the most robust activation 
observed after 16 hours and longer durations of serum-withdrawal did not further 
increase PLD activity (Figure 1A). By contrast, we did not observe increased PLD 
activity in the non-tumorigenic HEK293 line under the same conditions (Figure 1A), 
suggesting a cancer line specific PLD response. Serum deprivation leading to PLD 
activation in U87MG cells is consistent with published reports on other cancer cell lines 
showing similar trends (Zheng et al., 2006).!
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Two isoforms of PLD have been identified, PLD1 and PLD2 and each 
demonstrates distinct regulatory properties (see Chapter I). To better understand the 
role of each isoform in this stress pathway we explored which PLD isoform was 
preferentially activated following serum-withdrawal using both pharmacological and 
genetic tools. In the first approach, U87MG cells were serum deprived overnight and 
then treated with various concentrations of previously reported, isoform-preferring PLD 
inhibitors. VU0359595 is a 1,700-fold PLD1-preferring compound (Lewis et al., 2009) 
and VU0364739 is a 75-fold PLD2-preferring compound (Lavieri et al., 2010), as 
determined with cell-based assays designed to measure activity of individual PLD 
isoforms. In the U87MG cells, which express both PLD1 and PLD2, VU0359595 and 
VU0364739 attenuated PLD activity following serum-withdrawal with IC50 values of 
approximately 500 nM and 100 nM, respectively (Figure 1B). The five-fold greater 
potency of the PLD2-preferring compound suggests that the PLD2 isoform is responsible 
for the vast majority of PLD activity in these cells following serum-withdrawal, although 
the PLD1 isoform may partially compensate following acute inhibitor treatment. To 
further explore the contribution of individual isoforms to the total PLD activity, we utilized 
isoform-specific siRNA to knock down either PLD1 or PLD2 and measure PLD activity 
following overnight serum-withdrawal. Silencing of PLD2, but not PLD1, resulted in a 
significant decrease in PLD activity (Figure 1C), further implicating PLD2 as the 
predominant isoform in the serum-withdrawal response. !
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Figure 1. Serum-withdrawal stimulates PLD2 activity in GBM cells. A. Cells were 
seeded approximately 24 hours prior to washing and incubation in serum-free media for 
the indicated length of time. n-Butanol (n-butanol-d10) was added 30 minutes prior to 
glycerophospholipid extraction and subsequent PtdBuOH quantification. B. U87MG cells 
were seeded as in (A) and serum was withdrawn for 24 hours. Cells were pretreated 
with inhibitors 30 minutes prior to measurement of PLD activity. Data is presented as the 
percent activity remaining after PLD inhibitor treatment relative to control. C. U87MG 
cells were transfected with siRNA targeting either PLD1 or PLD2 for 48 hours prior to a 
24-hour serum starvation before measuring PLD activity. Note the PLD2 antibody 
recognizes a non-specific band of similar molecular weight to PLD2 and the band of 
interest is directly above the non-specific band. * p < 0.5, ** p < 0.01, *** p < 0.001, NS - 
not significant, unpaired Student’s t-test. Error bars - standard error of the mean (SEM)!
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In order to determine if PLD activity was required for viability in U87MG cells 
following serum-withdrawal, we measured cell viability following overnight treatment with 
various concentrations of PLD inhibitors. U87MG cell viability decreased in a 
concentration-dependent manner (Figure 2A), consistent with concentrations needed to 
completely ablate PLD activity (Figure 1B), suggesting that complete suppression of 
PLD activity compromises viability in these cells. By contrast, treatment of HEK293 cells 
with PLD inhibitors resulted in significantly less cell death when compared to U87MG 
cells (Figure 2B), further implicating PLD as necessary for cancer cell survival. !
Although U87MG cells are a well-characterized GBM line, we wanted to extend 
our study on PLD to a more disease-relevant model, namely cells isolated from biopsies 
of primary human GBMs. Glioma stem cells can be isolated from patient tumors by 
sorting for surface expression of the CD133 antigen. These stem cells are tumorigenic 
and phenocopy the patient’s original tumor when injected into immunocompromised 
mice (Singh et al., 2004). Two glioma stem cell clones (Wang et al., 2010a), derived 
from individual patients, both showed reduced viability following PLD inhibitor treatment 
under growth factor starvation (Figure 2C). Anchorage-independent growth, the most 
important measure of tumorigenicity (Shin et al., 1975), was then assessed in these 
stem cells.  Following PLD inhibitor treatment, GBM stem cells formed significantly fewer 
colonies than vehicle control samples in soft agar, even in the presence of growth factor 
supplements (Figure 2D). Together these results demonstrate that PLD activity is 
required for proliferation and survival in glioma cells.!
!
!
!
!
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Figure 2. PLD activity is required for cell viability and AIG in GBM cells. A. Cells were 
treated with indicated concentration of PLD inhibitor for 24 hours in serum-free media. 
Following inhibitor treatment, viability was measured using the WST-1 reagent. B. 
U87MG or HEK293 cells were grown in complete growth media for 24 hours. Cells were 
then treated for 24 hours with 10 µM VU0364739 or 20 µM VU0359595 in serum-free 
DMEM. Viability was measured using the WST-1 reagent. *** p < 0.001, two-way 
ANOVA with Sidek’s post-hoc test to compare viability between each cell line within 
each inhibitor treatment group. C. CD133+ glioma stem cells were seeded into 96-well 
plates in media containing growth supplements and laminin to facilitate adhesion. 24 
hours after seeding, cells were treated with 10 µM VU0364739 or 20 µM VU0359595 in 
neurobasal media without supplements for an additional 24 hours. Viability was 
measured as in (A). D. Anchorage independent growth of glioma stem cell clone 4302 
was assessed using soft-agar colony formation. Growth media was replaced every 2-3 
days with 10 µM PLD inhibitor or vehicle. Colonies were allowed to form for 8 weeks. 
Large colonies were scored after visualization with Crystal Violet. For (C and D), * p < 
0.5, ** p < 0.01, *** p < 0.005, NS - not significant, unpaired Student’s t-test. Error bars - 
(SEM).!
!
PLD2 is required for Akt activation in GBM cells!
After establishing a requirement for PLD2 in glioma cell viability, we wanted to 
determine the mechanism by which PLD2 regulates survival signaling. The PI3K/Akt 
pathway is frequently upregulated in cancer and promotes survival by inhibiting apoptotic 
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processes and by regulating metabolism and nutrient utilization (reviewed in Manning 
and Cantley, 2007). Additionally, extracellular pathogens are known to engage the Akt 
pathway upon infection, and bacterial PLD from N. gonorrhoeae was demonstrated to 
interact with and activate human Akt upon infection of human cervical epithelial cells 
(Edwards and Apicella, 2006). Thus, we hypothesized that human PLD may also interact 
with Akt. In order to determine if human PLD2 regulates Akt activation in PTEN-null 
glioma lines, we measured Akt phosphorylation following treatment with PLD inhibitors 
under various growth conditions. Under the canonical Akt activation sequence, PI3K 
generates PIP3, which serves as a membrane recruitment signal for Akt (Franke et al., 
1995; James et al., 1996). Membrane-bound Akt is subsequently activated via a 
phosphorylation dependent mechanism whereby 3-phosphoinositide dependent kinase 1 
phosphorylates Akt at threonine 308 in the activation loop and other kinases such as the 
mTOR complex 2 (mTORC2) phosphorylate Akt in its hydrophobic motif at serine 473 
(Alessi et al., 1997; Sarbassov et al., 2005). Cells were treated overnight with PLD 
inhibitors in either serum-free DMEM, DMEM + 10% FBS, or DMEM followed by 
stimulation for 10 minutes the following day with 20% FBS. Since the PLD1- and PLD2-
preferring inhibitors are chemically unique compounds that have few structural 
similarities, using either inhibitor individually at concentrations high enough to inhibit both 
isozymes (Figure 1B) without causing substantial cell death (Figure 2A) allowed us to 
minimize possible off-target effects associated with an individual compound. Inhibition of 
PLD in the PTEN-null U87MG (Figure 3A and B) and U118MG (Figure 3C and D) cell 
lines resulted in decreased levels of activated Akt under serum-depleted conditions as 
assessed by phosphorylation of threonine 308 and serine 473. Akt phosphorylation was 
less affected by PLD inhibition when cells were cultured normally or when stimulated 
with 20% FBS. These results strongly suggest that PLD regulates Akt activation 
predominantly under stressful, serum-depleted conditions. Additionally, these results 
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suggest that the PLD inhibitors do not inhibit upstream kinases or Akt directly since 
growth factor signaling to Akt remains unperturbed. By contrast, PLD inhibitors do not 
reduce phosphorylated Akt in the non-tumorigenic HEK293 cell line under any condition 
(Figure 3E and F), suggesting a cell-type specific regulation of Akt by PLD. We next 
knocked down either PLD1 or PLD2 to dismiss any off-target effects of PLD inhibitors 
and also to further link a specific PLD isoform to this process. Transfection of U87MG 
cells with PLD2, but not PLD1, siRNA resulted in a significant decrease in 
phosphorylated Akt at both threonine 308 and serine 473 (Figure 3G and H). Taken 
together, the data demonstrate that PLD regulates Akt activation under serum-depleted 
conditions and that regulation is due to the PLD2 isoform.!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
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Figure 3. Akt activation requires PLD activity in GBM cells. U87MG (A and B), U118MG 
(C and D), or HEK293 (E and F) were incubated overnight in the presence of 10 µM 
VU0359595 or 5 µM VU0364739 in either DMEM ("starved") or DMEM + 10% FBS 
("normal"). Another set of cells were starved overnight then stimulated the following day 
with 20% FBS for 10 minutes (“stimulated”) for comparison. Akt activation was assessed 
by immunoblotting for phosphorylation at T308 and S473. Blots were quantified by 
calculating the ratio of phospho-Akt at T308 to total Akt using densitometry. S473 was 
not quantified since no qualitative differences were seen between S473 and T308. * p < 
0.05, ** p < 0.01, *** p < 0.005, ANOVA with Dunnett’s post-hoc test comparing the PLD 
inhibitor treatment to vehicle within the growth condition. G. U87MG cells were 
transfected with either PLD1 or PLD2 siRNA for 48 hours prior to overnight serum 
starvation and immunoblotting. H. Quantification of phospho-Akt (T308 and S473) 
following PLD siRNA treatment in U87MG cells. Data represent the fold change in 
phospho-Akt relative to the non-targeting siRNA controls and are averages from three 
independent experiments. * p < 0.05, paired Student’s t-test. Error bars - SEM.  NS - not 
significant.!
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Phosphatidic acid regulates Akt activation!
Since PLD is required for Akt activation following serum-withdrawal in GBM cells, 
we next determined whether human PLD forms a protein complex with Akt, as was 
suggested with PLD from N. gonorrhoeae (Edwards and Apicella, 2006). Due to the lack 
of available antibodies suitable for immunoprecipitating endogenous PLD proteins, 
FLAG-tagged PLD1 or PLD2 was transfected and IP’ed from U87MG cells to probe for 
co-IP of endogenous Akt. When PLD complexes were probed for binding of Akt, co-IP 
was detected in PLD2 but not PLD1 complexes (Figure 4A). Since overexpression of 
proteins is prone to artifacts, we next IP’ed endogenous Akt from U87MG cells to probe 
for co-IP of endogenous PLD2. Under conditions of native levels of protein expression, 
we detected co-IP of PLD2 with Akt, confirming the formation of a protein complex 
between PLD2 and Akt in U87MG cells (Figure 4B). In order to determine if PLD2 
interacts directly with Akt, we expressed and purified recombinant Akt1 and PLD2 from 
Sf21 insect cells (Figure 4C) and performed in vitro binding assays using strep-tactin 
affinity resin to capture protein complexes. Purified Akt1 bound PLD2 in the absence of 
other proteins in vitro, suggesting that the PLD2 and Akt1 form a direct interaction 
(Figure 4D).  
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Figure 4. Akt and PLD2 form a direct protein complex. A. U87MG cells were transfected 
with vector or FLAG-tagged PLD1 or PLD2 for 48 hours. FLAG-PLD1 or PLD2 was 
immunoprecipitated and binding of endogenous Akt was assessed by immunoblotting 
FLAG-PLD complexes for Akt. B. U87MG cells were lysed and endogenous Akt 
immunoprecipitated overnight using a pan-specific Akt antibody. Non-specific proteins 
were immunoprecipitated using normal rabbit IgG. Note, approximately 0.5% of the 
material used for IP was loaded into the lysate lanes for (A) and (B). C. Coomassie 
brilliant blue stained gel of PLD2 and Akt to demonstrate protein purity. Numbers 
indicate molecular weights in kDa. D. Purified Akt was incubated with either PLD2 or PtS 
tag for 2 hours and complexes captured using affinity resin. Bound Akt was determined 
by immunoblotting for Akt to demonstrate a direct protein-protein interaction between 
PLD2 and Akt. 
 
In order to gain insight into the nature of the PLD2-Akt interaction, we sought to 
determine which domains of each protein were responsible for mediating the interaction. 
Akt has three main domains including a PH domain, a kinase domain, and hydrophobic 
motif (HM). We created truncation mutants based on published crystal structures; the 
Akt PH domain construct encoded amino acids 1-123 (Thomas et al., 2002) and the Akt 
kinase domain encoded amino acids 146-480 (Akt.d145) (Yang et al., 2002). 
Additionally, we created two PLD2 truncation mutants encoding the PX and PH domains 
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(amino acids 1-308) and a C-terminal fragment (amino acids 309-933), known to retain 
catalytic activity (Sung et al., 1999a). Full-length proteins and deletion mutations were 
ligated into vectors to express N-terminal epitope tags including PtS, maltose-binding 
protein (MBP), glutathione S-transferase (GST), or 6xHis to facilitate protein purification 
and in vitro binding assays. In order to assess Akt fragment binding to PLD2, we 
performed saturation binding assays by incubating 25 nM PLD2 or PLD2 fragment with 
increasing concentrations of full-length Akt, Akt-PH, or Akt.d145. PLD2 fragments were 
captured using affinity resin. We assessed specific binding of Akt to PLD2 by subtracting 
any Akt bound to PtS or MBP tag control proteins. Full-length PLD2 specifically bound 
full-length Akt and Akt.d145 but did not bind the Akt PH domain (Figure 5). On the other 
hand, PLD2.d308 did not specifically bind any of the Akt constructs (Figure 6). The 
PLD2-PXPH construct specifically bound full-length Akt and Akt.d145, similarly to full-
length PLD2, suggesting that the PLD2-PXPH domain interacts with the kinase domain 
and hydrophobic motif of Akt (Figure 7). 
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Figure 5. Saturation binding analysis of Akt fragments to full-length PLD2. Full-length 
PtS-PLD2 or PtS tag (25nM) was incubated with the indicated concentration of Akt 
fragment for 2 hours before incubating complexes for 2 hours with strep-tactin affinity 
resin. Complexes were washed and eluted by boiling in 2x SDS-PAGE loading buffer. 
Specific binding is assessed as increased levels of Akt protein present in the PtS-PLD2 
samples versus PtS tag controls. Coomassie stained gels of Akt.d145 and Akt-PH are 
shown to demonstrate purity. Numbers are molecular weights in kDa. 
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Figure 6. Saturation binding analysis of Akt fragments to PLD.d308. MBP-tagged 
PLD2.d308 or MBP tag (25nM) was incubated with the indicated concentration of Akt 
fragment for 2 hours before incubating complexes for 2 hours with amylose resin to 
capture MBP proteins. Complexes were washed and eluted by boiling in 2x SDS-PAGE 
loading buffer. Specific binding is assessed as increased levels of Akt protein present in 
the PLD2.d308 samples versus MBP tag controls. Coomassie stained gel of PLD2.d308 
is shown to demonstrate purity. Numbers are molecular weights in kDa. 
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Figure 7. Saturation binding analysis of Akt fragments to PLD-PXPH. MBP-tagged 
PLD2-PXPH or MBP tag (25nM) was incubated with the indicated concentration of Akt 
fragment for 2 hours before incubating complexes for 2 hours with amylose resin to 
capture MBP proteins. Complexes were washed and eluted by boiling in 2x SDS-PAGE 
loading buffer. Specific binding is assessed as increased levels of Akt protein present in 
the PLD2-PXPH samples versus MBP tag controls. Coomassie stained gel of PLD2-
PXPH is shown to demonstrate purity. Numbers are molecular weights in kDa. 
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After establishing that PLD2 interacts with the Akt C-terminus through its PX and 
PH domains, we next determined whether the protein interaction regulates enzymatic 
activity. First, we performed in vitro choline release PLD activity assays in the presence 
or absence of Akt protein. We saw no changes in PLD activity by including Akt protein in 
the reaction mixture (data not shown). However, full-length PLD2 stimulated Akt kinase 
activity towards a substrate peptide around two-fold (Figure 8A). Likewise, the PLD2-
PXPH domain also stimulates Akt kinase in vitro consistent with observation that the 
PLD2-PXPH domains interact with the Akt kinase domain (Figure 8B). The observation 
that PLD2 stimulates Akt kinase activity in the absence of substrate or product lipids 
suggests that PLD regulates Akt kinase activity in a lipase-independent manner. 
 
 
 
Figure 8. Full-length PLD2 and the PX/PH domains of PLD2 stimulate Akt kinase activity 
in vitro. 50 nM of purified Akt kinase was incubated with or without 50 nM (A) PtS-PLD2 
or (B) PLD2-PXPH protein in the presence of 100 µM ATP and a GST-GSK3 Akt 
substrate peptide. Kinase reactions were terminated by boiling samples in 2x SDS-
PAGE loading buffer. Akt kinase activity was determined by immunoblotting with a 
phospho-GSK3 antibody. Note; no lipids were included in the assay. Data is presented 
as the fold change in Akt kinase activity due to the presence of PLD proteins over the 
amount of Akt kinase activity in the absence of PLD proteins. * p < 0.05, ** p < 0.01, 
unpaired Student’s t-test. 
 
In order to determine if PLD inhibitors disrupted the PLD2-Akt complex, we 
performed in vitro binding assays in the presence of VU0359595 and VU0364739 or the 
allosteric pan-Akt inhibitor MK2206 (Hirai et al., 2010). PLD inhibitors did not disrupt the 
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PLD2-Akt complex, suggesting that PLD inhibitors decreased Akt activation 
independently of the PLD2-Akt interaction (Figure 9). Since PLD inhibitors did not disrupt 
the PLD2-Akt protein complex, we investigated a potential regulation of Akt by PtdOH, 
the catalytic product of PLD. To confirm that the decrease in Akt phosphorylation 
following PLD inhibitor treatment or siRNA knockdown was due to the decrease in 
PtdOH production, we attempted to rescue Akt phosphorylation by co-treatment of 
U87MG cells with PLD inhibitors and exogenously added PtdOH. Our laboratory recently 
published a detailed lipidomic characterization of PtdOH species generated by PLD in an 
astrocytoma cell line (Scott et al., 2013). Based upon this analysis and others, we 
attempted to rescue Akt phosphorylation using 36:2 PtdOH, a species generated by PLD 
(Scott et al., 2013). We observed complete rescue of Akt phosphorylation with 
exogenously added PtdOH (Figure 10A and B), suggesting that decreased Akt 
phosphorylation following PLD inhibitor treatment was due to decreased production of 
PtdOH by PLD.!
!
!
!
Figure 9. PLD inhibitors do not disrupt the PLD2-Akt complex. 50 nM Akt was incubated 
with either 25 nM PLD2 or PtS tag for 2 hours and complexes captured using strep-tactin 
affinity resin. Where indicated, 10 µM VU0359595, VU0364739, or Akt inhibitor MK2206 
was included in the reaction mixture. Akt binding was assessed by immunoblotting strep-
tactin-bound PLD2 for the presence of Akt. 
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Figure 10. PtdOH increases Akt activation. A. U87MG cells were treated overnight with 
10 µM VU0359595 or 5 µM VU0364739 in DMEM containing 0.25 mg/ml fatty-acid free 
BSA. Where indicated, cells were co-treated with 1 mM PtdOH or BSA control and Akt 
phosphorylation was assessed by immunoblotting T308 and S473. B. Quantification of 
PtdOH rescue of Akt phosphorylation following PLD inhibitor treatment. Fold changes in 
phospho-Akt (T308) were determined relative to the vehicle treated, BSA control. Data 
were analyzed by repeated measures ANOVA across all conditions and post-hoc paired 
t-tests in indicated conditions. * p < 0.05; ** p < 0.01; *** p < 0.001. C. 5 nM recombinant 
Akt was incubated overnight with nitrocellulose membranes containing 2 µg of the 
indicated lipid. Bound Akt was measured using an Akt specific antibody. Phospholipids 
are denoted XX;Y, where XX refers to the number of carbon atoms in the acyl chain and 
Y indicates the degree of unsaturation.  
 
Several studies have recently suggested that Akt binds other phospholipids in 
addition to phosphoinositides including phosphatidylserine (Huang et al., 2011) and 
PtdOH (Mahajan et al., 2010). To compare the relative affinity of Akt for various 
phospholipids, we measured Akt binding using a commercially available protein-lipid 
overlay assay (Dowler et al., 2002) in which phospholipids are spotted onto 
nitrocellulose and binding of recombinant protein is detected immunologically. In 
agreement with other studies, recombinant Akt bound PtdOH and with higher affinity 
than other phospholipids (Figure 10C).!
!
PtdOH enhances Akt binding to PIP3 and subsequent membrane recruitment!
In order to understand the mechanism by which PtdOH regulates Akt activation, 
we first determined whether PtdOH and PIP3 share a binding site on Akt. Recombinant 
Akt was incubated with lipid vesicles composed of PC alone or PC with PtdOH. Akt 
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binding to PtdOH and PIP3 was then assessed using a protein-lipid overlay assay. When 
pre-incubated with vesicles containing PtdOH, binding of Akt to PtdOH on nitrocellulose 
was diminished, and this condition served as an internal control for the experiment 
(Figure 11A). Intriguingly, binding of Akt to PIP3 was strongly enhanced by pre-
incubation with PtdOH-containing vesicles (Figure 11A). Since PIP3 is known to bind the 
Akt PH domain based on published crystal structures (Thomas et al., 2002), we 
investigated whether the PH domain also mediates the interaction with PtdOH. GST-Akt 
PH domain fusion proteins were purified from E. coli and lipid binding was again 
assessed using a protein-lipid overlay. We purified the wild-type (WT) Akt PH domain 
and an Akt PH domain mutant deficient in PIP3 binding, R25C (Thomas et al., 2002),  to 
determine if perturbing PIP3 binding would also alter PtdOH binding. The WT PH domain 
of Akt was sufficient to bind PtdOH and disruption of PIP3 binding with the R25C mutant 
had no effect on PtdOH binding (Figure 11B). These results suggest that PtdOH binds a 
distinct site on the PH domain of Akt and that the binding of PtdOH acts cooperatively to 
increase the affinity of Akt for PIP3.!
Since PIP3 recruits Akt to membranes (Bellacosa et al., 1991; Franke et al., 
1995) and PtdOH increased Akt binding to PIP3, we investigated the possibility that PLD-
generated PtdOH regulates membrane localization of Akt. Membranes from serum-
starved U87MG cells treated with vehicle or PLD inhibitors were prepared by flotation 
through a discontinuous iodixanol gradient. Under control conditions, Akt was present in 
both cytosolic and membrane fractions and as we hypothesized, inhibition of PLD 
decreased the levels of both total and phosphorylated Akt in the membrane fraction 
(Figure 11C). Akt membrane recruitment was less sensitive to PLD inhibition in the 
presence of serum and Akt was not detected in the membrane fractions of serum-
starved HEK293 cells except under conditions where film was extremely overexposed 
(data not shown), consistent with constitutive activation of Akt in PTEN-null GBM cells. 
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To confirm that PLD inhibitors decreased Akt membrane localization in a PtdOH 
dependent manner, we co-treated U87MG cells with PLD inhibitors and the PLD product 
PtdOH before preparing membranes. Interestingly, co-treatment of cells with PtdOH not 
only rescued Akt membrane localization but PtdOH treatment resulted in a dramatic 
relocalization of cytosolic Akt to the membrane fraction (Figure 11D). These data 
implicate PLD-generated PtdOH as a crucial mediator of Akt-membrane recruitment in 
GBM cells.!
!
!
!
Figure 11. Akt recruitment to membranes is enhanced by binding to PtdOH. A. 
Recombinant Akt (3 nM) was incubated with 200 µM bulk lipid vesicles for 1 hour then 
the Akt-vesicle mixtures were incubated overnight with nitrocellulose spotted with PtdOH 
or PIP3. Bound Akt was determined using an Akt specific antibody. B. Protein-lipid 
overlay measuring wild-type or R25C PIP3 binding deficient mutant Akt PH domain (3 
nM) binding to PtdOH or PIP3. C and D. U87MG cells were treated for 6 hours with 10 
µM PLD inhibitor in the absence (C) or presence (D) of 1 mM 36:2 PtdOH in DMEM + 
0.25 mg/ml BSA and separated into cytosol and membranes for immunoblotting. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and pan-cadherin were used as 
cytosolic and membrane markers, respectively.  Error bars - SEM. WCL – whole cell 
lysate, NS – not significant.!
!
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PLD2 inhibition induces autophagy-dependent cell death!
After establishing a requirement for PLD2-generated PtdOH in the activation of 
Akt in U87MG cells, we next determined the mechanism of cell death following inhibition 
of the PLD2-Akt pathway by first measuring markers for apoptosis in U87MG cells. PLD 
inhibition only modestly induced caspase-3/7 cleavage relative to a well-characterized 
apoptotic stimulus, staurosporine (Bertrand et al., 1994) and treatment of U87MG cells 
with a pan-caspase inhibitor failed to rescue PLD-inhibitor induced cell death (Figure 
12). Together, these results suggest that PLD inhibition predominantly leads to non-
apoptotic cell death in this GBM line. !
!
!
!
Figure 12. PLD inhibition does not induce apoptotic cell death. A. U87MG cells treated 
overnight with PLD inhibitor in the presence of 50 µM z-VAD-fmk, a pan caspase 
inhibitor. 24 hours after treatment, caspase 3/7 cleavage was measured using the 
luminometric Caspase-Glo 3/7 kit from Roche. B. Viability was measured using the 
WST-1 reagent.  Staurosporine was included as a positive apoptotic control. Error bars - 
SEM.!
!
In addition to apoptosis, cells undergo another type of programmed cell death 
requiring autophagy (Tsujimoto and Shimizu, 2005), a process known to be stimulated 
by nutrient or growth factor deprivation (Kroemer et al., 2010). Autophagy is a multistep 
process involving formation of double-membrane autophagosomes that engulf cytosolic 
components and deliver cargo to lysosomes for digestion and nutrient recycling 
A B 
!"
#$%
&"
'(
!)
!*
(+
,-
,-
,
'(
!)
!*
(+
./
0+
-
1!
)
23
45
67
89
76
$:"
(
,(
1((
1,(
;"
6%
":
3<
$4
=$
&$3
>
?7
<"
6<
"#
$%
&"
%7
:3
67
&@ !"#$%&"
'(!)*(+,-
!"
#$%
&"
'(
!)
!*
(+
,-
,-
,
'(
!)
!*
(+
./
0+
-
1!
)
23
45
67
89
76
$:"
(
'
/
.
;
<7
&=
%4
89
48
"
+>
0
%&
"4
?4
@" !"#$%&"
'(!)*(+,-
 150!
(Ravikumar et al., 2009). In order to determine if autophagy was perturbed following PLD 
or Akt inhibitor (MK2206) (Hirai et al., 2010) treatment, we measured the expression 
levels of the well-characterized autophagy markers microtubule-associated protein 
1A/1B-light chain 3 (LC3) and p62. Autophagosome number is frequently assessed by 
measuring conversion of cytosolic LC3-I to the membrane-associated, lipidated LC3-II 
which is readily measured as a faster migrating species of LC3 during SDS-PAGE 
(Kabeya et al., 2000). The other marker, p62, is an LC3 and ubiquitin-binding protein 
involved in the regulation of protein aggregates and is degraded by autophagy (Komatsu 
et al., 2007). Induction of autophagy and successful degradation of autophagosomes 
would thus be accompanied by a decrease in p62 levels. Overnight treatment of U87MG 
cells with PLD or Akt inhibitors robustly induced LC3-II conversion and also increased 
p62 levels (Figure 13A and B). These results suggest an increased number of 
autophagosomes resulting from a deficiency in autophagosome turnover as is often 
observed under conditions where autophagy is defective (Wang et al., 2006). In the 
presence of PtdOH, PLD inhibitors failed to increase autophagy markers, which further 
validates the specificity of our inhibitors (Figure 13C, D, and E). LC3-II and p62 levels 
also increased in other glioma cell lines including the CD133+ glioma stem cells (Figure 
13F) and U118MG cells (data not shown) following PLD inhibitor treatment.!
To determine if the effects on autophagy following PLD inhibition were cell-type 
specific, we compared LC3/p62 levels between U87MG cells and HEK293 cells. PLD 
and Akt inhibitors increased LC3-II conversion in both cell types (Figure 13G). However, 
the levels of LC3 and p62 under basal conditions were much higher in the U87MG cells, 
suggesting that glioma cells utilize autophagy more so than other cell types, rendering 
them particularly sensitive to compounds that perturb autophagy.!
To confirm that U87MG cells were undergoing autophagy-dependent cell death, 
we measured the ability of PLD inhibitors to decrease viability when machinery required 
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for autophagosome formation was perturbed by siRNA knockdown. Autophagy-related 
protein 7 (Atg7) is a ubiquitination E1-like enzyme required for autophagosome 
formation (Komatsu et al., 2005). Knockdown of Atg7 significantly increased viability 
(Figure 13H) and decreased LC3-II conversion (Figure 13I) following PLD inhibition in 
U87MG cells. These results strongly suggest that GBM cell death resulting from PLD 
inhibition is predominantly through an autophagy-dependent mechanism.!
!
!
!
!
!
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Figure 13. PLD inhibitors induce autophagy dependent cell death in GBM. A. 
Immunoblot of autophagy markers from U87MG cells treated overnight with 10 µM 
VU0359595, 5 µM VU0364739, or 10 µM MK2206 in serum-free DMEM. B. 
Quantification of LC3-II and p62 increase in U87MG cells following PLD or Akt inhibition. 
Fold change in immunoreactivity relative to vehicle control. * p < 0.05, ** p < 0.01, 
ANOVA with Dunnett’s post-hoc test comparing inhibitor treatment to vehicle control. C. 
Immunoblot of autophagy markers from U87MG cells treated overnight with PLD 
inhibitors with or without 1 mM 36:2 PtdOH in DMEM + 0.25 mg/ml BSA. D and E. 
Quantification of LC3-II and p62 from (C). * p < 0.05, ** p < 0.01, ANOVA with Dunnett’s 
post-hoc test comparing inhibitor treatment to vehicle control within the PtdOH treatment 
conditions. F. Immunoblot of autophagy markers from CD133+ glioma stem cells treated 
overnight with 10 µM VU0359595 or 5 µM VU0364739 in neurobasal media without 
growth supplements. G. Comparison of autophagy marker expression in U87MG or 
HEK293-TREx cells treated overnight with 10 µM VU0359595, 5 µM VU0364739, or 10 
µM MK2206 in serum-free DMEM. H. Viability assay from U87MG cells treated with 
siRNA targeting Atg7.  Cells were treated overnight with PLD or Akt inhibitors in serum-
free DMEM before measuring viability with the WST-1 reagent. * p < 0.05, ** p < 0.01, 
two-way ANOVA with post-hoc Sidak multiple comparison test on Atg7 siRNA effect 
within inhibitor treatment groups. I. Immunoblot of LC3 and Atg7 for experiment in panel 
(H). Error bars - SEM. N/T – non-targeting siRNA.!
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PLD and Akt inhibition reduces autophagic flux!
The increased conversion of LC3-II and increased expression of p62 after inhibitor 
treatments in glioma cells suggests that autophagic flux requires PLD and Akt activity. 
To conclusively determine that flux, rather than autophagosome initiation, is regulated by 
PLD, we measured LC3-II conversion in the presence of the lysosomal proton pump 
inhibitor bafilomycin A1, which prevents autophagosome fusion to lysosomes and 
inhibits degradation of autophagosomes. Thus, bafilomycin A1 is commonly used to 
discriminate the effects of a compound on autophagy initiation versus flux by assessing 
LC3-II levels in the presence of a test compound after clamping degradation of 
autophagosomes (Yamamoto et al., 1998a). Bafilomycin A1, PLD, and Akt inhibitor 
treatment increased LC3-II levels relative to vehicle control (Figure 14A and B). 
However, no additional accumulation of LC3-II was measured when PLD or Akt 
inhibitors were added in the presence of bafilomycin A1, confirming that PLD and Akt 
were controlling degradation of autophagosomes.!
To further demonstrate decreased degradation of autophagosomes following 
PLD2/Akt inhibition, we generated a stable U87MG cell line to express a tandem-
fluorescent LC3 reporter (tf-LC3) used to assess autophagosome maturation (Kimura et 
al., 2007). This reporter system consists of a red fluorescent protein (RFP) and green 
fluorescent protein (GFP) fused to LC3. As autophagosome numbers increase, either 
due to increased autophagy initiation or decreased degradation, fluorescence intensity 
increases as LC3 clusters on autophagosome membranes. Unlike RFP, GFP is 
quenched by low pH and LC3 present in lysosomes should predominantly emit an RFP 
signal. Under situations where autophagosome degradation is perturbed, the GFP and 
RFP signals co-localize since autophagosomes do not fuse to acidic lysosomes. The tf-
LC3 U87MG cells were treated with PLD or Akt inhibitors overnight, fixed, and imaged 
for GFP and RFP signals. Under vehicle treated conditions, numbers of LC3 puncta 
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were low and predominantly visualized with the pH-insensitive RFP tag, indicative of 
functional autophagy. However, PLD or Akt inhibitor treatments induced a robust 
relocalization of cytosolic LC3-I to large fluorescent puncta and when merged, the 
GFP/RFP signals highly co-localized, indicating a perturbation in the ability of the cell to 
effectively degrade and process autophagosomes (Figure 14C).!
!
!
!
Figure 14. PLD inhibition decreases autophagic flux. A. Immunoblot of LC3 from 
U87MG cells treated with 10 nM bafilomycin A1 for 30 minutes followed by treatment 
with 10 µM VU0359595, 5 µM VU0364739, or 10 µM MK2206 for 6 hours in serum-free 
DMEM before cell harvest. B. Quantification of LC3-II conversion in the presence of 
bafilomycin A1 and PLD/Akt inhibitors. Data are presented as the ratio of band intensity 
for LC3-II relative to Actin.  * p < 0.05, *** p < 0.005, two-way ANOVA with Tukey’s post-
hoc test on PLD/Akt inhibitor effects versus vehicle control, NS – no significant impact of 
PLD inhibitors in conditions with bafilomycin A1. C. Representative images of U87MG 
stable cells expressing a GFP/RFP-LC3 tandem-fluorescent tag. Cells were treated 
overnight in serum-free DMEM with 10 µM VU0359595, 5 µM VU0364739, 10 µM 
MK2206, or 10 nM Bafilomycin A1 then fixed and imaged using confocal microscopy. 
Error bars - SEM.!
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After establishing that PLD and Akt promote autophagic flux, we sought to 
understand the molecular mechanism. The mTOR pathway suppresses autophagy 
under nutrient rich conditions and PLD has been implicated as an upstream positive 
regulator of mTOR (reviewed in Foster, 2009). Although we measured diminution of 
mTOR activity with Akt inhibition, we measured little to no change in mTOR effector 
phosphorylation status with PLD inhibition (Figure 15A), suggesting the mTOR pathway 
was not mediating the effects of PLD inhibitors on autophagy and also suggesting that 
PLD2 and mTOR signaling are uncoupled in the U87MG cell line. Since mTOR 
regulation did not explain the effects of PLD inhibition on autophagy, we investigated 
other Akt substrates. Recently, Akt was shown to phosphorylate beclin1 and promote 
autophagy (Wang et al., 2012). Beclin1 is a component of the core autophagy complex 
(Liang et al., 1999) and exists in multiple protein complexes during progressive stages of 
autophagy (Kihara, 2001). Autophagosome maturation and subsequent degradation is, 
in part, regulated by the interaction of beclin1 with RUN-domain cysteine rich domain 
containing, Beclin1 interacting protein (rubicon) (Matsunaga et al., 2009; Zhong et al., 
2009), which is believed to negatively impact autophagosome maturation. We 
hypothesized that the phosphorylation of beclin1 by Akt might inhibit the interaction with 
rubicon and either PLD2 or Akt inhibition would thereby enhance the interaction. As 
expected, The PLD2 inhibitor VU0364739 and Akt inhibitor MK2206 increased the 
amount of rubicon that co-immunoprecipitated with beclin1 from U87MG cells (Figure 
15B and C). To address whether the interaction of rubicon with beclin1 was mediated by 
Akt phosphorylation, we mutated the two putative Akt phosphorylation residues on 
beclin1, serine 234 and serine 295 (Wang et al., 2012), and assessed rubicon binding. 
Previous studies identified serine 295 as the predominant Akt phosphorylation site on 
beclin1 (Wang et al., 2012). Alanine mutation of serine 295, but not 234, increased 
rubicon binding to beclin1 compared to wild type controls (Figure 15B). PLD and Akt 
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inhibition failed to increase binding of rubicon to the S295A mutant of Beclin1, supporting 
the model that Akt activity enhances autophagic flux by preventing binding of Rubicon to 
Beclin1 (Figure 15B and C).!
!
!
!
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Figure 15. PLD and Akt promote autophagic flux by dissociating rubicon from beclin1. A. 
U87MG cells were treated overnight with 10 µM VU0359595, 5 µM VU0364739, 10 µM 
MK2206, or 1 µM mTOR inhibitor Torin1. Cells were immunoblotted for total and 
phosphorylated p70S6K1. B. U87MG cells were transfected with HA-tagged wild type or 
mutant beclin1 for 48 hours. Cells were treated with 10 µM VU0364739 or MK2206 for 6 
hours in serum-free DMEM prior to cell harvest and immunoprecipitation of HA-beclin1 
with a HA-antibody. Immunoprecipitates were probed for co-IP of endogenous rubicon. 
C. Quantification of the increased binding of rubicon to beclin1 following PLD or Akt 
inhibition. Band intensities of rubicon and beclin1 were determined and the ratio of 
rubicon to beclin1 was calculated for each sample. Fold changes in this ratio were 
calculated by comparing inhibitor conditions to the vehicle treated conditions within the 
wild-type or S295A beclin1 groups (n=4). ** p < 0.01, ANOVA with Dunnett’s post-hoc 
test. Error bars = SEM.!
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Functional rescue of Akt restores autophagic flux and viability in glioma cells 
following PLD inhibition!
In order to confirm that the effects on autophagy and cell death following PLD 
inhibition in glioma cells were due to the regulation of Akt by PLD2, we developed a 
stable U87MG cell line expressing a constitutively active form of Akt under the 
transcriptional control of the tetracycline repressor protein. This Akt construct contains 
the myristoylation sequence from Src kinase (Kohn et al., 1996) and is constitutively 
membrane associated and active. Myr-Akt functions in dominant-positive manner and is 
the most widely used construct for assessing the cellular effects of constitutive Akt 
activation (Manning and Cantley, 2007). If PtdOH serves to enhance membrane docking 
of Akt then PLD inhibition should not decrease phosphorylation of myristoylated Akt 
(myrAkt1) since this construct bypasses lipid recruitment signals for membrane 
association. As expected, PLD inhibitors failed to reduce levels of phosphorylated Akt in 
myrAkt1 U87MG cells (Figure 16A). Unlike PLD inhibitors, Torin1, an ATP-site mTOR 
inhibitor (Thoreen et al., 2009), decreased phosphorylation of myrAkt1, demonstrating 
that mTORC2 activity is still required for myrAkt1 phosphorylation and that inhibition of 
PLD activity does not decrease mTORC2 activity in this cell line (Figure 16B). This result 
is consistent with PLD regulating Akt by enhancing membrane recruitment rather than 
regulating kinases or phosphatases that modulate phosphorylation of threonine 308 and 
serine 473.!
Since phosphorylation of myrAkt1 was resistant to PLD inhibition, we next 
determined whether autophagic flux was restored following myrAkt1 expression in PLD 
inhibitor treated cells. Expression of myrAkt1 produced a modest increase in the basal 
level of LC3-II versus the parental U87MG line (Figure 16C). However, the fold induction 
of LC3-II due to PLD inhibitor treatment versus vehicle control was significantly less than 
in the parental U87MG line (Figure 16C and D), suggesting that the decrease in 
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autophagic flux was due to inactivation of Akt via a PLD dependent mechanism. 
Mechanistically, expression of myrAkt1 should prevent the increased binding of rubicon 
to beclin1 following treatment with PLD inhibitors. Treatment of myrAkt1 U87MG cells 
with Akt inhibitor MK2206, but not VU0364739, increased beclin1 binding to rubicon 
even in the presence of myrAkt1 (Figure 16E and F), supporting the proposed 
mechanism that PLD2 inhibition results in the inactivation of Akt, which promotes the 
Rubicon-Beclin1 interaction and inhibits autophagic flux.!
Finally, to confirm that the decrease in viability following PLD inhibition was due 
to inhibition of Akt, we measured U87MG cell viability in the parental and myrAkt1 lines. 
Restoration of Akt function significantly increased viability and protected the GBM cells 
from PLD inhibitor induced cell death (Figure 16G). Taken together, these data suggest 
that PLD activity is required for full Akt activation in GBM cells and that when inhibited, 
cells undergo autophagic death.!
!
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Figure 16. Restoration of Akt function rescues cell viability following PLD inhibitor 
treatment. A. Immunoblot of phosphorylated Akt from parental or myrAkt1-expressing 
U87MG cells treated overnight with 10 µM VU0359595 or 5 µM VU0364739 in serum-
free DMEM. B. Parental or myrAkt1 U87MG cells were treated with the indicated 
inhibitors as in (A) overnight before blotting for phosphorylated and total Akt. C. 
Immunoblot of LC3 from parental or myrAkt1 U87MG following 6 hour treatment with 
PLD or Akt inhibitors in serum-free DMEM. D. Quantification of LC3-II conversion in 
parental and myrAkt1 U87MG cells following PLD and Akt inhibition. Fold changes were 
determined by calculating the ratio of LC3-II in inhibitor treated samples to vehicle 
treated samples within each cell line. * p < 0.05, *** p < 0.005, two-way ANOVA with 
Tukey’s post-hoc test. E. MyrAkt1-U87MG cells were seeded and treated as in Figure 
15B. F. Quantification of Rubicon binding to Beclin1 in myrAkt1 U87MG cells. Binding 
was quantified as in Figure 15C and * p < 0.05 using a paired student’s t-test (n=4). G. 
WST-1 viability assay with parental or myrAkt1 U87MG cells treated for 24 hours with 20 
µM VU0359595 or 10 µM VU0364739 in serum-free DMEM. Data is presented as the 
viability remaining following inhibitor treatment compared to the vehicle control within 
each cell type.  *** p < 0.005, two-way ANOVA with Sidek’s post-hoc test.  Error bars - 
SEM.!
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Discussion!
Although cancer research has improved the lives and long-term survival of many 
patients over recent decades, the prognoses and treatment options for patients with 
GBM remain grim. Treatment of drug-resistant GBM demands new understanding of the 
survival mechanisms used to sustain GBM growth and viability under stress conditions. 
The insight that most GBM are resistant to apoptotic stimuli has prompted investigators 
to examine autophagy as a survival mechanism that may be exploited for drug treatment 
(Lefranc et al., 2007). The chemotherapeutic drugs most successful in treating GBM, 
such as temozolomide, induce autophagy (Kanzawa et al., 2004). Drugs that interfere 
with autophagic flux, such as the anti-malarial drug chloroquine, have shown promise in 
clinical trials for potentiating cell death induced by conventional GBM chemotherapies 
(Sotelo et al., 2006). Therefore, identification of novel autophagy drug targets is clinically 
relevant for GBM. 
In this chapter, we identified PLD, specifically the PLD2 isoform as a regulator of 
autophagy and cell survival in gliomas through its regulation of Akt kinase (Figure 17). 
Phosphorylation of Akt, under serum depleted conditions, requires PLD2-generated 
PtdOH for recruitment to membranes (Figures 3 and 11). The phosphorylation status of 
a constitutively membrane-associated Akt, myrAkt, is unperturbed by PLD inhibition 
(Figure 16A and B), suggesting that PLD2 functions to regulate Akt activation by 
membrane recruitment as opposed to modulating the activities of upstream kinases such 
as the mTORC2 complex, as has been suggested in other cell lines (Chen et al., 2012; 
Toschi et al., 2009). Additionally, we report that PLD2 and Akt co-IPfrom U87MG cell 
lysates and form a direct protein-protein interaction (Figure 4). Several Akt-interacting 
proteins have been identified and mediate a variety of effects including modulation of 
kinase activity and enhancing the ability of upstream kinases to activate Akt by rendering 
Akt a better kinase substrate (Du and Tsichlis, 2005). An interesting hypothesis emerges 
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in which PLD2-generated PtdOH recruits Akt to membranes and allows PLD2 to directly 
interact with Akt and regulate kinase activity or activation by upstream kinases, and this 
is the subject of ongoing investigation. 
 
 
 
Figure 17. Mechanism of Akt and autophagy regulation by PLD. A. In the absence of 
inhibitors, PLD generates PtdOH and recruits Akt to the membrane allowing for 
phosphorylation of beclin1 by Akt at serine 295 and disruption of the Beclin1/rubicon 
complex and promotion of autophagic flux. B. PLD inhibitors reduce PtdOH production 
and subsequent Akt membrane recruitment. The inactivation of Akt results in reduced 
phosphorylation of beclin1 at serine 295 and formation of the beclin1/rubicon complex. 
 
The coupling of PtdOH to Akt activation is apparent in GBM lines but not other 
cells such as the non-tumorigenic HEK293 line (Figure 3). The GBM cell lines used in 
this study, U87MG and U118MG, are both PTEN-null and have higher basal levels of 
Akt relative to other cell lines. Studies are emerging that suggest Akt-lipid binding 
profiles may be altered by post-translational modifications and could account for the 
differences we observe between various cell lines. For example, Mahajan et al. reported 
that phosphorylation at tyrosine 176 increases the affinity of Akt for PtdOH (Mahajan et 
al., 2010). In our study, PtdOH appears to increase the affinity of Akt for PIP3 by binding 
a distinct site in the Akt PH domain, suggesting that PLD and PI3K might either work 
together or independently to activate Akt (Figure 11). Crystal structures of the PX 
domain from the NADPH oxidase protein p47Phox revealed a PtdOH binding pocket 
distinct from the well-characterized phosphoinositide binding site (Karathanassis et al., 
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2002). Similar to our findings with Akt, occupation of the PtdOH binding pocket on 
p47Phox dramatically increased binding affinity for phosphoinositide-containing 
membranes (Karathanassis et al., 2002). These findings open the possibility that other 
lipid-binding proteins are subject to dual-regulation by PtdOH and phosphoinositides and 
expose the potential for alternative therapy strategies targeting one or both pathways as 
PLD and PI3K may function together to fine-tune subcellular localization and regulate 
specific effector pathways. In tandem, selective inhibitors might reduce the effective 
concentrations and thereby minimize undesired side effects. 
Akt kinase has emerged as a regulator of autophagy and chemical inhibitors or 
genetic silencing can modulate autophagy in GBM cells (Degtyarev et al., 2008), 
although the mechanisms have not been fully elucidated. Here, we have characterized a 
novel function for the Akt-mediated phosphorylation of beclin1. Phosphorylation of 
Beclin1 by Akt appears to prevent binding to Rubicon (Figure 15B and C), an interaction 
that is known to inhibit autophagosome maturation (Matsunaga et al., 2009; Zhong et al., 
2009). Further elucidation of novel Akt substrates in autophagy pathways will potentially 
shed light on other molecular mechanisms underlying the regulation of autophagy by 
PLD2 and Akt. 
Our results support PLD as a novel drug target for GBM therapy.  By regulating 
specific functions of Akt, such as autophagy (Figure 17), the side effects of global Akt 
inhibition (Carlson, 2013; Yap et al., 2011) are potentially avoided by targeting PLD2.  
Knockout mice for PLD1 and PLD2 (Elvers et al., 2010; Oliveira et al., 2010) are viable 
and show no overt phenotypes, suggesting that small-molecule inhibition of PLD may 
circumvent toxic side effects seen with conventional chemotherapies. Although we 
characterized the molecular mechanisms of cell survival in a model system, U87MG 
cells, PLD inhibitors decreased autophagic flux, reduced viability, and reduced 
anchorage independent growth in two glioma stem cell lines isolated from human 
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biopsies (Figure 2C and Figure 13F), which are notoriously resistant to conventional 
chemotherapies (Eramo et al., 2006). Therefore, the development of PLD inhibitors as a 
stand-alone or combination therapy has exciting potential for GBM treatment. 
 
Materials and methods 
 
Cell culture 
myrAkt1-U87MG cells were maintained in DMEM + 10% tetracycline-free FBS 
(Atlanta Biologicals) + 1% P/S. Sf21 insect cells were obtained from Orbigen and 
maintained in Grace’s Media (Life Technologies) supplemented with lactalbumin 
hydrolysate, yeastolate, sodium bicarbonate, and 10% FBS.  Sf21 cells were maintained 
at 27 °C. Cell culture methods for other cell lines were described in chapter II. 
 
Plasmids and baculovirus production 
The following plasmids were obtained from Addgene: pcDNA3 T7 Akt1 (PI: 
William Sellers (Ramaswamy et al., 1999, plasmid 9003), pcDNA3 myr HA Akt1 (PI: 
William Sellers (Ramaswamy et al., 1999, plasmid 1036), ptfLC3 (PI: Tamotsu Yoshimori 
(Kimura et al., 2007, plasmid 21074), and pcDNA4 Beclin1-HA (PI: Qing Zhong (Sun et 
al., 2008b, plasmid 24399). FLAG-PLD1 and PLD2 were created by PCR amplification of 
the PLD open reading frames (PLD1 cDNA was obtained from Open Biosystems MGC 
collection, clone #6068382 and PLD2 cDNA was a generous gift from Dr. David 
Lambeth at Emory University) using forward primer containing FLAG epitope sequences 
and ligating into pcDNA5/TO (Life Technologies). To create the PtS-tagged PLD2 
construct (PtS-PLD2), the PtS tag from p31-N-PtS (a kind gift from Dr. Yisong Wang 
(Giannone et al., 2007) was shuttled into pcDNA5/TO to create PtS-pcDNA5/TO and the 
PLD2 ORF was subsequently ligated 3’ of the PtS ORF into PtS-pcDNA5 to create a 
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PLD2 construct with an N-terminal PtS tag. To create the PtS-PLD2 baculovirus, the 
PtS-PLD2 ORF was ligated into pENTR1A (Life Technologies). After LR recombination 
into pDEST8 (Life Technologies), baculovirus was produced according to manufacturer 
instructions. A bacterial expression vector for the PtS tag was created by amplification of 
the PtS tag from PtS-pcDNA5/TO and ligated into pET16b (EMD Millipore). To make 
PLD2.d308, amino acids 309-933 of human PLD2 were amplified and ligated into a 
pDEST derivative containing N-terminal His, MBP, FLAG, and TEV (HMFT) tags 
(Henage et al., 2006). HMFT-PLD2.d308 in pDEST8 was used to create bacmid DNA 
according to manufacturer instructions. PLD2-PXPH was created by amplifying the first 
308 amino acids of PLD2 and ligating into pSV278 (Vanderbilt structural biology core). 
The pSV278 plasmid encodes a 6xHis-MBP tag 5’ of a multiple cloning site so resulting 
constructs have an N-terminal tag. 
For 6xHis-Akt1 and 6xHis-Akt1.d145 baculovirus production, the Akt1 ORF was 
amplified from pcDNA3 myr HA Akt1 and ligated into pENTR3C (Life Technologies). The 
full-length Akt protein encoded amino acids 2-480 and Akt.d145 encoded 146-480. 
pENTR3C was LR recombined into pDEST10 (Life Technologies) to generate a 6xHis-
Akt1 construct and baculovirus was produced according to manufacturer instructions. 
 
Transfection and RNAi 
For protein expression, cells were transfected using Fugene 6 (Roche) according 
to the manufacturer instructions. All siRNA was obtained from Dharmacon as a pool of 4 
oligonucleotide targeting sequences per relevant target (ON-TARGETplus). Cells were 
transfected according to manufacturer instructions using the Dharmafect 1 reagent and a 
final concentration of 100 nM siRNA.   
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Endogenous PLD activity assays 
PLD activity assays were performed essentially as previously described (Brown 
et al., 2007). Following experimental treatments, cells were treated with 0.3% deuterated 
n-butanol (n-butanol-d10) for 30 minutes prior to phospholipid extraction and 
quantification of PLD-generated phosphatidylbutanol species. To generate concentration 
response curves, U87MG cells were serum starved for approximately 24 hours. Cells 
were treated with the indicated concentration of PLD inhibitor for 15 min prior to addition 
of n-butanol-d10 and phospholipid extraction. 
 
Viability assays 
Cells were seeded into clear-bottom, black-walled 96-well tissue culture plates 
and allowed to adhere overnight to achieve approximately 60% confluence the following 
day.  Cells were serum-starved in the presence of indicated inhibitors overnight.  Viability 
was measured by addition of the WST-1 reagent (Roche) and reading absorbance at 
450 nm. Time of WST-1 incubation was cell line dependent and ranged from 30 minutes 
to 2 hours. 
To measure viability following RNAi treatment, cells were seeded in 60 mm 
tissue culture plates at 540,000 cells/plate and transfected with 100 nM siRNA. The next 
day, cells were split into 96-well plates, allowed to adhere overnight, and serum starved 
in the presence of inhibitors the following day. Viability was assessed approximately 72 
hours post siRNA transfection. 
 
Anchorage-independent growth assays 
Base layers of 0.5 ml of 0.7% agarose (SeaKem GTG agarose, Cambrex Bio 
Science, Rockland, ME) containing complete neurobasal growth media were prepared in 
12-well tissue culture plates. PLD inhibitors or DMSO vehicle controls were incorporated 
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into the base layers. A 0.5 ml overlayer of 0.35% agarose containing CD133+ cells (5.0 
x 103) in compete growth medium with PLD inhibitors was applied. Each condition was 
plated in triplicate wells. Plates were incubated at 37 °C in a humidified atmosphere of 
5% CO2 in air. Cells were fed every 2-3 days with complete growth media plus PLD 
inhibitor. Colony formation progressed for 8 weeks.  Crystal Violet (0.005%) was used to 
stain colonies. Large colonies (>50 cells) were scored at 10! magnification with an 
inverted phase microscope using the average of 4 random fields per sample. 
 
Immunoblotting 
Lysates were prepared by incubating cell pellets in lysis buffer (50 mM Tris pH 
8.0, 150 mM NaCl, 0.5% Nonidet P-40, 40 mM !-glycerophosphate, 20 mM sodium 
pyrophosphate, 1 mM Na3VO4, 2 mM EDTA, 2 mM EGTA, 5 mM NaF, 1 mM DTT, and 
Roche complete protease inhibitor cocktail for 30 minutes at 4 °C. Protein concentrations 
were measured using the Bio-Rad protein assay reagent. Pan-Akt, Akt-S473, Akt-T308, 
beclin1, p62, Atg7, p70S6K, p70S6K-T389 antibodies were from Cell Signaling; GAPDH 
and PLD1 antibodies were from Santa Cruz; b-actin and FLAG (M2) antibodies were 
from Sigma; pan-cadherin and rubicon antibodies were from Abcam; and PLD2, HA-tag, 
strep-tag and LC3 antibodies were from Abgent, Covance, Qiagen and Novus, 
respectively. Bands were quantified using the gel analyzer function of ImageJ (NIH). 
 
Protein purification 
PtS-PLD2 infected Sf21 cells were harvested and collected by centrifugation at 
500 ! g for 5 min. Cells were lysed by sonication in lysis buffer (50 mM Tris pH 8.0, 500 
mM NaCl, 0.5% Nonidet P-40, 2.5 mM EDTA, and 50 µg/ml Avidin, 1 mM DTT, complete 
protease inhibitor tablet (Roche), and 1 mM PMSF added immediately prior to 
sonication). Lysate was cleared by centrifugation at 12,000 ! g for 10 min. Cleared 
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lysate was incubated with strep-tactin affinity resin (IBA) overnight at 4 °C. Beads were 
washed 3 times with wash buffer (lysis buffer with 0.01% Nonidet P-40). PtS-PLD2 was 
batch eluted by incubation of beads with 5 mM desthiobiotin (Sigma) in wash buffer for 
10 minutes, centrifugation at 1,000 ! g, and collecting supernatants containing soluble 
PtS-PLD2. For protein-protein interaction studies, PtS-PLD2 eluates were dialyzed 
(5,000 MWCO, Gibco) overnight against wash buffer to remove desthiobiotin. 
The PtS protein, used as a control for protein interaction experiments, was 
produced by transforming BL21 E. coli (Agilent) with the pET16b-PtS plasmid. Bacteria 
were grown at 37 °C until OD600 reached 0.7. At that point, protein expression was 
induced by adding 100 µM IPTG and growing bacteria overnight at 18 °C. Bacteria were 
lysed by incubating in lysis buffer (30 mM sodium phosphate buffer pH 7.4, 500 mM 
NaCl, complete protease inhibitor cocktail, and 1 mg/ml lysozyme) for 30 min followed by 
sonication. Lysates were clarified by centrifugation at 14,500 ! g for 30 minutes at 4 °C 
and then loaded onto a 1 ml Hi-Trap chelating column (GE). The column was washed 
until OD280 returned to baseline and non-specific proteins were eluted using a 40 mM 
imidazole step gradient. Once OD280 returned to baseline, PtS was eluted in a linear 
imidazole gradient from 40-500 mM. Eluates were pooled and loaded onto a 120 ml 
Sephadex 75 gel filtration column (GE), previously equilibrated with 50 mM Tris pH 7.4, 
0.5 mM EGTA, 150 mM NaCl, and 2 mM DTT. Fractions containing PtS protein were 
collected and pooled for use in binding assays. 
For 6xHisMBP-PLD2-PXPH purification, BL21 E. coli were induced with 100 µM 
IPTG overnight at 18 °C. Cells were harvested by centrifugation at 6,000 ! g for 15 
minutes. Cells were lysed by incubation for 30 minutes in lysis buffer (30 mM sodium 
phosphate buffer pH 7.5, 500 mM NaCl, 1mg/ml lysozyme, Roche complete protease 
inhibitor cocktail, and 1 mM PMSF) followed by sonication.  Lysates were clarified by 
centrifugation at 14,500 ! g for 30 minutes.  Cleared lysates were loaded onto a 5 ml 
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MBPtrap (GE) that had previously been equilibrated with lysis buffer minus protease 
inhibitors. The column was washed until OD600 returned to baseline at which time 
6xHisMBP-PLD2-PXPH was eluted using a 10 mM maltose step gradient. Eluates were 
pooled and loaded onto a 1 ml HiTrap nickel chelating column that had been equilibrated 
in the maltose elution buffer. Column was washed until OD600 returned to baseline and 
non-specific proteins were eluted using a 40 mM imidazole step gradient. To elute 
PLD2-PXPH, an imidazole gradient from 40-500 mM was run over the column for 30 
minutes. The fractions around the UV peak that eluted during the imidazole gradient 
were pooled (approximately 5 ml) and loaded onto a 120 ml sephadex 75 gel filtration 
column that had been equilibrated with 50 mM Tris pH 7.5, 150 mM NaCl, 0.5 mM 
EDTA, and 2 mM DTT.  The column was run overnight at 0.25 ml/min. Correct protein 
folding was assessed by measuring binding of PLD2-PXPH to PI(3)P-containing protein-
lipid overlays. 
For PLD2.d308 purification, suspension cultures of Sf21 insect cells were 
infected with HMFT-PLD2.d308 baculovirus for 72 hours before harvest. Cells were 
collected by centrifugation at 500 ! g for 5 minutes. Cells were lysed by resuspending in 
lysis buffer (8.1 mM Na2HPO4, 1.5 mM KH2PO4 pH 7.5, 137 mM NaCl, 2.5 mM KCl, 40 
mM !-glycerophosphate, 0.5 mM DTT and Roche complete (EDTA free) protease 
inhibitor cocktail and sonicating. Lysates were clarified by ultracentrifugation at 100,000 
! g for 45 min at 4 °C. Clarified lysates were loaded onto a 1 ml HiTrap nickel chelating 
column that had previously been equilibrated with lysis buffer minus !-glycerophosphate, 
DTT and protease inhibitors. The column was washed until OD600 returned to base line 
and non-specific proteins were eluted using a 32 mM imidazole step gradient. 
PLD2.d308 was eluted using a linear gradient from 32-400 mM imidazole. Elutates were 
pooled and concentrated to 0.5 ml and loaded onto a 24 ml Sephadex 200 (GE) gel-
filtration column that had previously been equilibrated with 8.1 mM Na2HPO4, 1.5 mM 
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KH2PO4 pH 7.5,137 mM NaCl, and 2.5 mM KCl. Column was run at 0.5 ml/min to elute 
PLD2.d308. 
N-terminal Akt PH domain 6xHis-GST fusion proteins were produced by PCR 
amplifying the first 123 amino acids of Akt1 (Thomas et al., 2002), ligating into pBG105 
(Vanderbilt structural biology core), and transforming BL21 E. coli. Bacteria were grown 
at 37 °C until OD600 reached 0.7. At that point, protein expression was induced by adding 
250 µM IPTG and growing bacteria overnight at 27 °C. Bacteria were lysed by 
incubating in lysis buffer (50 mM Tris buffer pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM 
EDTA, 1 mM Na3VO4, 10 mM !-glycerophosphate, 50 mM NaF, 5 mM DTT, Roche 
complete protease inhibitor cocktail, and 1 mg/ml lysozyme) for 30 min followed by 
sonication. Lysates were clarified by centrifugation at 14,500 ! g for 30 min at 4 °C then 
applied to glutathione agarose (Sigma) for 2 h at 4 °C.  Resin was washed twice with 
lysis buffer and twice with wash buffer (50 mM Tris pH 7.5, 300 mM NaCl, 0.1 mM 
EGTA, and 5 mM DTT) and eluted by incubating in wash buffer containing 10 mM 
reduced glutathione.  
6xHis-Akt1 and 6xHis-Akt1.d145 was purified from Sf21 cells essentially as 
previously described (Kumar et al., 2001). 
 
Immunoprecipitation and in vitro protein-protein interaction assays 
Cells were resuspended in lysis buffer (see Immunoblotting section) and lysed 
with three freeze/thaw cycles in dry ice/ethanol, drawing lysate through a 25G syringe 
needle between cycles.  Clarified (10,000 ! g for 10 min) lysates were pre-cleared with 
protein-G agarose (Millipore) and immunoprecipitating antibodies were incubated with 
lysate overnight. Complexes were captured using protein-G agarose, washed three 
times in lysis buffer, then eluted by boiling in 2! SDS-PAGE loading buffer. 
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For in vitro protein-protein interaction assays, 25 nM PtS-PLD2, HMFT-
PLD2.d308, 6xHisMBP-PLD2-PXPH, or protein tag controls were incubated with the 
indicated concentration of Akt construct for two hours in 50 mM Tris pH 8.0, 0.01% 
Nonidet P-40, 150 mM NaCl, and 0.5 mM EDTA. For strep-tactin pull-down experiments, 
50 µg/ml avidin was included in the incubation buffer to reduce non-specific binding. 
Where indicated, 10 mM inhibitor was included in the reaction mixture.  PtS-tagged 
proteins were captured by incubation with strep-tactin resin and MBP-tagged proteins 
were with amylose agarose for 2 h.  Resin was washed 3 times and proteins eluted by 
boiling in 2! SDS-PAGE loading buffer. 
 
In vitro Akt kinase assay 
Kinase reaction mixtures included 50 nM 6xHis-Akt1, 100 mM ATP, and 125 ng 
GST-GSK3 substrate peptide (Cell Signaling) in a buffer containing 25 mM Tris pH 7.5, 5 
mM !-glycerophosphate, and 2 mM DTT. Reactions were initiated by spiking a stock 
concentration of MgCl2 to achieve a final concentration of 1 mM and reactions were 
incubated in a 30 °C water bath for 30 minutes. To terminate the kinase reactions, SDS-
PAGE loading buffer was added to each tube and samples were boiled for 5 minutes. 
Kinase activity was determined by immunoblotting a portion of each sample with a 
phospho-GSK3 antibody (cell signaling). Where indicated, PLD2 proteins were included 
in the reaction mixtures at a final concentration of 50 nM. 
 
Protein-lipid binding 
The general procedure for measuring Akt binding to lipid spots on nitrocellulose 
membranes has been previously described (Dowler et al., 2002). The membrane 
containing various classes of lipids was obtained from Avanti Polar Lipids and contained 
2 µg of the indicated lipid per spot. For vesicle competition assays, vesicles were 
prepared by drying lipids under N2 gas and resuspending in 50 mM Tris pH 7.4, 150 mM 
 172!
NaCl, and 2 mM EGTA.  Lipids were vortexed and sonicated until in solution.  The 
vesicles were composed of either 100% 32:0 PC or 95% PC + 5% 32:0 PtdOH (mol %).  
Recombinant Akt was incubated for 2 hours with 200 µM bulk vesicles, and then 
incubated with nitrocellulose membranes overnight.  Lipid-bound Akt was determined 
using a total Akt antibody and chemiluminescence.    
 
Exogenous PtdOH rescue 
Lipids were obtained as chloroform solutions from Avanti Polar Lipids.  Lipids 
were dried under N2 gas in glass Pyrex tubes.  Dried lipid film was vortexed in DMEM + 
0.25 mg/ml fatty-acid-free BSA and then sonicated for 10 minutes.  The sonicated lipid 
mixture was further diluted in the DMEM/BSA mixture to a final concentration of 1 mM 
and cells were treated for the duration of time indicated in the text.   
 
Membrane isolation from U87MG cells 
U87MG cells were seeded on 150 mm tissue culture plates at 2.6 ! 106 
cells/plate (4 plates per condition) and allowed to adhere overnight. The following day, 
cells were washed and media replaced with DMEM plus indicated inhibitor or vehicle 
and cells were treated for 6 hours.  Cells were washed twice in 1x PBS then scraped in 
homogenization buffer (20 mM HEPES pH 7.4, 1 mM EDTA, 250 mM sucrose). Cells 
were pelleted by centrifugation at 1,000 ! g for 5 minutes at 4 °C. Cell pellets were 
resuspended in homogenization buffer containing Roche complete protease inhibitor 
cocktail, 10 mM !-glycerophosphate, 1 mM sodium pyrophosphate, 1 mM Na3VO4, and 
5 mM NaF and lysed by nitrogen cavitation (1000 psi for 5 minutes, 4 °C). Lysate was 
collected dropwise then centrifuged at 2,000 ! g for 10 minutes to pellet unbroken cells, 
nuclei, and heavy debris. The supernatant was subsequently centrifuged at 100,000 ! g 
for 60 minutes. The supernatant was saved as the cytosolic fraction and the 100,000 ! g 
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pellet was washed once by resuspension in lysis buffer then centrifuged again under the 
same conditions. 
A stock iodixanol (Optiprep, Sigma) gradient solution was prepared by diluting 
the 60% iodixanol solution from the manufacturer in dilution buffer (120 mM HEPES pH 
7.4, 250 mM sucrose, 6 mM EDTA, 60 mM !-glycerophosphate, 6 mM Na3VO4, and 60 
mM sodium pyrophosphate) in a ratio of 5 parts 60% iodixanol to 1 part dilution buffer to 
create a 50% iodixanol working solution. 2.5%, 10%, 17.5%, 25%, and 30% iodixanol 
solutions were prepared by mixing the appropriate ratios of 50% iodixanol with 
homogenization buffer. Washed membranes from the second 100,000 ! g spin were 
resuspended in 30% iodixanol (approximately 500 ml) and added to 11 ml polycarbonate 
ultracentrifuge tubes (Beckman Coulter). Equal volumes of 25%, 17.5%, 10%, 2.5% 
iodixanol were layered on top of the membrane suspension and tubes were centrifuged 
for 3.5 hours at 165,000 ! g in a swinging bucket rotor. 1 ml fractions were collected 
from the bottom by introducing a small hole with a 25G syringe needle and collecting 
droplets. Samples were then boiled in 6! SDS-PAGE loading buffer prior to 
immunoblotting. Membranes predominantly banded at the 10%/17.5% iodixanol 
interface. 
 
Immunofluorescence 
U87MG-tfLC3 cells were seeded on glass coverslips in 6-well plates in complete 
media and allowed to adhere overnight. The following day, cells were washed and 
treated with inhibitors in serum-free DMEM for 24 hours. Cells were fixed for 15 minutes 
in 2% paraformaldehyde followed by washing in PBS.  Coverslips were removed and 
mounted onto glass slides in Vectashield mounting media containing DAPI (Vector 
Labs). GPF/RFP images were acquired using Nikon A1R laser scanning confocal 
microscope equipped with a Plan Apo VC 60x 1.4 N.A. and 40! oil immersion lens. 
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Statistical analysis 
Statistical analyses used for each figure are listed in the figure legend. Graphs of 
PLD activity and cell viability are representative from at least three experiments. 
Quantified immunoblots represent pooled data from at least three independent 
experiments unless otherwise noted in the text. 
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CHAPTER IV 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
When we initiated this project, significant progress had been made towards 
understanding the activators and inhibitors of PLD proteins. Many of these proteins, 
such as those involved in vesicular trafficking and cytoskeletal remodeling provided 
insights into the physiological roles of PLD. On the other hand, many of the molecular 
mechanisms for the cellular functions of PLD were not well characterized. The purpose 
of this project was to identify and characterize novel PLD-protein interactions to further 
understand the molecular mechanisms by which PLD promotes processes needed for 
cancer cell survival. The initial question for this project was to determine the common 
and unique binding partners for PLD1 and PLD2 following stimulation of a prototypical 
GPCR (M1 muscarinic receptor) and RTK (EGF receptor) in order to define specific 
signaling complexes. Although we did not detect unique protein complexes as a result of 
EGFR stimulation, our analyses identified novel PLD2-protein interactions that revealed 
a role for PLD in regulating cellular bioenergetics and in regulating Akt kinase to promote 
autophagic flux. 
 The discovery that PLD from N. gonorrhoeae interacts with and activates human 
Akt upon infection of human cervical epithelial cells (Edwards and Apicella, 2006) 
prompted us to investigate the regulation of Akt by human PLD in cancer. Since Akt is 
an important cancer-survival kinase, we hypothesized that PLD may promote cancer cell 
survival by regulating Akt activation and prompted us to investigate three main 
questions: How does PLD2 control activation of Akt kinase? How do PLD2 and Akt 
promote GBM cell survival? What are the molecular targets for PLD2-stimulated Akt 
activity? PLD-derived PtdOH targets Akt for membrane recruitment and activation in 
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GBM cells, leading to an autophagy-dependent cell death following inhibition of PLD. 
Downstream of PLD activation, Akt phosphorylates beclin1 and prevents the anti-
autophagic interaction between beclin1 and rubicon. We also demonstrated a direct 
protein-protein interaction between PLD2 and Akt and presented data showing that 
PLD2 stimulates Akt kinase activity in vitro, independent of PLD2 lipase activity (chapter 
III). These data provide some molecular insight into how PLD regulates Akt-mediated 
GBM cell survival, and paves the way for several follow-up studies. 
 One of the unanswered questions regarding the PLD2-Akt interaction concerns 
the binding site of PtdOH on Akt. Since there is no canonical PtdOH-binding domain, 
either by sequence or structure (see Chapter I), determination of the PtdOH binding site 
will probably require mutagenesis or structural analysis. As shown in Figure 11 (Chapter 
III), PtdOH binds the Akt-PH domain in a location distinct from PIP3-binding domain. 
Multiple crystal structures have been published of the Akt-PH domain, laying the 
groundwork for crystallizng Akt-PH bound to PtdOH. Additionally, NMR studies have 
provided structural insights into short chain PtdOH binding to mTOR (Veverka et al., 
2007) and may also provide insights into the binding of PtdOH to Akt. Determination of 
the Akt PtdOH binding site may uncover a conserved PtdOH binding motif useful for the 
identification of unknown PtdOH binding proteins. 
 Another unanswered question regarding the PLD2-Akt interaction concerns the 
identification of Akt substrates regulated by the PLD2-Akt interaction. As shown in Figure 
8 (Chapter III), PLD2 protein activates Akt kinase activity in vitro towards a substrate 
peptide. We proposed a scenario where PLD2 recruits Akt to membranes via PtdOH and 
then directly influences kinase activity via the PLD2-Akt protein-protein interaction. 
Treatment of glioblastoma cells with PLD inhibitors did not decrease phosphorylation of 
Akt substrates such as glycogen synthase kinase 3 (GSK3), TSC2, Bcl-2-associated 
death promotor (BAD), proline-rich Akt substrate of 40 kDa (PRAS40), or FoxO1. 
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Therefore, future experiments should use phosphoproteomic analyses to compare global 
phosphorylation status of known Akt substrates following inhibition of PI3K or PLD. In 
theory, these analyses may uncover PLD-specific regulation of known Akt substrates 
under certain conditions. Additionally, cells may be separated into various subcellular 
fractions to track co-localization of PLD2 and Akt. Phosphoproteomic analyses may 
identify PLD-regulated, Akt substrates in these fractions. Known Akt substrates can be 
immunoblotted with phospho-specific antibodies and other identified proteins may be 
searched bioinformatically for Akt phosphorylation consensus sequences as a starting 
point for further validation. These experiments may uncover uncharacterized Akt 
substrates that function independently of the canonical PI3K/Akt pathway through PLD. 
Additionally, the regulation of Akt by PLD and PtdOH may explain previously 
characterized effects on proteins such as p53. As mentioned in Chapter I, increased 
PLD activity is associated with a decrease in p53 levels. MDM2 controls p53 levels by 
targeting p53 for destruction. Since Akt is known to activate MDM2 (Mayo 2001), the 
increase in p53 degradation observed with increasing PLD activity may be explained by 
PLD promoting Akt activity. Characterization of Akt substrates regulated by PLD and/or 
PI3K will certainly enhance understanding of Akt-mediated cancer cell survival. 
The loss of glioma viability following PLD inhibition appears to be mediated by 
inactivation of Akt as expression of constitutively active myrAkt protects cells from PLD 
inhibitor-induced cell death. Modulation of autophagy at either the initiation or 
degradation steps appear to have varying outcomes on cell viability when GBM cells are 
treated with compounds that induce autophagy. For example, GBM cell death induced 
by temozolomide (Kanzawa et al., 2004) or imatinib (Shingu et al., 2009) is potentiated 
by inhibition of autophagosome degradation with bafilomycin A1. Paradoxically, chemical 
or genetic inhibition of autophagosome initiation protects GBM cells against 
temozolomide (Kanzawa et al., 2004) or imatinib (Shingu et al., 2009) induced cell 
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death. In our study and others (Dall'Armi et al., 2010), PLD inhibition decreased 
autophagic flux and inhibition of autophagy initiation via siRNA knockdown of Atg7 
protected U87MG cells against PLD inhibitor induced cell death (Figure 13H and I, 
chapter III). Therefore, PLD inhibition may result in the accumulation of cytotoxic 
molecules that must be cleared by autophagy for survival. The accumulation of 
autophagosomes containing cytotoxic cargo cannot be degraded following PLD inhibition 
or bafilomycin A1 treatment, due to inhibition of autophagic flux, and cell viability is 
ultimately compromised. A major unanswered question concerns the identification of the 
cytotoxic contents of these autophagosomes. 
Mitochondria are frequently damaged during normal cell proliferation and by 
treatment with compounds such as those used for chemotherapy. Damaged 
mitochondria are cleared by a specialized autophagy, known as mitophagy, to maintain 
cell viability (Liu et al., 2009; Kim et al., 2007). Although we presented no data that 
directly links PLD activity to mitophagy, several lines of evidence from chapter II strongly 
suggest that PLD may regulate cellular bioenergetics at the level of the mitochondria. 
First, proteomic analysis of PLD2 complexes from HEK293-TREx-EGFR cells revealed a 
large list of putative mitochondrial interacting proteins. We confirmed the interaction 
between PLD2 and ATP synthase through immunoprecipitation experiments (Figure 6, 
chapter II), which suggested that PLD2 is at least partially localized to the mitochondria. 
However, the formation of a PLD2-ATP synthase complex following cell lysis does not 
necessarily mean the two proteins interact in vivo. Detergent solubilization could trigger 
non-physiological interactions between proteins that would normally be segregated 
through differences in subcellular localizations. Future studies should use subcellular 
fractionation techniques to determine if PLD co-localizes with mitochondria under 
experimental conditions used in chapter II. The second line of evidence for PLD 
participating in mitochondrial function is that proliferative signals such as serum and 
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growth factors increase ATP levels in a PLD-dependent manner in PTEN-null GBM and 
breast cancer cells, but not HEK293 cells. This second line of evidence answers two of 
our main questions from this chapter: What circumstances does PLD regulate 
intracellular ATP and which types of cells require PLD activity to maintain ATP levels?   
Non-dialyzed serum stimulated an increase in ATP whereas dialyzed serum stimulated 
both an increase in ATP and lactate, suggesting that non-dialyzed and dialyzed serum 
stimulates ATP synthesis through mitochondrial oxidative phosphorylation and 
glycolysis, respectively. PLD inhibition only blocks the non-dialyzed serum ATP 
response, suggesting that PLD functions at the level of the mitochondria (Figure 17, 
chapter II). Finally, inhibition of mitochondrial ATP synthesis with oligomycin upregulates 
glycolysis to produce the requisite ATP following serum stimulation (Figure 15, chapter 
II). PLD inhibitors block the oligomycin-induced increase in glycolysis, suggesting that 
PLD may function to relay signals about mitochondrial health (Figure 15, chapter II) and 
partially answering the final question from chapter III: What is the molecular mechanism 
of bioenergetic regulation by PLD? This hypothesis is partially substantiated by our 
observations that PLD2 activity is modulated by ATP and ADP (Figure 16, chapter II). 
When mitochondrial integrity is normal, mitochondrial ADP and ATP levels would be high 
and suppress PLD activity. Following mitochondrial damage, or oligomycin treatment, 
mitochondrial ADP/ATP levels would presumably decrease, and release the inhibitory 
clamp on PLD activity. Therefore, damaged mitochondria may rely on PLD activity to 
trigger mitophagy for cell survival. Whether PLD functions as a sensor of mitochondrial 
 Preliminary experiments suggest that mitochondrial morphology changes 
following treatment with our small-molecule PLD inhibitors. In U118MG cells, 
mitochondria display a filamentous morphology in serum-starved, vehicle-treated 
conditions. By contrast, the mitochondria of U118MG cells treated with VU0359595 and 
VU0364739 display a punctate morphology, similar to LC3 puncta seen in U87MG cells 
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following treatment with the same PLD inhibitors (Figure 1). Although these data are not 
conclusive, the mitochondrial morphology changes following PLD inhibitor treatment are 
consistent with mitophagy. A potential criticism of our work is that we did not address the 
possibility that mitoPLD mediates some of our observations in mitochondrial function. 
Previous studies using FIPI, a PLD inhibitor that shares a chemical scaffold to 
VU0359595, determined that mitoPLD is not inhibited by this series of PLD inhibitors (Su 
et al., 2009). Therefore, the effects on mitochondrial function and morphology following 
VU0359595 and VU0364739 treatment are most likely mediated by the conventional 
PLD isoforms. 
 
 
 
Figure 1. PLD inhibitor treatment results in altered mitochondrial morphology in 
U118MG cells. U118MG cells were serum-starved overnight and pretreated with 10 µM 
PLD inhibitor for 30 minutes prior to a 4-hour stimulation with 20% FBS. 100 nM 
MitoTracker Deep Red FM (Molecular Probes) was added to cell media during the final 
30 minutes of the serum-stimulation. Cells were washed twice in PBS and fixed for 15 
minutes in 2% PFA. Cells were mounted in Vectashield mounting media and imaged 
using an LSM 510 confocal microscope. 
 
If the hypothesis that PLD functions as a bioenergetic sensor of mitochondrial 
health is true, future studies should focus on characterizing the downstream effectors of 
PLD in clearing damaged mitochondria. A recent study on mitophagy induction has 
suggested that leucine-rich pentatricopeptide repeat-containing protein (LRPPRC) 
Vehicle VU0359595 VU0364739 
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functions as a mitophagy suppressor (Zou et al., 2013). LRPPRC was first implicated in 
mitophagy following the observation that LRPPRC interacts with microtubule-associated 
protein 1S, a protein known to recruit LC3 to microtubules (Xie et al., 2011). When 
LRPPRC is silenced using siRNA, basal levels of mitophagy increase. Zou and 
colleagues demonstrated that LRPPRC interacts with beclin1 and prevents beclin1-
induced activation of Vps34 to suppress autophagosome initiation (Zou et al., 2013). 
LRPPRC was identified in our proteomic screen as a PLD2 interaction partner (Table 1, 
chapter II). Although we have not validated the PLD2-LRPPRC interaction, an intriguing 
possible signaling pathway emerges. If PLD regulates LRPPRC localization or activity, 
then PLD activity could inhibit mitophagy through a positive regulation of LRPPRC. 
Likewise, PLD inhibitors would downregulate LRPPRC activity and promote mitophagy. 
This scenario is speculative, but may provide insight into the molecular mechanisms by 
which PLD inhibition induces mitophagy and subsequently prevents serum-stimulated 
ATP synthesis. 
 In addition to LRPPRC, PLD may signal through Akt to relay information 
concerning mitochondrial bioenergetic status. As discussed in chapter II, PLD inhibitors 
ablate the serum-induced increase in intracellular ATP. Similar results were observed 
with two structurally distinct Akt inhibitors, MK2206 and a dual Akt1/2 inhibitor, Akti1/2 
(Lindsley et al., 2005). When U118MG cells were pretreated with either Akt inhibitor, the 
cells did not increase intracellular ATP when stimulated with ATP (Figure 2). 
Additionally, endogenous PLD2 and Akt were found to co-IP with endogenous ATP 
synthase !, suggesting that PLD2, Akt, and ATP synthase exist in a protein complex 
(Figure 2C). Phosphoproteomic characterization of Akt substrates in mitochondrial 
fractions may yield insight into the mechanisms by which PLD participates in cellular 
bioenergetics. 
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Figure 2. Akt participates in the serum-induced increase in intracellular ATP in U118MG 
cells. A and B. U118MG cells were serum deprived overnight and pretreated with 10 µM 
VU0359595, Akti1/2, (A) or MK2206 (B) for 30 minutes before a 4-hour stimulation with 
20% FBS. Data is presented as the ratio of ATP to total cellular protein and 
representative experiments are shown with triplicate samples in each condition. ** p < 
0.01, *** p < 0.001, one-way ANOVA with Tukey’s multiple comparison test comparing 
FBS-stimulated ATP levels between vehicle and PLD/Akt inhibitor groups. C. PLD2 and 
Akt form a complex with ATP synthase. HEK293-TREx cells were serum-starved 
overnight before lysis the following day. Endogenous ATP synthase ! was 
immunoprecipitated and complexes were probed for co-IP of endogenous PLD2 and Akt. 
An antibody of the same isotype as ATP synthase ! served as a negative IP control. 
 
 The research contained herein has provided the tools to further understand the 
mechanisms by which PLD regulates cancer cell survival. This project may be used as a 
starting point for future studies to analyze PLD complexes in cancer cells versus non-
cancer cells in order to gain insight into cancer-cell specific PLD complexes. Analyzing 
PLD complexes under stress conditions, such as serum-starvation or stimulation with 
apoptotic stimuli may also pave the way to identifying other PLD targets that promote 
cancer survival and chemotherapy resistance. Until then, by characterizing the 
regulation of Akt by PLD in GBM, we have provided a novel means of therapeutic 
intervention without directly targeting the Akt kinase. 
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